UID,Searchword,API,URL,Title,Summary,Article,Title_Sentiment,Title_Positive,Title_Neutral,Title_Negative,Article_Sentiment,Article_Positive,Article_Neutral,Article_Negative,Verified,Language,Topics,Date,Load_Date,Source
44613,Euroclear,NewsApi.org,https://www.project-syndicate.org/commentary/kamala-harris-ukraine-war-policy-correcting-biden-administration-mistakes-by-anders-aslund-2024-08,Kamala Harris Must Correct US Ukraine Policy by Anders √Öslund,As US vice president  Kamala Harris has followed the Biden administration line on Ukraine; but as president  she could turn the war around and make it a winning issue. Doing so will require a comprehensive strategy backed by sufficient resources  all of which‚Ä¶,As US vice president  Kamala Harris has followed the Biden administration line on Ukraine; but as president  she could turn the war around and make it a winning issue. Doing so will require a comprehensive strategy backed by sufficient resources  all of which are already available in the form of frozen Russian assets.STOCKHOLM ‚Äì By providing Ukraine with early military  political  and financial support  US President Joe Biden‚Äôs administration saved it from being overrun by Russia. Yet since November 2022  the conflict has been locked in a stalemate  which is not to Ukraine‚Äôs advantage. If elected  Kamala Harris should make it an explicit goal to turn today‚Äôs horrendous war of attrition into a Ukrainian victory. Ukraine‚Äôs surprising offensive in Russia‚Äôs Kursk region may be the beginning of a more promising development.Ukraine‚Äôs own goals are clear: to restore full territorial integrity; to allow all displaced Ukrainian citizens ‚Äì including the thousands of children kidnapped by Russia ‚Äì to return; and to receive full compensation for the damage Russia has caused. By contrast  the United States currently has no strategy to speak of. The Biden administration merely claims that it will support Ukraine ‚Äúfor as long as it takes ‚Äù whereas Harris‚Äôs Republican challenger  Donald Trump  promises to end the war in a day  implying complete capitulation to the Kremlin.For Harris  the current impasse is an opportunity. Two-thirds of Americans are rooting for Ukraine‚Äôs victory  and she has already dealt extensively with Ukraine  having met President Volodymyr Zelensky six times and led the US delegation to the Ukraine Peace Summit in Switzerland in June. As US vice president  she has followed Biden‚Äôs lead; but as president  she could turn the war around and make Ukraine one of her big winning issues.Doing so will require a comprehensive strategy backed by sufficient resources. The Biden administration‚Äôs policy (presumably the work of National Security Adviser Jake Sullivan) is to defend Ukraine without provoking Russian President Vladimir Putin. Owing to irrational fears about nuclear attacks or World War III  the White House has created imaginary Russian red lines  thus offering Russia a sanctuary from Ukrainian attacks with Western arms. But given that Putin would not survive a nuclear war  he is exceedingly unlikely to go down that path.Another fundamental shortcoming of the Biden policy is the lack of any clear goal. The goal should be to provide Ukraine with enough support to defeat Russia. Harris should appoint a national security adviser who is whole-heartedly committed to that objective. The Ukrainians are bravely fighting on their own. They are not calling for foreign troops; but they do need potent arms  the right to use them to target Russian bases  and sufficient funding from the West.Ukraine received about $100 billion in 2023 (half of it military assistance  and the rest budget support and humanitarian aid)  and it is on track to receive around the same amount in 2024. While substantial  that is not enough to tip the balance. For an outright victory  Ukraine would probably need $150 billion per year  with a doubling of military support to $100 billion. That would equip it to win the war  which would then reduce future costs (not to mention Ukrainian suffering).Introductory Offer: Save 30% on PS Digital Introductory Offer: Save 30% on PS Digital Access every new PS commentary  our entire On Point suite of subscriber-exclusive content ‚Äì including Longer Reads  Insider Interviews  Big Picture/Big Question  and Say More ‚Äì and the full PS archive.Subscribe NowIt is no secret where such funding can be found. The West has frozen $280 billion in Russian reserves  two-thirds of which are held in the private Euroclear system in Belgium. Moreover  the US Congress has sensibly passed legislation authorizing the Department of the Treasury to seize frozen Russian assets  while demanding that the European Union do the same. But the EU has refused  owing mainly to opposition from France and Germany.This European resistance makes no sense. With Russia violating international law on a daily basis  the Kremlin cannot credibly demand the protection of international law. Like the US  the EU needs to adopt legislation allowing for Russian funds to be seized and used to support Ukraine. Though only around $5 billion has been located in the US  that money can be seized and delivered to Ukraine immediately to set an example for the Europeans. True  in June  the US persuaded other G7 members to lend Ukraine $50 billion by drawing on the future yields from frozen Russian funds. That was a good start. But Ukraine needs the money as soon as possible to defeat Russia.After Russia launched its full-scale invasion in February 2022  the US  the United Kingdom  and Canada were Ukraine‚Äôs primary sources of military aid and training. During the war‚Äôs early months  they were understandably reluctant to furnish the Ukrainians with the most sophisticated arms  for fear that Russia would seize them. But these fears were alleviated by the summer of 2022. For two years now  the US could have been providing Ukraine with the weapons it needed to push the Russians back.Very little will happen unless America leads. The US remains globally dominant in arms production and exports  whereas the Europeans have too few arms to change the balance in the war.Finally  we come to the most absurd flaw in America‚Äôs Ukraine policy: the prohibition against using US-supplied weapons to hit Russian bases from which Ukraine is being attacked. This policy is not even in keeping with the right to self-defense enshrined in the UN Charter. It should be revoked immediately.The war in Ukraine could be a boon for Harris  but she must correct Biden‚Äôs mistakes and provide the additional resources Ukraine needs to defeat Russia. By seizing Russian sovereign assets and persuading US allies to do the same  she can help Ukraine win without placing any additional budgetary burden on Americans.,neutral,0.06,0.92,0.02,mixed,0.11,0.16,0.73,True,English,"['US Ukraine Policy', 'Kamala Harris', 'Anders √Öslund', 'National Security Adviser Jake Sullivan', 'imaginary Russian red lines', 'PS Digital Introductory Offer', 'Russian President Vladimir Putin', 'US President Joe Biden', 'PS Digital Access', 'new PS commentary', 'Big Picture/Big Question', 'private Euroclear system', 'other G7 members', 'full PS archive', 'frozen Russian assets', 'President Volodymyr Zelensky', 'full territorial integrity', 'big winning issues', 'rest budget support', 'Biden administration line', 'US vice president', 'The Biden administration', 'World War III', 'Ukraine Peace Summit', 'Russian bases', 'Russian reserves', 'Russian funds', 'full compensation', 'financial support', 'enough support', 'military support', 'Biden policy', 'sufficient resources', 'surprising offensive', 'Kursk region', 'promising development', 'Ukrainian citizens', 'United States', 'Republican challenger', 'Donald Trump', 'complete capitulation', 'current impasse', 'US delegation', 'nuclear attacks', 'White House', 'Ukrainian attacks', 'Western arms', 'fundamental shortcoming', 'The Ukrainians', 'foreign troops', 'potent arms', 'military assistance', 'humanitarian aid', 'same amount', 'future costs', 'Ukrainian suffering', 'Point suite', 'subscriber-exclusive content', 'Longer Reads', 'Insider Interviews', 'The West', 'US Congress', 'European Union', 'European resistance', 'international law', 'daily basis', 'future yields', 'good start', 'full-scale invasion', 'United Kingdom', 'primary sources', 'military aid', 'early months', 'sophisticated arms', 'comprehensive strategy', 'explicit goal', 'Ukrainian victory', 'clear goal', 'outright victory', 'horrendous war', 'irrational fears', 'nuclear war', 'sufficient funding', 'Kamala Harris', 'form', 'STOCKHOLM', 'November', 'conflict', 'stalemate', 'advantage', 'attrition', 'beginning', 'goals', 'thousands', 'children', 'damage', 'contrast', 'day', 'Kremlin', 'opportunity', 'Two-thirds', 'Americans', 'Switzerland', 'June', 'lead', 'work', 'sanctuary', 'path', 'lack', 'objective', 'half', 'track', 'balance', 'year', 'doubling', 'entire', 'secret', 'Belgium', 'legislation', 'Department', 'Treasury', 'opposition', 'France', 'Germany', 'sense', 'protection', 'money', 'example', 'Europeans', 'February', 'Canada', 'training']",2024-08-13,2024-08-14,project-syndicate.org
44614,Clearstream,Bing API,https://www.finanzwire.com/press-release/notice-of-extraordinary-general-meeting-of-multitude-se-yF4TWKJ27Mv,NOTICE OF EXTRAORDINARY GENERAL MEETING OF MULTITUDE SE,With finanzwire.com  you can follow all the latest financial news in real time from the best sources for companies listed on the Paris  Brussels  Amsterdam  Lisbon  Frankfurt and New York stock exchanges. You'll have access to summary articles written by ...,"EQS-News: Multitude SE / Key word(s): AGM/EGMNOTICE OF EXTRAORDINARY GENERAL MEETING OF MULTITUDE SE (news with additional features)14.08.2024 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement.MULTITUDE SE (SE 21)ST Business Centre  120  The StrandGzira  GZR 1027MaltaNOTICE OF EXTRAORDINARY GENERAL MEETING OF MULTITUDE SENotice is given to the shareholders of Multitude SE (‚ÄúCompany‚Äù and/or ‚ÄúMultitude‚Äù) that an Extraordinary General Meeting of the Company is to be held on 5 September 2024 at 08:00 a.m. UTC (10:00 a.m. CEST) (the ‚ÄúMeeting‚Äù).The Meeting will be held at ST Business Centre  120  The Strand  Gzira  GZR 1027  Malta. Instructions for participation are provided in section 3 of this notice.The Meeting will be conducted in the English language and will be held in person.1 MATTERS ON THE AGENDA OF THE MEETINGAt the Meeting  the following matters will be considered:General:Opening of the Meeting and appointment of chairmanThe appointment of the chairman shall be carried out in terms of article 59 of the Company‚Äôs articles of association (the ‚ÄúArticles‚Äù).QuorumIn terms of article 56 of the Articles at least one (1) shareholder  present in person or by proxy  entitled to attend and vote at the Meeting shall constitute a quorum.Special business (extraordinary resolutions):Approval of the Redomiciliation of the Company to Switzerland after completion of the ConversionAs part of the Company‚Äôs wider relocation project  the Board proposes that  subject to the successful implementation of the conversion of Multitude from a societas europaea to a Maltese public limited liability company (which is being proposed at the Extraordinary General Meeting of the Company to be held on 21 August 2024) (‚ÄúConversion‚Äù)  the Company proceeds to commence the process of redomiciling out of Malta and into Switzerland in accordance with the provisions of the Continuation of Companies Regulations (Subsidiary Legislation 386.05 of the laws of Malta) and Swiss law (more specifically the relevant provisions of the Swiss International Private Law Act). The Board also notes that the redomiciliation to Switzerland is subject to the Board confirming that  in its reasonable assessment  there are no Swiss financial markets regulatory obstacles that the Board would reasonably expect to render the relocation to Switzerland inadvisable.The Company has received advice that  under the laws of Switzerland  the Company‚Äôs registration in the Commercial Register of the Canton Zug  Switzerland as a company continuing in Switzerland shall not operate to prejudice or affect the continuity of the Company nor shall it affect the property of the Company and the Company shall retain all its assets  rights  liabilities and obligations.In this regard  the Board has prepared  for the benefit of the shareholders  a table comparing the rights enjoyed by minority shareholders under Maltese law to those enjoyed by minority shareholders under Swiss law (the ‚ÄúComparative Table‚Äù).The Board therefore proposes that the Meeting adopts the following extraordinary resolution  which includes an approval of the revised articles of association in accordance with Swiss corporate law which will begin to apply when the redomiciliation from Malta to Switzerland takes effect (the ‚ÄúSwiss Articles of Association‚Äù):‚Äú(1) Change of domicile from Malta to Zug (Canton Zug)  SwitzerlandTo approve the redomiciliation of the Company from Malta to Zug  Switzerland in accordance with the provisions of the Continuation of Companies Regulations (Subsidiary Legislation 386.05 of the laws of Malta) and Swiss law  upon and subject to (a) the Conversion (i.e. the conversion of Multitude from a societas europaea to a Maltese public limited liability company) becoming effective (i.e. once the Company‚Äôs Revised M&A is registered by the Malta Business Registry) and (b) the Board confirming that  in its reasonable assessment  there are no Swiss financial markets regulatory obstacles that the Board would reasonably expect to render the relocation to Switzerland inadvisable (the ‚ÄúRedomiciliation‚Äù);(2) Change of registered seatThat following the Redomiciliation  the Company's new registered office will be located in the City of Zug (Canton Zug  Switzerland);(3) Change of the name of the CompanyTo approve the change to the Company name from Multitude p.l.c. to Multitude AG (with translations: ""Multitude Ltd"" and ""Multitude SA"")  upon and subject to the Redomiciliation becoming effective.As a result  and taking into account the transfer of the registered office under resolution (2) above  article 1 of the Swiss Articles of Association (as defined in resolution (5) below) will therefore read as follows:1. Firma und SitzUnter der FirmaMultitude AG(Multitude Ltd)(Multitude SA)besteht mit Sitz in Zug auf unbestimmte Dauer eine Aktiengesellschaft gem√§ss Art. 620 ff. des Schweizerischen Obligationenrechts (OR) (die ""Gesellschaft"").1. Name and Registered SeatUnder the corporate name ofMultitude AG(Multitude Ltd)(Multitude SA)exists for an unlimited period of time a corporation limited by shares according to art. 620 et seq. of the Swiss Code of Obligations (CO) with registered seat in Zug (the ""Company"").(4) Change of the purpose of the CompanyTo approve to change the wording relating to the Company's purpose in article 2 of the Swiss Articles of Association (as defined in resolution (5) below)  upon and subject to the Redomiciliation becoming effective  to read as follows:2. Zweck1 Zweck der Gesellschaft ist der Erwerb  das Halten  die Verwaltung  die Verwertung und die Ver√§usserung von in- und ausl√§ndischen Beteiligungen  ob direkt oder indirekt  unter anderem an Unternehmen  die insbesondere in den Bereichen Finanzdienstleistungen wie Verbraucherkrediten  Mikrokrediten und anderen Krediten und Finanzierungen t√§tig sind  sowie die Erbringung von Dienstleistungen  intern oder f√ºr andere Tochtergesellschaften des Konzerns  zu dem die Gesellschaft geh√∂rt.2 Die Gesellschaft kann Beteiligungen an Gesellschaften aller Art in der Schweiz und im Ausland erwerben  halten  verwalten und ver√§ussern.3 Die Gesellschaft kann ausserdem alle Gesch√§fte abschliessen und Vereinbarungen eingehen  die direkt oder indirekt dem Gesellschaftszweck dienen oder mit diesem in direktem Zusammenhang stehen.4 Die Gesellschaft kann ihren direkten oder indirekten Tochtergesellschaften (direkt oder indirekt) Darlehen oder andere Finanzierungen gew√§hren. Die Gesellschaft kann f√ºr Verbindlichkeiten von solchen Gesellschaften Garantien  Sicherheiten und andere Verpflichtungen jeglicher Art gew√§hren  einschliesslich durch fiduziarische √úbereignungen oder Abtretungen von und Pfandrechten an Verm√∂genswerten der Gesellschaft. Die Gesellschaft kann ferner ein Cash-Pooling (jeglicher Art) betreiben oder daran teilnehmen. Jede in diesem Absatz genannte Transaktion kann unabh√§ngig von allf√§lligen Klumpenrisiken und mit oder ohne Gegenleistung erfolgen.5 Die Gesellschaft kann Zweigniederlassungen und Tochtergesellschaften in der Schweiz und im Ausland errichten und Grundst√ºcke erwerben  halten  verwalten und ver√§ussern. 2. Purpose1 The purpose of the Company is to acquire  hold  manage  exploit and sell  whether directly or indirectly  interests in participations in Switzerland and abroad  inter alia in companies active among other things in financial services  such as consumer credits  microcredits and other credits and financing  as well as to provide services internally or to other subsidiaries of the group to which the Company belongs.2 The Company may acquire  hold  manage and sell participations in companies of all kinds in Switzerland and abroad.3 The Company may also carry out any and all transactions and enter into any and all agreements which serve directly or indirectly its corporate purpose or are directly related thereto.4 The Company may (directly or indirectly) grant loans or provide other types of financing to its direct or indirect subsidiaries. The Company may grant guarantees  security interests and other undertakings of any kind in respect of obligations of such companies  including by means of fiduciary transfers or fiduciary assignments of  and pledges over  assets of the Company. The Company may further operate or participate in cash pooling arrangements of any kind. Any transaction referred to in this paragraph may be entered into irrespective of any concentration of risk and with or without any compensation.5 The Company may set up branch offices and subsidiaries in Switzerland and abroad and acquire  manage  hold and sell real estate.(5) General revision of the Articles of Association and the adaptation of the Articles of Association to Swiss lawTo dispense with article-by-article discussion and approve the revised articles of association entirely in accordance with Swiss corporate law (the ‚ÄúSwiss Articles of Association‚Äù)  upon and subject to the Redomiciliation becoming effective. The draft of the Articles of Association is on hand;(6) Ascertainment of Swiss law as the authoritative legislationTo accept and resolve Swiss law (in particular  Swiss stock corporation law) as the authorative law for the Company  upon and subject to the Redomiciliation becoming effective;(7) Ascertainment of the principal place of businessTo resolve and ascertain that the principal place of business of the Company will be Zug  Switzerland  upon and subject to the Redomiciliation becoming effective;(8) Confirmation of the election members of the Board and the chairman of the Board(8.1) Confirmation of Ari Tiukkanen as a member of the BoardTo confirm the election of Ari Tiukkanen as member of the Board for a term ending at the end of the next Annual General Meeting;(8.2) Confirmation of Goutam Challagalla as a member of the BoardTo confirm the election of Goutam Challagalla as member of the Board for a term ending at the end of the next Annual General Meeting;(8.3) Confirmation of Jorma Jokela as a member of the BoardTo confirm the election of Jorma Jokela as member of the Board for a term ending at the end of the next Annual General Meeting;(8.4) Confirmation of Kristiina Lepp√§nen as a member of the BoardTo confirm the election of Kristiina Lepp√§nen as member of the Board for a term ending at the end of the next Annual General Meeting;(8.5) Confirmation of Lea Liigus as a member of the BoardTo confirm the election of Lea Liigus as member of the Board for a term ending at the end of the next Annual General Meeting;(8.6) Confirmation of Marion Kh√ºny as a member of the BoardTo confirm the election of Marion Kh√ºny as member of the Board for a term ending at the end of the next Annual General Meeting;(8.7) Confirmation and election of the chairman of the BoardTo confirm the election of Ari Tiukkanen as chairman of the Board for a term ending at the end of the next Annual General Meeting;(9) Appointment of the People and Culture CommitteeThat upon the Redomiciliation becoming effective   the People and Culture Committee shall assume the duties of the compensation committee in accordance with article 733 of the Swiss Code of Obligations.(9.1) Appointment of Ari Tiukkanen as a member of the People and Culture CommitteeTo appoint Tiukkanen as member of the People and Culture Committee for a term ending at the end of the next Annual General Meeting;(9.2) Appointment of Goutam Challagalla as a member of the People and Culture CommitteeTo appoint Goutam Challagalla as member of the People and Culture Committee for a term ending at the end of the next Annual General Meeting;(9.3) Appointment of Jorma Jokela as a member of the People and Culture CommitteeTo appoint Jorma Jokela as member of the People and Culture Committee for a term ending at the end of the next Annual General Meeting;(10) Election of the auditorsTo elect PricewaterhouseCoopers AG  Birchstrasse 160  8050 Z√ºrich  CHE-106.839.438 as Auditors for the business years 2024 and 2025  upon and subject to the Redomiciliation becoming effective;(11) That subject to  and conditional on  the successful implementation of the Conversion (i.e. the conversion of Multitude from a societas europaea to a Maltese public limited liability company)  the Company be  and hereby is  authorised to:(i) apply to the Malta Business Registry (‚ÄúMBR‚Äù) for the purpose of seeking authorisation for continuance in Switzerland;(ii) apply to the Commercial Register of the Canton Zug  for the purpose of being registered as a company continuing in Switzerland;(iii) notify the MBR of the Company‚Äôs decision to be registered as a company continuing in Switzerland; and(iv) take all such steps and issues such documents as may be necessary for it to obtain its registration as a company continuing in Switzerland and it will be known as Multitude AG (with translations: ""Multitude Ltd"" and ""Multitude SA"") with registered address located in in the City of Zug (Canton Zug  Switzerland);(12) That any one director of the Company be hereby authorised to make all declarations  applications and statements as may be required to register the Company as continued in Switzerland and to do all related and ancillary acts and sign and register any documents in connection with the registration of the Company in Switzerland  and generally to do all such things in the interest of the Company as is considered necessary and for it to cease to be registered in Malta and to do all ancillary acts thereto.‚ÄùClosing of the Meeting2 MEETING MATERIALSThis notice (which includes the proposals of the Board of Directors relating to the agenda of the Meeting) as well as the Comparative Table and the Swiss Articles of Association are available on the Company‚Äôs website (www.multitude.com). The aforementioned documents are also appended to this notice. Such documents will also be (a) sent to shareholders who so request and who inform the Company of their mailing address and (b) made available at the Meeting.The minutes of the Meeting will be made available on the Company‚Äôs website no later than one week after the date of the Meeting.3 PARTICIPATION INSTRUCTIONSIMPORTANT NOTE: THESE INSTRUCTIONS ARE DIFFERENT TO THE INSTRUCTIONS GIVEN IN PREVIOUS GENERAL MEETINGS OF THE COMPANY WHICH WERE HELD WHILE THE COMPANY WAS STILL REGISTERED IN FINLAND. YOU ARE THEREFORE ADVISED TO READ THE INSTRUCTIONS CAREFULLY AND SEEK ADVICE WHERE NEEDED. YOU ARE ALSO ENCOURAGED TO CONTACT YOUR RESPECTIVE CUSTODIAN / NOMINEE AS SOON AS POSSIBLE. PLEASE SEND AN EMAIL TO agm@multitude.com FOR ANY QUESTIONS YOU MAY HAVE.SHAREHOLDERS ARE ALSO INFORMED THAT ANY VOTING INSTRUCTIONS SUBMITTED IN RESPECT OF THE EXTRAORDINARY GENERAL MEETING OF THE COMPANY TO BE HELD ON 21 AUGUST 2024 ARE NOT RELEVANT FOR THE PURPOSES OF THE MEETING (TO BE HELD ON 5 SEPTEMBER 2024). ACCORDINGLY  ANY SHAREHOLDER WISHING TO PARTICIPATE AT THE MEETING WILL NEED TO SUBMIT FRESH VOTING INSTRUCTIONS.3.1 Record dateTo be entitled to attend and vote at the Meeting (and for the Company to be able to determine the number of votes that may be cast)  shareholders must have been entered in the register of members maintained by Clearstream Banking AG (‚ÄúClearstream‚Äù) on 6 August 2024.3.2 PreliminaryShareholders are advised to ask their custodian bank / nominee without delay for the necessary information regarding registration for the Meeting  the issuing of proxy documents and voting instructions. In any case  shareholders should ensure that all relevant instructions are submitted by their custodian / nominee to Clearstream as soon as possible  within any applicable deadline. Clearstream will process all instructions received and will transmit them to the Malta Stock Exchange (as ‚Äòissuer CSD‚Äô). In turn the Malta Stock Exchange will transmit the aggregated instructions to the Company.In terms of the Company‚Äôs articles of association  the Company must receive all relevant shareholder instructions from the Malta Stock Exchange (as ‚Äòissuer CSD‚Äô) no later than 10:00 a.m. CEST on 3 September 2024  and any instructions submitted to the Company after this deadline shall not be treated as valid. Accordingly  shareholders are encouraged to reach out to the respective custodians / nominees as soon as possible in order to ensure that their respective instructions are submitted to Clearstream within any applicable deadline.The Meeting will be held in person at the address indicated above. Shareholders and proxy representatives who wish to attend the Meeting will therefore be required to follow the Meeting registration requirements and will be required to make their own arrangements to attend the Meeting.3.3 Participation in personShareholders who wish to attend and vote at the Meeting in person must notify their intention to their respective custodians / nominees as soon as possible. Custodians / nominees will in turn be required to notify shareholders‚Äô intention to participate at the Meeting by electronic instruction to Clearstream as soon as possible and in line with any deadlines that may be imposed by Clearstream  which instructions must be delivered in terms of Clearstream‚Äôs existing procedures.Custodians/nominees may request shareholders‚Äô full names  passport numbers/company registration numbers (or similar)  full addresses  date of birth and daytime telephone number  number of shares in the Company  as well as  if applicable  details of proxies. Information submitted in connection with the notification will be computerised and used exclusively for the Meeting.3.4 Proxy representativesA shareholder  who is entitled to attend and vote at the Meeting  is also entitled to appoint one or more proxies to attend and vote on such shareholder‚Äôs behalf. A proxy does not need to be a shareholder. The appointment of a proxy must be in writing and (a) where the shareholder is an individual  be signed by him/her or (b) where the shareholder is a corporation  be signed by a duly authorised officer of the corporation. The proxy form to be used by shareholders is available on the Company‚Äôs website: www.multitude.com.Proxy forms must clearly indicate whether the proxy is to vote as she/he wishes or in accordance with the voting instructions sheet attached to the proxy form. Shareholders are advised that by submitting voting instructions they will effectively be voting in advance.The signed proxy form and  where the shareholder is a corporation  a certified copy of a certificate of registration  constitutive documents or similar document evidencing the signatory right of the officer signing the proxy form  must be submitted to each shareholder‚Äôs respective custodian / nominee as soon as possible. Custodians / nominees will in turn be required to deliver shareholders‚Äô proxy data to Clearstream as soon as possible  within any applicable deadline  which data must be delivered in terms of Clearstream‚Äôs existing procedures.Shareholders are  therefore  encouraged to send or deliver their proxy forms (and  if applicable certified copies of certificates of registration or similar) as soon as possible.Notice for the Malta Stock Exchange (as issuer CSD): Aggregated attendance notifications and proxy data processed by and received from Clearstream must be sent by the Malta Stock Exchange to the Company by email at agm@multitude.com not less than 48 hours before the time appointed for the Meeting and in default shall not be treated as valid.3.5 Right to ask questionsEach shareholder (or proxy holder) shall have the right to ask questions which are pertinent and related to items on the agenda of the Meeting to the Company by e-mail to agm@multitude.com by not later than 29 August 2024 by 21:59 (UTC) (23:59 (CEST)).An answer to a question will not be given in those cases specified in article 70 of the Articles (a copy of which is available on the Company‚Äôs website).3.6 Other informationAs at the date of this notice the total number of shares in Multitude SE is 21 723 960 and each of these shares carries one vote. Multitude SE holds 154 993 of its own shares as treasury shares. Pursuant to article 109 of the Maltese Companies Act  those shares which the Company holds in itself do not carry voting rights. Accordingly  the number of voting rights carried by the outstanding shares is 21 568 967.Please refer to the document titled ‚ÄòPrivacy Notice ‚Äì Extraordinary General Meeting 2024‚Äô available at www.multitude.com for additional information on the processing of personal data. Kindly also refer to Clearstream‚Äôs Notice of European Union Data Protection Terms which sets out how sets out how personal data is used  stored  transferred or otherwise processed by Clearstream (https://www.clearstream.com/clearstream-en/about-clearstream/due-diligence/gdpr/dataprotection).‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚Äì‚ÄìIn Malta on 14 August 2024MULTITUDE SEThe Board of DirectorsAPPENDICESComparative Table Swiss Articles of Association (Swiss law)About Multitude SE:Multitude is a listed European FinTech company  offering digital lending and online banking services consumers  small and medium-sized businesses  and other FinTechs overlooked by traditional banks. The services are provided through three independent business units  which are served by our internal Banking- as-a-Service Growth Platform. Multitude‚Äôs business units are consumer banking (Ferratum)  SME banking (CapitalBox) and wholesale banking (Multitude Bank). Multitude Group employs over 700 people in 25 countries and offers services in 16 countries  achieving a combined turnover of 230 million euros in 2023. Multitude was founded in Finland in 2005 and is listed on the Prime Standard segment of the Frankfurt Stock Exchange under the symbol 'E4I'. www.multitude.com",neutral,0.01,0.93,0.06,negative,0.02,0.24,0.74,True,English,"['EXTRAORDINARY GENERAL MEETING', 'MULTITUDE SE', 'NOTICE', 'Swiss financial markets regulatory obstacles', 'Swiss International Private Law Act', 'Maltese public limited liability company', 'ST Business Centre', 'Swiss corporate law', 'Revised M&A', 'wider relocation project', 'new registered office', 'EXTRAORDINARY GENERAL MEETING', 'Malta Business Registry', 'Maltese law', 'The Strand Gzira', 'Swiss law', 'Special business', 'extraordinary resolutions', 'Swiss Articles', 'registered seat', 'Key word', 'additional features', 'English language', 'one (1) shareholder', 'successful implementation', 'societas europaea', 'Companies Regulations', 'Subsidiary Legislation', 'reasonable assessment', 'Commercial Register', 'unbestimmte Dauer', 'Schweizerischen Obligationenrechts', 'corporate name', 'Multitude SE', 'Multitude AG', 'Multitude Ltd', 'Multitude SA', 'following matters', 'minority shareholders', 'Comparative Table', 'Canton Zug', 'relevant provisions', 'Company name', '08:00 a', '1 MATTERS', 'EQS-News', 'AGM/EGM', 'NOTICE', '10:00 CET', 'CEST', 'issuer', 'content', 'announcement', 'GZR', '5 September', 'Instructions', 'participation', 'section', 'person', 'AGENDA', 'Opening', 'appointment', 'chairman', 'terms', 'association', 'Quorum', 'proxy', 'Approval', 'Redomiciliation', 'Switzerland', 'completion', 'Conversion', 'Board', '21 August', 'process', 'accordance', 'Continuation', 'laws', 'advice', 'registration', 'continuity', 'property', 'assets', 'rights', 'liabilities', 'obligations', 'regard', 'benefit', 'effect', 'domicile', 'Change', 'City', 'translations', 'result', 'account', 'transfer', '1. Firma', 'Sitz', 'Aktiengesellschaft', 'Art. 620']",2024-08-14,2024-08-14,finanzwire.com
44615,Deutsche Boerse,NewsApi.org,https://techreport.com/crypto-news/kfw-prepares-to-issue-new-blockchain-based-bond-part-of-ecb-trials/,German Banking Giant KfW and BSD Prepares To Issue New Blockchain-Based Bond As Part of ECB‚Äôs Trials,German banking giants KfW and the Deutsche Bundesbank are exploring crypto as part of the ECB‚Äôs tests for leveraging blockchain technology to manage central bank funds. KfW will soon launch...The post German Banking Giant KfW and BSD Prepares To Issue New Bl‚Ä¶,Why Trust Tech Report Tech Report is one of the oldest hardware  news  and tech review sites on the internet. We write helpful technology guides  unbiased product reviews  and report on the latest tech and crypto news. We maintain editorial independence and consider content quality and factual accuracy to be non-negotiable.The European Central Bank (ECB) is testing blockchain technology‚Äôs ability to manage central bank funds .The European Central Bank (ECB) is testing . As part of the initiative  Kreditanstalt f√ºr Wiederaufbau (KfW) is launching a blockchain-based digital bond in partnership with Boerse Stuttgart Digital (BSD)  an infrastructure provider.As part of the initiative  Kreditanstalt f√ºr Wiederaufbau (KfW) is in partnership with Boerse Stuttgart Digital (BSD)  an infrastructure provider. Additionally  the Deutsche Bundesbank is merging blockchain technology and central banking to enhance the traditional financial system‚Äôs transaction speed and security.Additionally  the to enhance the traditional financial system‚Äôs transaction speed and security. Each of these blockchain ventures signifies Germany‚Äôs move to become a hub for innovative financial solutions.German banking giants KfW and the Deutsche Bundesbank are exploring crypto as part of the ECB‚Äôs tests for leveraging blockchain technology to manage central bank funds.KfW will soon launch a blockchain-powered digital bond (a crypto security)  while Deutsche Bundesbank is exploring how blockchain technology can enhance transaction speed and security.Let‚Äôs explore what joining the blockchain movement means for traditional finance entities.Leading German Entities Back KfW‚Äôs Blockchain BondsCashlink Technologies GmbH is the crypto securities registrar for KfW‚Äôs blockchain-based digital bond. Boerse Stuttgart Digital (BSD) will manage and safeguard the private keys and digital wallets under the Electronic Securities Act (eWpG).eWpG facilitates the modernization and digitalization of securities in Germany  enabling the trading and issuance of securities without a physical certificate through blockchain technology‚Äôs transparency.There are several benefits to KfW and BSD‚Äôs bond partnership:Ensures compliance : Financial regulations and central bank oversight enhance investor confidence in blockchain assets.: Financial regulations and central bank oversight enhance investor confidence in blockchain assets. Safeguards transactions : BSD overseeing the crypto wallets and private keys mitigates the risk of crypto fraud during bond issuance and redemption.: BSD overseeing the crypto wallets and private keys mitigates the risk of crypto fraud during bond issuance and redemption. Enhances efficiency : Blockchain technology reduces transaction times and minimizes delays compared to traditional financial bonds.: Blockchain technology reduces transaction times and minimizes delays compared to traditional financial bonds. Drives innovation: Bond issuance boosts technological advancements in Germany and across Europe.Notably  KfW introduced Germany‚Äôs first blockchain bond in 2024 ‚Äì a ‚Ç¨100M Polygon-based crypto security with a 3.125% yield that expires on December 10  2025.Leading German banks Deutsche Bank  LBBW  DZ Bank  and Bankhaus Metzler were the bond‚Äôs bookrunning consortium. They helped ensure the rest of Germany‚Äôs banking system got involved.Other ECB Blockchain-Powered TestsAs part of the ECB‚Äôs blockchain technology trials for settling centralized financial transactions  the Deutsche Bundesbank created a new system dubbed the ‚ÄòTrigger Solution.‚ÄôThe Trigger Solution connects blockchain platforms with existing Eurozone payment systems  making transactions faster and more secure.Initially  it was developed by the Finance Agency and Deutsche B√∂rse. However  it has since migrated to TARGET2 and T2 infrastructure.Verdict ‚Äì Blockchain May Enhance Germany‚Äôs Financial SystemsBoth the KfW and BSD  and Deutsche Bundesbank‚Äôs blockchain initiatives signify the next step in uniting traditional financial systems with the blockchain.By leveraging blockchain technology  Germany may become a hub for innovative financial solutions and technological talent.If the tests are successful  decentralized technology will likely be integrated into more financial systems under the ECB.ReferencesDisclaimer: The opinions expressed in this article do not constitute financial advice. We encourage readers to conduct their own research and determine their own risk tolerance before making any financial decisions. Cryptocurrency is a highly volatile  high-risk asset class.üîéLooking for the next 10X crypto?Check out the best crypto presales to invest now,neutral,0.0,1.0,0.0,mixed,0.31,0.36,0.34,True,English,"['German Banking Giant KfW', 'New Blockchain-Based Bond', 'BSD', 'Part', 'ECB', 'Trials', 'Trust Tech Report Tech Report', 'volatile, high-risk asset class', 'existing Eurozone payment systems', 'The European Central Bank', '‚Ç¨100M Polygon-based crypto security', 'Other ECB Blockchain-Powered Tests', 'tech review sites', 'central bank funds', 'central bank oversight', 'unbiased product reviews', 'Leading German Entities', 'Cashlink Technologies GmbH', 'Leading German banks', 'Boerse Stuttgart Digital', 'blockchain-powered digital bond', 'The Trigger Solution', 'innovative financial solutions', 'traditional finance entities', 'best crypto presales', 'German banking giants', 'traditional financial systems', 'traditional financial bonds', 'blockchain-based digital bond', 'helpful technology guides', 'Deutsche B√∂rse', 'Electronic Securities Act', 'next 10X crypto', 'centralized financial transactions', 'crypto securities registrar', 'first blockchain bond', 'blockchain technology trials', 'latest tech', 'central banking', 'Deutsche Bank', 'DZ Bank', 'digital wallets', 'banking system', 'Blockchain Bonds', 'Financial regulations', 'financial advice', 'financial decisions', 'new system', 'Finance Agency', 'next step', 'crypto wallets', 'crypto fraud', 'decentralized technology', 'Deutsche Bundesbank', 'bond issuance', 'editorial independence', 'content quality', 'factual accuracy', 'infrastructure provider', 'transaction speed', 'blockchain ventures', 'blockchain movement', 'private keys', 'physical certificate', 'several benefits', 'investor confidence', 'blockchain assets', 'Safeguards transactions', 'transaction times', 'technological advancements', 'Bankhaus Metzler', 'bookrunning consortium', 'blockchain platforms', 'T2 infrastructure', 'blockchain initiatives', 'technological talent', 'References Disclaimer', 'crypto news', 'bond partnership', 'risk tolerance', 'internet', 'ability', 'Kreditanstalt', 'Wiederaufbau', 'KfW', 'BSD', 'Germany', 'hub', 'eWpG', 'modernization', 'digitalization', 'trading', 'transparency', 'compliance', 'redemption', 'efficiency', 'delays', 'innovation', '3.125% yield', 'December', 'LBBW', 'rest', 'TARGET2', 'Verdict', 'opinions', 'article', 'readers', 'research', 'Cryptocurrency']",2024-08-13,2024-08-14,techreport.com
44616,Deutsche Boerse,Bing API,https://news.europawire.eu/eckert-ziegler-and-telix-partner-to-support-phase-iii-prostate-cancer-study-with-advanced-radiopharmaceutical-manufacturing/eu-press-release/2024/08/14/09/39/54/138841/,Eckert & Ziegler and Telix Partner to Support Phase III Prostate Cancer Study with Advanced Radiopharmaceutical Manufacturing,Eckert & Ziegler has signed a multi-year agreement with Telix Pharmaceuticals to serve as the European contract manufacturing organization fo,(IN BRIEF) Eckert & Ziegler has signed a multi-year agreement with Telix Pharmaceuticals to serve as the European contract manufacturing organization for Telix‚Äôs ProstACT GLOBAL Phase III study. The agreement includes supplying patients from Eckert & Ziegler‚Äôs Berlin facility and providing high-purity GMP-grade Lutetium-177. The partnership aims to advance Telix‚Äôs research on PSMA-positive prostate cancer  furthering both companies‚Äô contributions to the radiopharmaceutical field.(PRESS RELEASE) BERLIN  14-Aug-2024 ‚Äî /EuropaWire/ ‚Äî Eckert & Ziegler and Telix Pharmaceuticals Limited (Telix) have announced a significant multi-year agreement in which Eckert & Ziegler will act as the European contract manufacturing organization (CMO) for Telix‚Äôs ProstACT GLOBAL Phase III study. Under this agreement  Eckert & Ziegler will supply all European patients involved in the study from their advanced manufacturing facility in Berlin. Additionally  the company will provide the essential starting material  high-purity  non-carrier added GMP-grade Lutetium-177 (Lu-177)  crucial for the study.Telix‚Äôs ProstACT GLOBAL study focuses on evaluating the benefits and risks of Lutetium (Lu 177) rosopatamab tetraxetan  a radio-labeled antibody drug conjugate (rADC)  in adult men with prostate-specific membrane antigen (PSMA) positive prostate cancer  in combination with standard care treatments.Dr. Harald Hasselmann  CEO of Eckert & Ziegler SE  expressed enthusiasm about the partnership: ‚ÄúWe are pleased to expand our long-standing and successful collaboration with Telix. This contract highlights the significance of our state-of-the-art facility in Berlin and reinforces our position as a key service provider in the rapidly growing radiopharmaceutical market.‚ÄùDarren Patti  Group Chief Operating Officer of Telix  added: ‚ÄúEckert & Ziegler‚Äôs exceptional expertise and the quality of their facilities were key factors in our decision to partner with them. We believe that this continued strategic partnership will play a significant role in the success of our ProstACT GLOBAL study.‚ÄùThis collaboration marks a pivotal advancement in the ongoing efforts of both companies to drive innovation in the radiopharmaceutical sector. Eckert & Ziegler operates multiple CMO sites globally and provides a comprehensive range of services across the entire value chain.About Eckert & ZieglerEckert & Ziegler SE  with more than 1 000 employees  is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry  from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche B√∂rse. Contributing to saving lives.Media Contact:Robert-R√∂ssle-Str. 1013125 Berlin  GermanyJan Sch√∂pflinMarketingKarolin RiehleInvestor Relationsjan.schoepflin@ezag.de / karolin.riehle@ezag.deTel.: +49 (0) 30 / 94 10 84-138www.ezag.comSOURCE: Eckert & Ziegler SE,neutral,0.0,1.0,0.0,positive,0.92,0.08,0.0,True,English,"['Phase III Prostate Cancer Study', 'Advanced Radiopharmaceutical Manufacturing', 'Telix Partner', 'Eckert', 'Ziegler', 'ProstACT GLOBAL Phase III study', 'radio-labeled antibody drug conjugate', 'Group Chief Operating Officer', 'Jan Sch√∂pflin Marketing', 'PSMA) positive prostate cancer', 'European contract manufacturing organization', 'ProstACT GLOBAL study', 'PSMA-positive prostate cancer', 'Investor Relations jan', 'essential starting material', 'prostate-specific membrane antigen', 'standard care treatments', 'Dr. Harald Hasselmann', 'entire value chain', 'early development work', 'Deutsche B√∂rse', 'key service provider', 'growing radiopharmaceutical market', 'advanced manufacturing facility', 'Lu 177) rosopatamab tetraxetan', 'multiple CMO sites', 'high-purity GMP-grade Lutetium', 'Telix Pharmaceuticals Limited', 'significant multi-year agreement', 'European patients', 'key factors', 'significant role', 'radiopharmaceutical field', 'radiopharmaceutical sector', 'radiopharmaceutical industry', 'IN BRIEF', 'PRESS RELEASE', 'adult men', 'Darren Patti', 'exceptional expertise', 'pivotal advancement', 'ongoing efforts', 'comprehensive range', 'leading specialist', 'isotope-related components', 'nuclear medicine', 'radiation therapy', 'broad range', 'TecDAX index', 'Media Contact', 'Robert-R√∂ssle-Str.', 'Karolin Riehle', 'karolin.riehle', 'companies‚Äô contributions', 'successful collaboration', 'Ziegler SE', 'strategic partnership', 'Ziegler shares', 'Berlin facility', 'Telix.', '13125 Berlin', 'Eckert', 'research', 'company', 'carrier', 'benefits', 'risks', 'rADC', 'combination', 'CEO', 'enthusiasm', 'long-standing', 'significance', 'position', 'rapidly', 'quality', 'facilities', 'decision', 'innovation', 'services', '1,000 employees', 'products', 'distribution', 'ISIN', 'lives', 'Germany', 'schoepflin', 'ezag', 'Tel.', 'SOURCE', '49']",2024-08-14,2024-08-14,news.europawire.eu
44617,Deutsche Boerse,Bing API,https://www.moneyweb.co.za/mny_sens/deutsche-konsum-reit-ag-dkr-reports-solid-operational-business-performance-in-the-first-nine-months-of-the-2023-2024-financial-year/,DEUTSCHE KONSUM REIT-AG ‚Äì DKR reports solid operational business performance in the first nine months of the 2023/2024 financial year,At the end of June 2024  DKR successfully issued two registered bonds in exchange for three corporate bonds it had previously issued  with a total volume of EUR 145.9 million. This transaction extends the maturity of these financial liabilities until 30 September 2025.,At the end of June 2024  DKR successfully issued two registered bonds in exchange for three corporate bonds it had previously issued  with a total volume of EUR 145.9 million. This transaction extends the maturity of these financial liabilities until 30 September 2025.,neutral,0.04,0.96,0.0,neutral,0.08,0.92,0.0,True,English,"['solid operational business performance', 'DEUTSCHE KONSUM REIT-AG', 'first nine months', '2023/2024 financial year', 'DKR', 'two registered bonds', 'three corporate bonds', 'total volume', 'financial liabilities', 'end', 'June', 'DKR', 'exchange', 'transaction', 'maturity', '30 September']",2024-08-14,2024-08-14,moneyweb.co.za
44618,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/08/13/2929484/0/en/EVS-reports-first-half-2024-results.html,EVS reports first half 2024 results,Publication on August 13  2024 at 18:30 CEST after market closingRegulated / Inside informationEVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR)  Bloomberg (EVS BB)  Reuters (EVSB.BR),Publication on August 13  2024 at 18:30 CEST after market closingRegulated / Inside informationEVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR)  Bloomberg (EVS BB)  Reuters (EVSB.BR)EVS reports first half 2024 resultsLi√®ge  Belgium  August 13th  2024 ‚Äì Today EVS (Euronext Brussels: EVS.BR; Bloomberg: EVS BB; Reuters: EVSB.BR) announced results for the six-month period ended 30 June 20241.Half year results confirm profitable growth ambition for 2024The financial performance of the first semester of 2024 confirms the growth track set out by EVS.First half financial performance highlightsOrder intake of EUR 87.0 million  including EUR 7.8 million for 2024 Big Event Rental  demonstrating a growth of 7.1%. The overall pipeline for the year is strong (+44%)  supporting growth of order intake at full year level  securing long-term growth perspectives.Revenue in the first six months of the year amounts to EUR 98.1 million  growing +12.2% YoY  including EUR 4.5 million Big Event Rental revenue.Gross margin performance remains strong at 71.9%  partly influenced by a change in accounting treatment of internal assets (+1.2Pts vs. 1H23 post adjustment).Net profit amounts to EUR 21.8 million  leading to a diluted earnings per share of EUR 1.54 (an improvement of EUR 0.02 compared to 1H23 results).OutlookThe secured revenue for 2024 is at EUR 172.2 million at the end of June  providing a solid base to confirm our growth ambition for the year 2024. Out of this total secured revenue number  EUR 14.4 million is linked to Big Event Rental revenue.Based on the secured revenue for 2024 and the solid pipeline  but also taking into account the M&A transaction signed  the revenue guidance is increased from an initial range of EUR 180-195 million to EUR 190-200 million.The long-term order book - beyond 2024 - is growing to EUR 67.6 million  an increase of EUR 14.9 million compared to the beginning of the year 2024.The full-year EBIT guidance is increased from the initial range of EUR 38-45 million to EUR 40-46 million.Overall pipeline is strong  growing by 44% compared to last year  and confirms our ability to capture further growth in order intake in 2H24 as to prepare the year 2025.Key figuresEUR millions  except earnings per share expressed in EUR 1H24 1H23 1H23 Variance Reviewed Reviewed Adjusted (1) Revenue 98.1 87.4 87.4 10.7 Gross profit 70.6 61.2 61.8 8.8 Gross margin % 71.9% 70.1% 70.7% +1.2 Pts Operating profit ‚Äì EBIT 23.9 25.0 25.0 -1.1 Operating margin ‚Äì EBIT % 24.3% 28.6% 28.6% -4.3 Pts Net profit (Group share) 21.8 21.2 21.2 0.6 Fully diluted earnings per share (Group share) 1.54 1.52 1.52 0.02(1) Retrospective adjustment related to the change in accounting policy on the presentation of materials produced for internal purposes from inventory to other tangible assets  to allow comparability with 1H24. See additional details in the Half-Year Financial ReportCommentsSerge Van Herck  CEO  comments:‚ÄúI am proud to announce that 1H24 has marked a new milestone for EVS  with revenues reaching a newhigh of EUR 98.1 million. Our net profit has further grown to EUR 21.8 million  reflecting the continued success and execution of our PlayForward strategy that focuses on profitable and sustainable growth. Positive customer feedback on our latest solution launches like VIA MAP  has significantly contributed to the expansion of our total pipeline  reinforcing our confidence in achieving yet another record-breaking year.A notable highlight of this period is our successful support of key customers in delivering major sporting events earlier this year in Europe  contributing close to EUR 4.5 million to our Big Event Rental business. This achievement underscores our capability to handle large-scale  high-profile projects and further solidifies our reputation in the live production industry. Additionally  we are proud to announce the successful support and live production of another major international sporting event in Europe during this summer viewed by billions of people around the world  which will further boost our Big Event Rental business in the second half of the year.Our growth in H1 has been primarily driven by the expansion of our Live Audience Business and Big Event Rental. We are also pleased to see strong revenue growth in two of our main markets  EMEA and NALA  which continue to drive our overall business expansion.Furthermore  our Generative AI solutions  such as XtraMotion  are being increasingly utilized to enhance the emotional impact of slow-motion replays. These advanced solutions allow any type of broadcast camera to generate high-quality slow-motion footage  adding a new dimension to the viewing experience.Our operational costs remain under control and are mainly increasing due to inflation  the expansion of our teams  and the depreciation of the capex investments we made over the past two years to develop our VIA MAP solution. We are committed to maintaining a balanced approach to cost management while continuing to invest in key areas that drive our growth. While we are optimistic about our long-term prospects  we recognize the importance of being prudent in our financial and operational planning. Our focus remains on profitable and sustainable growth  ensuring operational efficiency  and maintaining a strong balance sheet to weather any potential disruptions.This remarkable performance would not have been possible without the unwavering support of our customers  the dedication of our team members  the crucial contributions of our channel partners  and the expertise of EVS operators around the world. Each of these actors plays a vital role in our success.Our recent announcement of the acquisition of MOG Technologies and our investment in Tinkerlist  will help us to further expand and support our future revenue ambitions.Given our robust performance in the first half  we are confident that we will deliver a new revenue record this year. Consequently  we are increasing our revenue guidance for 2024 to a range of EUR 190 million to EUR 200 million. This optimistic outlook is a testament to the collective effort and commitment of everyone involved in our journey.‚ÄùCommenting on the results and the outlook  Veerle De Wit  CFO  said:‚ÄúThe results of the 1st half of 2024 continue to underpin our growth trajectory. We confirm our continued growth track and this is reflected in our upgraded guidance.We continue to optimize our financial discipline by enhancing the transparency of our reporting. We have implemented new ways of working  that will improve the comparison of our financial data. In this context  we have implemented a new accounting treatment to follow up on our internal assets and are improving our reporting when it comes to project revenue (see further comments).Our gross profit evolution continues to be balanced  with nearly all solutions gaining ground in terms of profitability  demonstrating our ability to balance price increases  taking into account macro-economic challenges.Our costs demonstrate a growing pattern  but are well controlled: we keep monitoring the balance of a company with growing needs and profitability. Our growing cost base is primarily invested in additional team members to ensure we capture the opportunities we see in the market. Our cost base is also influenced by the depreciation of past intangibles (IAS38)  whilst we are closely monitoring the return of these investments. After the official commercial launch of the VIA-MAP on July 1st of 2024  we are currently deploying the first on-air installations of this new solution. We also identified multiple strategic must win opportunities  that we will be working on over the next few months.We have started the development of one new intangible project  with a limited impact in 1H24 of EUR 0.5 million  linked to evolution of technology foundations balancing HW with SW capabilities.Finally  our balance sheet remains strong with a very solid cash position and open receivables that demonstrate a very sound composure in terms of current versus aged receivables.All these promising results lead to an upgrade of our guidance both in revenue and EBIT: the revenue guidance is set at EUR 190-200 million with an associated EBIT guidance of EUR 40-46 million. The acquisition of MOG technology is expected to contribute to our revenue performance in 4Q24 for approximately EUR 0.9 million  with a neutral contribution at EBIT level.‚ÄùTechnologyEVS continues to further develop its 3 solutions (LiveCeption  MediaCeption and MediaInfra) with continuous improvements in terms of production efficiency and flexibility.Beyond XTRAMOTION  EVS will present at IBC new AI based effects that will be integrated as part of LiveCeption workflows. Thanks to these effects (cinematic & zoom)  the Live Service Providers and the Live Audience Business customers will enhance the images from any camera.VIA-MAP is bridging the gap between production and distribution: the workflows become more efficient and can be more automated. MediaHub benefits from new advanced search capabilities for the right-holders to retrieve faster the content they are looking for  allowing optimal monetization of their content.MediaInfra proposes new capabilities in the form of Neuron View and Neuron Bridge to increase the level of flexibility. Thanks to a new Cerebrum module dedicated to resource management  customers can better and dynamically manage their resources as part of the workflows  again improving the overall efficiency.The new pricing model supported by XT-VIA makes the replay server more relevant for budget productions at the same time allowing full flexibility to use different tiers of the same product later for a premium production.Corporate topicsEarlier in August  EVS announced two transactions that will strengthen the EVS solutions:acquisition of 100% of the shares of MOG Technologies ‚Äì a Portugal based company with around 50 highly skilled team members - renowned for its cloud and SW digital media and video production tools. Thanks to this acquisition  EVS will strengthen MediaCeption and MediaHub solutions. EVS will also have access to a pool of highly skilled talent and experts in the industry. The transaction closing still requires formal confirmations in the coming months  and the expected close date is set for 4Q24. MOG Technologies is expected to contribute to our revenue performance in 4Q24.acquisition of a minority stake position in the Belgian Company TinkerList  a leading innovator in the media production industry  having developed Cuez ‚Äì the World‚Äôs First Cloud-Based Rundown Management System ‚Äì as a cutting-edge web application and automation system designed to connect seamlessly with a wide variety of production devices. TinkerList products will be enhancing the EVS Flexible Control Room and MediaCeption solutions through a strategic partnership in addition to the M&A transaction.Beyond these M&A transactions  EVS continues to broaden the number of technology partners in its ecosystem to either ensure interoperability with 3rd-party systems or to include new capabilities in its solutions to simplify the operation of the ever more complex content factories.EVS initiated a new evolution of its HW technology foundations for mid-term smooth evolutions of its products and solutions as a new IAS-38 intangible asset project.Supply chain of electronic components remains a point of attention for the company  though the market is gradually stabilizing  considering the evolutions of the economy and the current geo-political tensions.During the first part of the year  many EVS team members have been involved in various kinds of support (development of cutting-edge features  integration of 3rd-party systems  Quality Assurance  project management  local support  etc‚Ä¶) of the major summer events  helping the host broadcasters to broadcast the best images  continuously creating return on emotion.In terms of governance  the leadership team has evolved with strategic promotions for Quentin Grutman and Nicolas Bourdon and the nomination of Oscar Teran  the 3 of them bringing a wealth of experience and deep understanding of our industry to deliver cutting-edge solutions and exceptional service to our global customer base. The rational for the evolution of the leadership team is to allow specific focus on strategic customer relationships  whilst driving global sales and marketing  and advancing product innovation.Ecovadis  a renowned provider of business sustainability ratings  has granted EVS a Silver medal in acknowledgment of its top sustainability performance for the year 2023.First half revenueRevenue reached EUR 98.1 million in 1H24  representing an increase of EUR 10.7 million or 12.2% compared to 1H23.The impact of exchange rate conversions was minimal  resulting in a growth of revenue at constant currency of 12.2% YoY. Taking out the seasonal impact of the Big Event Rental  the growth of 1H24 was of 7.2%.Revenue ‚Äì EUR millions 1H24 1H23 Variance Total reported 98.1 87.4 12.2% Total at constant currency 98.1 87.4 12.2% Total at constant currency and excluding Big Event Rentals 93.6 87.3 7.2%Currency fluctuations primarily impact EVS revenues by the EUR/USD conversion  which can have a significant impact on our results even if EUR/USD fluctuations also impact the cost of our US operations and partially our cost of goods sold.In the first half of the year  excluding Big Event Rentals  LSP represented 48% of the revenue (56% in 1H23) and LAB 52% (44% in 1H23). The trend demonstrated by this performance is reflecting the long-term growth patterns laid out in our PLAYForward strategic plan.Geographically  revenues are distributed as follows in 1H24 (excl. Big Event Rentals):Europe  Middle East and Africa (EMEA): EUR 49.2 million (EUR 41.8 million in 1H23)  growing 17.7% and reconfirming the strong growth in the region.EUR 49.2 million (EUR 41.8 million in 1H23)  growing 17.7% and reconfirming the strong growth in the region. Americas (NALA): EUR 34.1 million (EUR 28.6 million in 1H23)  growing 19.2% continuing the strong performance since multiple quarters.EUR 34.1 million (EUR 28.6 million in 1H23)  growing 19.2% continuing the strong performance since multiple quarters. Asia & Pacific (APAC): EUR 10.3 million (EUR 17.0 million in 1H23)  decreasing -39.4%  impacted by the timing for the completion of major customers projects in the Region (large order delivered in 1H23 vs. similar project expected to be delivered in 2H24).First half earningsConsolidated gross margin was 71.9% for 1H24  compared to 70.7% in 1H23. This increase is a combination of changes in the presentation of certain elements  which were previously included in our inventory and are now classified as other tangible assets  an overall improvement in our Bill Of Material cost and the fact that 2024 is a Big events rental year  which has a positive impact on our consolidated gross margin.Operating expenses increased by 23% YoY as a consequence of investments in resources (+42 FTE on average) made in the past 12 months as well as some transformation projects we are running as a company. All these investments are done to support our long term ambition. In addition to the impact related to team members  the increase in operating expenses is explained by the depreciation of internally developed intangible assets. Furthermore  as 2024 is a Big events rental year  additional expenses are required to support these events and ensure their success.In terms of intangible assets  EVS continues to invest: a new intangible asset project was launched that should fuel our future growth. This investment representsEUR 0.5 million in 1H24. The projected spend is of EUR 5.9 million over a period of 3 years  with planned return on invest as of 2027.The 1H24 EBIT margin remains strong at 24.3%  compared to 28.5% in 1H23: the strong revenue performance is coming with an increased cost base as a result of the hirings done over the past 9 months. The balance remains strong though and is in line with expectations.Financial result in the period amounts to EUR 1.1 million  mainly driven by EUR/USD foreign exchange gains realized and unrealized  interest revenue and valuation gains on short term deposits  and interests on leases to customers  partially offset by interest expenses mainly on office and car leases.Income taxes are at EUR 3.1 million  compared to EUR 3.7 million last year: this decrease is driven by a reduction in current tax expenses linked to the change in the Transfer Pricing profile of our entity in the Netherlands  leading to a decrease in its profit before taxes and current tax provision  and by a reduction in the deferred tax expenses linked to the consumption of the tax latencies from previous years in Belgium over the last 3 years  resulting in a reduced amount of deferred tax assets that can be utilized against future taxable profit compared to the same period last year.The group net profit amounted to EUR 21.8 million in 1H24  compared to EUR 21.2 million in 1H23. Fully diluted earnings per share amounted to EUR 1.54 in 1H24  compared to EUR 1.52 in 1H23.Second half outlookBased on the secured revenue on June 30  2024 at EUR 172.2 million (+8.5% growth compared to EUR 158.7 million last year at the same date)  and based on the strong profit performance  we are confident to achieve our ambitions of profitable growth for the year 2024.The results of the first semester  together with our perspectives for the following months  lead to an upgrade of our revenue guidance from an initial range of EUR 180-195 million towards a range EUR 190-200 million. At the same time  the EBIT range is also reviewed towards EUR 40-46 million (compared to an initial range of EUR 38-45 million)Next to our progress on 2024  we also continue to build the future. In addition to secured revenue for 2024  EVS has secured a long-term order book worth EUR 67.6 million (EUR +14.9 million compared to the situation at the beginning of the year). Our pipeline is also promising  demonstrating a strong growth and allowing us to continue increasing our order intake on the full year basis.GlossaryTerm Definition Secured revenue Revenue already recognized as well as open orders on hand that will be recognized as revenue in the fiscal year. Order book <date> Revenues planned to be recognized after the <date> based on current orders. LAB market pillar LAB ‚Äì Live Audience BusinessRevenue from customers leveraging EVS products and solutions to create content for their own purpose.This market pillar covers the following types of customers: Broadcasters  Stadium  House of Worship  Corporate Media Centers  Sports organizations  Government & institutions  University & Colleges. LSP market pillar LSP ‚Äì Live Service ProvidersRevenue from customers leveraging EVS products and solutions to serve ‚ÄúLAB customers‚ÄùThis market pillar covers the following types of customers: Rental & facilities companies  Production companies  Freelance operators  Technology partners & system integrators buying for their own purpose. BER market pillar BER ‚Äì Big Events RentalRevenue from major non-yearly big events rental.This market pillar covers the following types of customers: host broadcasters for major events. Bill of material cost The bill of material cost includes all components and parts required to produce the revenue. It does not include labor. Days of sales outstanding Days sales outstanding (DSO) is the average number of days it takes a company to receive payment for a sale. Working capital Working capital  also known as net working capital (NWC)  is the difference between a company's current assets‚Äîsuch as cash  accounts receivable/customers' unpaid bills  and inventories of raw materials and finished goods‚Äîand its current liabilities  such as accounts payable and debts.In case of discrepancies between the English and the French Version  the English Version prevails.Conference callEVS will hold a conference call in English tomorrow  August 14th 2024 at 10.00 am CET for financial analysts and institutional investors. Other interested parties may join the call in a listen-only mode. The presentation used during the conference call will be available shortly before the call on the EVS website.Participants must register for the conference using the link provided below. Upon registering  each participant will be provided with Participant Dial In Numbers  Direct Event Passcode and unique Registrant ID.Online registration: https://register.vevent.com/register/BIb5d20e576e17478f9c9f8342c104fde5 Webcast Player URL: https://edge.media-server.com/mmc/p/3hiwaw5vCorporate CalendarNovember 14th   2024: 3Q24 Trading update (post market closing)For more information  please contact:Veerle De Wit  CFO*EVS Broadcast Equipment S.A.  Liege Science Park  13 rue Bois Saint-Jean  B-4102 Seraing  BelgiumTel: +32 4 361 70 04. E-Mail:corpcom@evs.com; www.evs.com* representing a SRLForward Looking StatementsThis press release contains forward-looking statements with respect to the business  financial condition  and results of operations of EVS and its affiliates. These statements are based on the current expectations or beliefs of EVS's management and are subject to a number of risks and uncertainties that could cause actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. These risks and uncertainties relate to changes in technology and market requirements  the company‚Äôs concentration on one industry  decline in demand for the company‚Äôs products and those of its affiliates  inability to timely develop and introduce new technologies  products and applications  and loss of market share and pressure on pricing resulting from competition which could cause the actual results or performance of the company to differ materially from those contemplated in such forward-looking statements. EVS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.About usWe create return on emotionEVS is globally recognized as a leading provider in live video technology for broadcast and new media productions. Spanning the entire production process  EVS solutions are trusted by production teams worldwide to deliver the most gripping live sports images  buzzing entertainment shows and breaking news to billions of viewers every day ‚Äì and in real-time. As we continue to expand our footprint  our dedication to sustainable growth for both our business and the industry is clearly demonstrated though our ESG strategy. This commitment is not only reflected in our results  but also in our high ratings from different agencies.Headquartered in Li√®ge  Belgium  the company has a global presence with offices in Australia  Asia  the Middle East  Europe  North and Latin America  employing over 600 team members and ensuring sales  training and technical support to more than 100 countries.EVS is a public company traded on Euronext Brussels: EVS  ISIN: BE0003820371. EVS is  amongst others  part of the Euronext Tech Leaders and Euronext BEL Mid indices.For more information  please visit www.evs.com.1 Please refer to our Half-Year Financial Report for detailed financials and auditor‚Äôs review reportAttachments,neutral,0.01,0.99,0.01,positive,0.85,0.15,0.0,True,English,"['first half 2024 results', 'EVS', 'EVS Broadcast Equipment S.A', 'First half financial performance highlights', 'EUR 1H24 1H23 1H23 Variance', 'major international sporting event', 'Big Event Rental business', 'Comments Serge Van Herck', 'Big Event Rental revenue', '2024 Big Event Rental', 'M&A transaction', 'major sporting events', 'Half-Year Financial Report', 'first six months', '1H23 post adjustment', 'Live Audience Business', 'Positive customer feedback', 'latest solution launches', 'large-scale, high-profile projects', 'past two years', 'first half 2024 results', 'other tangible assets', 'Generative AI solutions', 'high-quality slow-motion footage', 'Gross margin performance', 'long-term order book', 'live production industry', 'VIA MAP solution', 'long-term growth perspectives', 'full year level', 'overall business expansion', 'full-year EBIT guidance', 'Half year results', 'strong revenue growth', 'profitable growth ambition', '1H23 results', 'broadcast camera', 'first semester', 'second half', 'revenue guidance', 'internal assets', '10.7 Gross profit', 'Operating margin', 'Retrospective adjustment', 'slow-motion replays', 'advanced solutions', 'overall pipeline', 'Order intake', 'revenue number', 'Euronext Brussels', 'EVS.BR', 'EVS BB', 'EVSB.BR', 'Li√®ge', 'Today EVS', 'accounting treatment', 'Net profit', 'solid base', 'solid pipeline', 'initial range', 'Key figures', 'Operating profit', 'accounting policy', 'internal purposes', 'additional details', 'new milestone', 'continued success', 'PlayForward strategy', 'notable highlight', 'successful support', 'key customers', 'main markets', 'emotional impact', 'new dimension', 'viewing experience', 'operational costs', 'capex investments', 'balanced approach', 'cost management', 'key areas', 'growth track', 'sustainable growth', 'diluted earnings', 'last year', 'record-breaking year', 'six-month period', 'total pipeline', 'Group share', 'Publication', 'August', '30 CEST', 'information', 'Bloomberg', 'Reuters', 'Belgium', 'YoY', 'change', 'Pts', 'improvement', 'Outlook', 'end', 'June', 'increase', 'beginning', 'ability', '2H24', 'presentation', 'materials', 'inventory', 'CEO', 'revenues', 'newhigh', 'execution', 'confidence', 'Europe', 'achievement', 'reputation', 'summer', 'billions', 'people', 'world', 'H1', 'EMEA', 'NALA', 'XtraMotion', 'type', 'control', 'inflation', 'teams', 'depreciation', '18']",2024-08-13,2024-08-14,globenewswire.com
44619,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/08/13/2928891/0/en/Unifiedpost-Group-Half-Year-2024-Financial-Results-Webcast-Invitation.html,Unifiedpost Group Half Year 2024 Financial Results Webcast Invitation,La Hulpe  Belgium ‚Äî 13 August 2024  7:00 am. CET ‚Äî Unifiedpost Group SA (Euronext Brussels: UPG) (‚ÄúUnifiedpost  Group‚Äù)  a leading provider of integrated business communications  will host a webcast on Tuesday  27 August 2024  at 11:00 am CET for analysts and‚Ä¶,La Hulpe  Belgium ‚Äî 13 August 2024  7:00 am. CET ‚Äî Unifiedpost Group SA (Euronext Brussels: UPG) (‚ÄúUnifiedpost  Group‚Äù)  a leading provider of integrated business communications  will host a webcast on Tuesday  27 August 2024  at 11:00 am CET for analysts and investors to discuss its financial results for the first half of 2024.To participate  please register using the following link .A registration confirmation email containing a link to access the webcast will be sent to participants upon successful registration.Contact:Alex NicollInvestor RelationsUnifiedpost Groupalex.nicoll@unifiedpost.comAbout Unifiedpost GroupUnifiedpost is a leading cloud-based platform for SME business services built on ‚ÄúDocuments‚Äù  ‚ÄúIdentity‚Äù and ‚ÄúPayments‚Äù. Unifiedpost operates and develops a 100% cloud-based platform for administrative and financial services that allows real-time and seamless connections between Unifiedpost‚Äôs customers  their suppliers  their customers  and other parties along the financial value chain. With its one-stop-shop solutions  Unifiedpost‚Äôs mission is to make administrative and financial processes simple and smart for its customers. For more information about Unifiedpost Group and its offerings  please visit our website: Unifiedpost Group | Global leaders in digital solutionsNoteworthy facts and figures:Established in 2001  with a proven track record2023 group revenue ‚Ç¨191 million1.200+ employeesOffices in 33 countriesDiverse portfolio of clients across a wide variety of industries (banking  leasing  utilities  media  telecommunications  travel  social security service providers  public organisations  etc.) ranging from large internationals to SMEsUnifiedpost Payments  a fully owned subsidiary  is recognised as a payment institution by the National Bank of BelgiumCertified Swift partnerInternational M&A track recordListed on the regulated market of Euronext Brussels  symbol: UPGCautionary note regarding forward-looking statements: The statements contained herein may include prospects  statements of future expectations  opinions  and other forward-looking statements in relation to the expected future performance of Unifiedpost Group and the markets in which it is active. Such forward-looking statements are based on management's current views and assumptions regarding future events. By nature  they involve known and unknown risks  uncertainties  and other factors that appear justified at the time at which they are made but may not turn out to be accurate. Actual results  performance or events may  therefore  differ materially from those expressed or implied in such forward-looking statements. Except as required by applicable law  Unifiedpost Group does not undertake any obligation to update  clarify or correct any forward-looking statements contained in this press release in light of new information  future events or otherwise and disclaims any liability in respect hereto. The reader is cautioned not to place undue reliance on forward-looking statements.Attachment,neutral,0.0,1.0,0.0,negative,0.0,0.13,0.86,True,English,"['Unifiedpost Group Half Year 2024 Financial Results Webcast Invitation', 'Belgium Certified Swift partner International M&A track record', 'Investor Relations Unifiedpost Group alex', 'social security service providers', 'proven track record', 'integrated business communications', 'registration confirmation email', 'SME business services', 'financial value chain', 'leading cloud-based platform', 'Such forward-looking statements', 'Unifiedpost Group SA', 'other forward-looking statements', 'Alex Nicoll', '100% cloud-based platform', 'financial services', 'leading provider', 'successful registration', 'other parties', '2023 group revenue', 'other factors', 'financial results', 'financial processes', 'La Hulpe', 'Euronext Brussels', 'first half', 'seamless connections', 'one-stop-shop solutions', 'Global leaders', 'digital solutions', 'Noteworthy facts', '1.200+ employees', 'Diverse portfolio', 'wide variety', 'public organisations', 'large internationals', 'payment institution', 'National Bank', 'regulated market', 'Cautionary note', 'future expectations', 'current views', 'unknown risks', 'Actual results', 'applicable law', 'press release', 'undue reliance', 'future events', 'following link', 'future performance', 'new information', 'Unifiedpost Payments', '13 August', 'CET', 'UPG', 'webcast', 'Tuesday', 'analysts', 'investors', 'participants', 'Contact', 'Documents', 'Identity', 'administrative', 'real-time', 'customers', 'suppliers', 'mission', 'offerings', 'website', 'figures', 'Offices', '33 countries', 'clients', 'industries', 'banking', 'leasing', 'utilities', 'media', 'telecommunications', 'travel', 'SMEs', 'subsidiary', 'symbol', 'prospects', 'opinions', 'markets', 'management', 'assumptions', 'nature', 'uncertainties', 'obligation', 'light', 'liability', 'respect', 'reader', 'Attachment', '7:00', '11:00', '2024']",2024-08-13,2024-08-14,globenewswire.com
44620,EuroNext,NewsApi.org,https://www.investing.com/news/press-releases/teleperformance-receives-two-top-awards-for-transformation-impact-in-banking-and-financial-services-sector-93CH-3569099,Teleperformance receives two top awards for transformation impact in banking and financial services sector By Investing.com,Teleperformance receives two top awards for transformation impact in banking and financial services sector,"The global leader in digital business services wins top honors for transformational digital CX and operational performanceNEW YORK   Aug. 13  2024 /PRNewswire/ -- Teleperformance   a global leader in digital business services  today announced it received a gold award at the 11th Annual Globee ¬Æ 2024 Awards for Customer Excellence in the 'Achievement in Transformational Impact' category for driving impactful digital transformation for a leading Middle East bank. The award recognizes Teleperformance for its impact in the banking and financial services (BFS) sector.Teleperformance worked with a leading Middle East bank with assets valued at over AED 122 billion to boost the bank's operational efficiencies and enable rapid service expansion. Teleperformance utilized its deep industry expertise to deploy advanced automation to help the bank transform its end-to-end operations  including seamlessly processing everything from opening an account to maintenance requests  and issuing check books and debit cards.Teleperformance also was recognized with the 2024 Frost and Sullivan Best Practices Customer Value Leadership Award in the Asia-Pacific Customer Care Outsourcing industry. The company earned the honor for its valuable and impactful achievements in transforming the customer experience in the banking and finance sector by combining the power of technology with empathy.""In the banking and financial services industry  Teleperformance has clearly demonstrated its capacity and experience by improving the customer experience with the use of robotic process automation  robust data security and artificial intelligence "" noted Michael DeSalles   Principal Analyst at Frost & Sullivan.Teleperformance has decades of industry-focused expertise supporting the banking and financial services sector  including helping banks with their digital transformation. This includes deep expertise supporting banking processes like cross border payments  cards  retail finance  account services and finance and risk mitigation.ABOUT TELEPERFORMANCE GROUPTeleperformance (TEP ‚Äú ISIN: FR0000051807 ‚Äú Reuters: TEPRF.PA - Bloomberg: TEP FP)  is a global leader in digital business services which consistently seeks to blend the best of advanced technology with human empathy to deliver enhanced customer care that is simpler  faster  and safer for the world's biggest brands and their customers. The Group's comprehensive  AI-powered service portfolio ranges from front office customer care to back-office functions  including operations consulting and high-value digital transformation services. It also offers a range of specialized services such as collections  interpreting and localization  visa and consular services  and recruitment process outsourcing services. The teams of multilingual  inspired  and passionate experts and advisors  spread in close to 100 countries  as well as the Group's local presence allows it to be a force of good in supporting communities  clients  and the environment. In 2023  Teleperformance reported consolidated revenue of ‚Ç¨8 345 million ( US$9 billion ) and net profit of ‚Ç¨602 million.Teleperformance shares are traded on the Euronext Paris market  Compartment A  and are eligible for the deferred settlement service. They are included in the following indices:     S&P Europe 350  MSCI Global Standard and Euronext Tech Leaders. In the area of corporate social responsibility  Teleperformance shares are included in the CAC 40 ESG since September 2022   the Euronext Vigeo Euro 120 index since 2015  the MSCI Europe ESG Leaders index since 2019  the FTSE4Good index since 2018 and the S&P Global 1200 ESG index since 2017.For more information: www.teleperformance.com.",neutral,0.23,0.77,0.0,positive,0.73,0.27,0.0,True,English,"['two top awards', 'financial services sector', 'transformation impact', 'Teleperformance', 'banking', 'Investing', 'com', 'Sullivan Best Practices Customer Value Leadership Award', 'comprehensive, AI-powered service portfolio ranges', 'Asia-Pacific Customer Care Outsourcing industry', 'MSCI Europe ESG Leaders index', 'S&P Global 1200 ESG index', '11th Annual Globee ¬Æ 2024 Awards', 'front office customer care', 'Euronext Vigeo Euro 120 index', 'recruitment process outsourcing services', 'leading Middle East bank', 'high-value digital transformation services', 'S&P Europe', 'enhanced customer care', 'Euronext Tech Leaders', 'MSCI Global Standard', 'rapid service expansion', 'deferred settlement service', 'Euronext Paris market', 'financial services industry', 'transformational digital CX', 'robotic process automation', 'robust data security', 'corporate social responsibility', 'digital business services', 'impactful digital transformation', 'deep industry expertise', ""Transformational Impact' category"", 'financial services sector', 'CAC 40 ESG', 'FTSE4Good index', 'Customer Excellence', 'gold award', 'customer experience', 'deep expertise', 'specialized services', 'consular services', 'global leader', 'advanced automation', 'impactful achievements', 'BFS) sector', 'industry-focused expertise', 'account services', 'top honors', 'operational performance', 'NEW YORK', 'operational efficiencies', 'end operations', 'maintenance requests', 'check books', 'finance sector', 'artificial intelligence', 'Michael DeSalles', 'Principal Analyst', 'border payments', 'risk mitigation', 'biggest brands', 'back-office functions', 'operations consulting', 'passionate experts', 'local presence', 'consolidated revenue', 'net profit', 'Compartment A', 'following indices', 'retail finance', 'The Group', 'debit cards', 'TEP FP', 'advanced technology', 'human empathy', 'Teleperformance shares', 'banking processes', 'TELEPERFORMANCE GROUP', 'Aug.', 'PRNewswire', 'assets', 'AED', 'everything', '2024 Frost', 'company', 'valuable', 'capacity', 'decades', 'banks', 'cross', 'ISIN', 'Reuters', 'TEPRF.', 'Bloomberg', 'world', 'customers', 'collections', 'interpreting', 'localization', 'visa', 'teams', 'advisors', 'close', '100 countries', 'force', 'communities', 'clients', 'environment', 'area', 'September', 'information']",2024-08-13,2024-08-14,investing.com
44621,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/08/13/2928923/0/en/Reduction-of-Resources-for-the-Liquidity-Contract-Agreement-with-Rothschild-Martin-Maurel.html,Reduction of Resources for the Liquidity Contract Agreement with Rothschild Martin Maurel,Press release  Reduction of Resources for the Liquidity Contract Agreement with Rothschild Martin Maurel  Paris  France ‚Äì August 13  2024   By means of...,"Press releaseReduction of Resources for the Liquidity Contract Agreement with Rothschild Martin MaurelParis  France ‚Äì August 13  2024By means of a contract dated February 14  2019  ATOS SE (ISIN: FR0000051732) (the ""Company"") entrusted Rothschild Martin Maurel with the implementation of a liquidity contract agreement (the ""Agreement"").This Agreement  with initial resources of 15 million euros  aims at facilitating the trading of ATOS SE shares on the regulated market of Euronext Paris. Following a decrease in the Company‚Äôs market capitalization  the Agreement was amended by an addendum dated August 13  2024  to reduce the resources allocated for the implementation of the Agreement to an amount of 2 million euros  with the requirement to maintain a minimum balance of 500 000 euros in the liquidity account at all times. The other provisions of the Agreement remain unchanged and fully effective.The reduction in resources allocated to the Agreement was carried out in accordance with the provisions of Regulation (EU) No. 596/2014 on market abuse (""MAR Regulation"")  Commission Delegated Regulation (EU) 2016/908 of February 26  2016  supplementing the MAR Regulation with regulatory technical standards on criteria  procedure  and requirements for establishing an accepted market practice and the conditions for its maintenance  removal  or modification  Articles L. 22-10-62 et seq. of the French Commercial Code  and AMF Decision No. 2021-01 of June 22  2021  applicable from July 1  2021.As at August 13  2024  the following resources were available in the liquidity contract account:‚Ä¢ 350 000 Atos shares‚Ä¢ 1 988 441.34 euros***About AtosAtos is a global leader in digital transformation with c. 92 000 employees and annual revenue of c. ‚Ç¨ 11 billion. European number one in cybersecurity  cloud and high-performance computing  the Group provides tailored end-to-end solutions for all industries in 69 countries. A pioneer in decarbonization services and products  Atos is committed to a secure and decarbonized digital for its clients. Atos is a SE (Societas Europaea)  and listed on Euronext Paris .The purpose of Atos is to help design the future of the information space. Its expertise and services support the development of knowledge  education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world  the Group enables its customers and employees  and members of societies at large to live  work and develop sustainably  in a safe and secure information space .ContactsInvestor relations: David Pierre-Kahn | investors@atos.net | +33 6 28 51 45 96Individual shareholders: 0805 65 00 75Press contact: globalprteam@atos.netAttachment",neutral,0.01,0.98,0.01,neutral,0.04,0.95,0.01,True,English,"['Liquidity Contract Agreement', 'Rothschild Martin Maurel', 'Reduction', 'Resources', 'Rothschild Martin Maurel', 'regulatory technical standards', 'French Commercial Code', 'accepted market practice', 'Commission Delegated Regulation', 'liquidity contract account', 'secure information space', 'Liquidity Contract Agreement', 'ATOS SE shares', 'liquidity account', 'regulated market', 'market capitalization', 'market abuse', '350,000 Atos shares', 'Press release', 'minimum balance', 'MAR Regulation', 'AMF Decision', 'global leader', 'digital transformation', 'annual revenue', 'European number', 'high-performance computing', 'end solutions', 'decarbonized digital', 'Societas Europaea', 'multicultural approach', 'technological excellence', 'Investor relations', 'David Pierre-Kahn', 'Individual shareholders', 'Press contact', '15 million euros', 'Euronext Paris', '2 million euros', 'atos.net', 'other provisions', 'decarbonization services', 'initial resources', 'following resources', '500,000 euros', 'Reduction', 'France', 'August', 'means', 'February', 'ISIN', 'Company', 'implementation', 'trading', 'decrease', 'addendum', 'amount', 'requirement', 'times', 'accordance', 'No.', 'criteria', 'procedure', 'conditions', 'maintenance', 'removal', 'modification', 'Articles', 'June', 'July', 'c.', '92,000 employees', 'cybersecurity', 'cloud', 'Group', 'tailored', 'industries', '69 countries', 'pioneer', 'products', 'clients', 'purpose', 'future', 'expertise', 'development', 'knowledge', 'education', 'research', 'scientific', 'world', 'customers', 'members', 'societies', 'large', 'safe', 'Contacts', 'investors', 'globalprteam', 'Attachment']",2024-08-13,2024-08-14,globenewswire.com
44622,EuroNext,NewsApi.org,https://www.hospitalitynet.org/news/4123272.html,Introducing La Dolce Vita Orient Express: Reservations Open For Italy‚Äôs First Luxury Train,"Italy's first luxury train  La Dolce Vita Orient Express  will commence its covetable journeys in Spring of 2025  with bookings now open at orient-express.com. The new all-inclusive train journey provides eight exclusive round-trip ""Made in Italy"" itineraries‚Ä¶","New York  New York - Italy's first luxury train  La Dolce Vita Orient Express  will commence its covetable journeys in Spring of 2025  with bookings now open at orient-express.com. The new all-inclusive train journey provides eight exclusive round-trip ""Made in Italy"" itineraries departing from Rome  highlighting sought-after destinations like Venice  Matera  Tuscany  Piedmont  Portofino  Abruzzo and Sicily. On-board  guests will enjoy dishes created by acclaimed three-Michelin starred Chef Heinz Beck  who will oversee cuisine onboard the rail journeys.Guided by newly-appointed General Manager Samy Ghachem  formerly the managing director at Sereno Hotels and Frosch  marks a partnership between Italian luxury hospitality group Arsenale S.p.A.  Orient Express  and Trenitalia-Gruppo Ferrovie dello Stato  Fondazione DFS and Treni Turistici Italian TTI.It is a privilege to join La Dolce Vita Orient Express at this key period in the revival of the iconic Orient Express brand and the launch of Italy‚Äôs first foray into luxury rail hospitality  stated Ghachem. La Dolce Vita Orient Express is set to offer an inimitable take on luxury rail travel  reigniting a bygone era through a contemporary lens  Italian style.A High-Designed Journey Through TimeDesign concept by Dimorestudio  the train‚Äôs aesthetic has been masterfully curated to communicate the art of Italian living  with a sumptuous interior that celebrates the timeless craftsmanship of the 1960s and 1970s ‚ÄúLa Dolce Vita‚Äù period. On-board  guests will enjoy an intimate travel experience with 12 carriages that host no more than 62 passengers. The train will boast 12 deluxe cabins  18 suites and one La Dolce Vita Suite  all of which combine romance  style  the art of immersive encounters and relaxation  supported by a cruising model for round-trip experiences.Embarking on Eight Exclusive ItinerariesAligning the train‚Äôs beauty with the country‚Äôs natural splendor  the trips cover over 9 941 miles of track  including nearly 4 350 miles of non-electrified railway  spread over 14 regions and 131 cities across Italy.As part of the experience  guests can enjoy thoughtfully-curated and memorable excursions  along with full-board accommodation. Taking in the breadth of the country  the eight itineraries provide journeys into the heart of nature  through its lakes  forests  sumptuous coasts and Alpine mountains  and an immersion into the center of cities that are international hubs of art and culture  from Venice and Rome.The itineraries also offer access to once remote destinations  such as Matera in Basilicata  the third oldest city in the world  with its ancient architecture  caves and stunning natural beauty  and Palena  a beautiful mountainous village in Abruzzo with medieval architecture  scenic views and rich cultural heritage. A remarkable itinerary also includes the world‚Äôs first passenger rail ferry  accessing the island of Sicily  where the train will decouple at Calabria and load onto a ferry  for the experience to resume on water before being reassembled and continuing the tracks in Messina. Beloved and favorite destinations like Tuscany  Portofino and Piedmont are additionally highlighted.The train journeys will include access to the newly established La Dolce Vita Orient Express Executive Lounge at Roma Ostiense for a comfortable and seamless travel experience.A Michelin-starred Culinary Journey-Within-A-JourneyAnnounced in collaboration with Beck & Maltese Consulting  renowned three Michelin-starred chef Heinz Beck will oversee the cuisine onboard the rail cruises. Guests will have the pleasure of experiencing curated menus by this world-renowned chef with a deep connection to Italy. With the ambition of its cuisine to become a recognized part of UNESCO heritage  the train will offer regional and thematic routes  celebrating the culinary diversity of each region traversed during every journey.Curated in partnership with Vinitaly  one of the world‚Äôs largest and most significant international wine and spirits expeditions  wines onboard will showcase a breadth of viticulture from the well-known labels to rare and undiscovered wineries  always synonymous with quality and the uniqueness typical of Italy. During the train adventures  guests can go on a spirited Italian journey through six Vinitaly-selected wine companies that represent north  south and central Italy. This ties into the wider brand goal of fostering associations with local Italian life and celebrating authentic symbols of Italian excellence. This is just one of many exciting brand collaborations to be announced with the purpose of highlighting the very best from each region that the ‚ÄúMade in Italy‚Äù itineraries will visit.La Dolce Vita Orient Express Honors Italian Design with a Modern ApproachLa Dolce Vita Orient Express train marries the golden age of Italian design with a more contemporary spirit of travel. The project takes inspiration from masters of Italian design  including Carlo Scarpa  Gio Ponti  and Ignazio Gardella through to the great artists of the Spatialism movement that put space and time at the center of its compositions  such as Lucio Fontana  Agostino Bonalumi  and Enrico Castellani. The design project was conceived to embody a flawless and understated balance between the historic and contemporary  while still maintaining its authenticity. The spaces are thoughtfully designed  and always well-curated and subtle details complement each other graciously.Guests may reserve directly online by visiting: www.orient-express.com/la-dolce-vita or by contacting their travel agent. Pricing is tailored to travel preferences and departure date. Starting prices referring to a one-night itinerary are EUR3 500 per person in a deluxe cabin and EUR4 700 per person in a suite.The launch of La Dolce Vita Orient Express precedes the anticipated openings of the first two Orient Express hotels: Orient Express La Minerva in Rome; followed by Orient Express Palazzo Don√† Giovannelli in Venice. More information to be announced later in 2024.About Accor  a world-leading hospitality groupAccor is a world leading hospitality group offering experiences across more than 110 countries in 5 600 properties  10 000 food & beverage venues  wellness facilities or flexible workspaces. The Group has one of the industry's most diverse hospitality ecosystems  encompassing more than 45 hotel brands from luxury to economy  as well as Lifestyle with Ennismore. Accor is committed to taking positive action in terms of business ethics & integrity  responsible tourism  sustainable development  community outreach  and diversity & inclusion. Founded in 1967  Accor SA is headquartered in France and publicly listed on Euronext Paris (ISIN code: FR0000120404) and on the OTC Market (Ticker: ACCYY) in the United States. For more information  please visit www.group.accor.com or follow us on X  Facebook  LinkedIn  Instagram and TikTok.Jessaline FynboAccor",neutral,0.02,0.98,0.0,positive,0.84,0.16,0.0,True,English,"['La Dolce Vita Orient Express', 'First Luxury Train', 'Reservations', 'Italy', 'La Dolce Vita Orient Express Executive Lounge', 'renowned three Michelin-starred chef Heinz Beck', 'La Dolce Vita Orient Express train', 'one La Dolce Vita Suite', 'three-Michelin starred Chef Heinz Beck', 'La Dolce Vita‚Äù period', 'iconic Orient Express brand', 'Arsenale S.p.A.', 'Trenitalia-Gruppo Ferrovie dello Stato', 'many exciting brand collaborations', 'six Vinitaly-selected wine companies', 'Treni Turistici Italian TTI', 'General Manager Samy Ghachem', 'Italian luxury hospitality group', 'first passenger rail ferry', 'wider brand goal', 'luxury rail hospitality', 'third oldest city', 'beautiful mountainous village', 'Michelin-starred Culinary Journey', 'significant international wine', 'local Italian life', 'luxury rail travel', 'rich cultural heritage', 'first luxury train', 'eight exclusive round-trip', 'spirited Italian journey', 'intimate travel experience', 'stunning natural beauty', 'seamless travel experience', 'Eight Exclusive Itineraries', 'world-renowned chef', 'key period', 'first foray', 'rail cruises', 'Italian living', 'Italian excellence', 'Italian Design', 'rail journeys', 'round-trip experiences', 'natural splendor', 'international hubs', 'UNESCO heritage', 'culinary diversity', 'eight itineraries', 'Italian style', 'managing director', 'Sereno Hotels', 'Fondazione DFS', 'inimitable take', 'bygone era', 'contemporary lens', 'Design concept', 'sumptuous interior', 'timeless craftsmanship', '12 deluxe cabins', 'immersive encounters', 'cruising model', 'non-electrified railway', 'memorable excursions', 'full-board accommodation', 'sumptuous coasts', 'Alpine mountains', 'ancient architecture', 'medieval architecture', 'scenic views', 'remarkable itinerary', 'Roma Ostiense', 'Maltese Consulting', 'deep connection', 'thematic routes', 'spirits expeditions', 'undiscovered wineries', 'train adventures', 'authentic symbols', 'Modern Approach', 'golden age', 'contemporary spirit', 'Carlo Scarpa', 'Gio Ponti', 'Ignazio Gardella', 'great artists', 'Spatialism movement', 'covetable journeys', 'train journeys', 'New York', 'remote destinations', 'favorite destinations', 'central Italy', 'Italy"" itineraries', 'Spring', 'bookings', 'orient-express', 'Rome', 'Venice', 'Matera', 'Tuscany', 'Piedmont', 'Portofino', 'Abruzzo', 'Sicily', 'guests', 'dishes', 'cuisine', 'Frosch', 'partnership', 'privilege', 'revival', 'launch', 'Dimorestudio', 'aesthetic', '1960s', '1970s', '12 carriages', '62 passengers', '18 suites', 'romance', 'relaxation', 'country', 'trips', '9,941 miles', 'track', '4,350 miles', '14 regions', '131 cities', 'curated', 'breadth', 'heart', 'nature', 'lakes', 'forests', 'immersion', 'center', 'culture', 'access', 'Basilicata', 'caves', 'Palena', 'island', 'Calabria', 'water', 'Messina', 'comfortable', 'pleasure', 'menus', 'ambition', 'regional', 'largest', 'wines', 'labels', 'rare', 'quality', 'uniqueness', 'north', 'south', 'associations', 'purpose', 'Made', 'project', 'inspiration', 'masters']",2024-08-13,2024-08-14,hospitalitynet.org
44623,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/08/13/2929447/0/en/Aramis-Group-Declaration-of-transactions-on-own-shares-conducted-from-August-5-to-August-9-2024.html,Aramis Group - Declaration of transactions on own shares conducted from August 5 to August 9  2024,PRESS RELEASE           Arcueil  August 13  2024           Declaration of transactions on own shares conducted from August 5 to August 9  2024         ...,PRESS RELEASEArcueil  August 13  2024Declaration of transactions on own sharesconducted from August 5 to August 9  2024Within the framework of the authorizations granted by the General Assembly on February 9  2024  to operate on its shares and in accordance with the regulations related to share buybacks  Aramis Group hereby declares the following purchases of own shares (FR0014003U94) made from August 5 toAugust 9  2024 (excluding the liquidity contract):Name of the issuer Issuer identifier code Transaction date Financial instrument identifier code Total daily volume (in number of shares) Daily weighted average purchase price of shares Market Aramis Group 9695002Q984W0T41WB42 2024-08-05 FR0014003U94 2 037 4.4199 XPAR Aramis Group 9695002Q984W0T41WB42 2024-08-06 FR0014003U94 6 414 4.6589 XPAR Aramis Group 9695002Q984W0T41WB42 2024-08-07 FR0014003U94 6 209 4.8312 XPAR Aramis Group 9695002Q984W0T41WB42 2024-08-08 FR0014003U94 6 483 4.9033 XPAR Aramis Group 9695002Q984W0T41WB42 2024-08-09 FR0014003U94 6 095 5.0637 XPAR TOTAL 27 238 4.8291Detailed information regarding these transactions is available on the Aramis Group website at the following address: https://aramis.group/investors/regulated-information/***About Aramis Group ‚Äì www.aramis.groupAramis Group is the European leader for B2C online used car sales and operates in six countries. A growing group  an e-commerce expert and a vehicle refurbishing pioneer  Aramis Group acts each day for more sustainable mobility with an offering that is part of the circular economy. Founded in 2001  it has been revolutionizing its market for over 20 years  focused on ensuring the satisfaction of its customers and capitalizing on digital technology and employee engagement to create value for all its stakeholders. With full-year revenues of ‚Ç¨2 billion  Aramis Group will sell more than 110 000 vehicles B2C this year and welcomes more than 70 million visitors across all its digital platforms each year. The Group employs more than 2 500 people and has eight industrial-scale refurbishing centers throughout Europe. Aramis Group is listed on Euronext Paris Compartment B (Ticker: ARAMI ‚Äì ISIN: FR0014003U94).Investor contactAlexandre LeroyHead of Investor Relations Financing and Cash Managementalexandre.leroy@aramis.group+33 (0)6 58 80 50 24Press contactBrunswickHugues Bo√´tonTristan Roquet Montegonaramisgroup@brunswickgroup.com+33 (0)6 79 99 27 15Attachment,neutral,0.0,1.0,0.0,neutral,0.03,0.97,0.01,True,English,"['Aramis Group', 'Declaration', 'transactions', 'shares', 'August', 'issuer Issuer identifier code Transaction date', 'Daily weighted average purchase price', 'B2C online used car sales', 'Financial instrument identifier code', 'Euronext Paris Compartment B', 'Tristan Roquet Montegon aramisgroup', 'eight industrial-scale refurbishing centers', 'XPAR Aramis Group 9695002Q984W0T41WB42', 'Market Aramis Group 9695002Q984W0T41WB42', 'Total daily volume', 'vehicle refurbishing pioneer', 'Hugues Bo√´ton', 'Cash Management alexandre', 'Aramis Group website', 'XPAR TOTAL', '110,000 vehicles B2C', 'aramis.group', 'growing group', 'The Group', 'PRESS RELEASE', 'General Assembly', 'share buybacks', 'following purchases', 'liquidity contract', 'Detailed information', 'following address', 'European leader', 'six countries', 'e-commerce expert', 'sustainable mobility', 'circular economy', 'digital technology', 'employee engagement', 'full-year revenues', '70 million visitors', 'digital platforms', 'Investor contact', 'Alexandre Leroy', 'Investor Relations', 'Press contact', 'Arcueil', 'Declaration', 'transactions', 'shares', 'August', 'framework', 'authorizations', 'February', 'accordance', 'regulations', 'Name', 'number', 'FR0014003U94', 'investors', 'regulated-information', 'offering', '20 years', 'satisfaction', 'customers', 'value', 'stakeholders', '2,500 people', 'Ticker', 'ISIN', 'Head', 'Financing', 'Brunswick', 'Attachment']",2024-08-13,2024-08-14,globenewswire.com
44624,EuroNext,NewsApi.org,https://www.finextra.com/pressarticle/101887/blik-code-payments-now-available-on-worldline-tap-on-mobile,Blik Code Payments now available on Worldline Tap on Mobile,Worldline (Euronext: WLN)  the global leader in payment services  in continued cooperation with BLIK  one of Poland‚Äôs most popular mobile payment systems  is rolling out for its clients the functionality of BLIK code payment on Worldline Tap on Mobile app.,Worldline (Euronext: WLN)  the global leader in payment services  in continued cooperation with BLIK  one of Poland‚Äôs most popular mobile payment systems  is rolling out for its clients the functionality of BLIK code payment on Worldline Tap on Mobile app.Under the partnership  businesses using Tap on Mobile on their mobile terminals will be able to accept payments with a BLIK code.The launch of BLIK code payments on Tap on Mobile is another step in the development of the app  which offers its users ever more options. Until now  clients were only able to accept BLIK contactless payments on Tap on Mobile. Thanks to the option of BLIK code payments  the number of potential customers who will be able to pay using a BLIK code will go up to 16.3 million.The Tap on Mobile app turns your Android device into a mobile payment terminal that allows acceptance of payments wherever you are. What‚Äôs more  a wide range of cashless payments - contactless BLIK  credit and debit cards  and mobile wallets - can be accepted with the app at no fixed costs and  most importantly  with no additional devices required.Partnership with BLIK brings Worldline one more step closer toward creating a universal solution for mobile payments. Given the rising popularity of BLIK and the planned launch of this service in other European markets  the Tap on Mobile app with the functionality of accepting BLIK payments will be an ideal solution for businesses in other European countries  enabling users to make and accept payments regardless of their location.Artur ≈ªyma≈Ñczyk  Country Manager at Worldline Poland  said: ‚ÄúOur Tap on Mobile app continues to develop  offering its users an ever wider range of payment options. We are pleased to add BLIK code payments to our flagship app  as this will enable us to reach an even larger group of users who would like to make use of quick  convenient and  above all  secure payment transactions that do not require a payment card.‚ÄùAdam Kokoszkiewicz  Sales Director at Polish Payment Standard  operator of BLIK  commented: ‚ÄûWith more than 16.3 million active users  BLIK is one of the most popular mobile payment methods in Poland today and Worldline is the global leader in electronic payments with a strong footprint in Europe. The benefits from our partnership for users are undeniable: easier payments regardless of location. By joining forces  we will spur on the development of the mobile payment market and provide customers with even more convenience in their daily payment transactions.‚Äù,neutral,0.0,1.0,0.0,positive,0.95,0.05,0.0,True,English,"['Blik Code Payments', 'Worldline Tap', 'Mobile', 'popular mobile payment systems', 'popular mobile payment methods', 'other European markets', 'other European countries', 'Artur ≈ªyma≈Ñczyk', 'secure payment transactions', 'Polish Payment Standard', 'daily payment transactions', 'mobile payment terminal', 'mobile payment market', 'BLIK code payment', '16.3 million active users', 'BLIK contactless payments', 'payment services', 'payment card', 'contactless BLIK', 'payment options', 'mobile payments', 'mobile terminals', 'mobile wallets', 'cashless payments', 'BLIK payments', 'electronic payments', 'easier payments', 'global leader', 'continued cooperation', 'Android device', 'wide range', 'debit cards', 'fixed costs', 'additional devices', 'universal solution', 'rising popularity', 'ideal solution', 'Country Manager', 'wider range', 'larger group', 'quick, convenient', 'Adam Kokoszkiewicz', 'Sales Director', 'strong footprint', 'Mobile app', 'flagship app', 'potential customers', 'The Tap', 'Worldline Poland', 'Worldline Tap', 'Euronext', 'WLN', 'clients', 'functionality', 'partnership', 'businesses', 'launch', 'step', 'development', 'number', 'acceptance', 'credit', 'location', 'operator', 'benefits', 'forces', 'convenience']",2024-08-13,2024-08-14,finextra.com
44625,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/08/13/2928900/0/en/BGHL-EUR-NAV-s.html,BGHL (EUR): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED      Ordinary Shares      The Directors of Boussard & Gavaudan...,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 12 Aug 2024.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 28.6669 ¬£ 25.6780 Estimated MTD return -0.01 % 0.03 % Estimated YTD return 4.06 % 4.51 % Estimated ITD return 186.67 % 156.78 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 27.00 N/A Premium/discount to estimated NAV -5.81 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 200.00 Premium/discount to estimated NAV N/A -14.32 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 299 516 123 090 Held in treasury N/A N/A Shares Issued 12 299 516 123 090Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 258.5242 Class GBP A Shares (estimated) ¬£ 137.5699The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,1.0,0.0,mixed,0.14,0.27,0.58,True,English,"['BGHL', 'EUR', 'NAV', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'Euro Shares Sterling Shares', 'A N/A Average Price', 'London Stock Exchange plc', 'Guernsey Financial Services Commission', 'N/A Sterling Shares Amsterdam', 'treasury N/A N/A Shares', 'Dutch Financial Supervision Act', 'US Investment Company Act', 'Euro Shares Amsterdam', 'Sterling Shares Shares', 'A N/A Range', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'investment manager fees', 'BG Fund NAV', 'The Shares', 'N/A GBX', 'A Premium/discount', 'Dutch Authority', 'Emmanuel Gavaudan', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'Aug', 'returns', 'AEX', 'LSE', 'Transactions', 'Number', 'Outstanding', 'respect', 'role', 'LLP.', 'Email', 'bgam', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2024-08-13,2024-08-14,globenewswire.com
44626,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/08/13/2928914/0/en/Appointment-of-Managing-Director.html,Appointment of Managing Director,Kenmare Resources plc (‚ÄúKenmare‚Äù or ‚Äúthe Company‚Äù or ‚Äúthe Group‚Äù)    13 August 2024    Appointment of Managing Director    Kenmare Resources plc...,"Kenmare Resources plc(‚ÄúKenmare‚Äù or ‚Äúthe Company‚Äù or ‚Äúthe Group‚Äù)13 August 2024Appointment of Managing DirectorKenmare Resources plc (LSE:KMR  ISE:KMR)  one of the leading global producers of titanium minerals and zircon  which operates the Moma Titanium Minerals Mine (the ""Mine"" or ""Moma"") in northern Mozambique  is pleased to announce that Tom Hickey  Finance Director  has been appointed as Managing Director  effective 15 August 2024.Tom will continue in his role as an Executive Director on Kenmare‚Äôs Board. He succeeds Michael Carvill  who will step down as Managing Director and from the Board on 14 August 2024  after 38 years in the role.Kenmare will now undertake a limited process to identify Tom‚Äôs successor as Chief Financial Officer. Further updates will be provided in due course.Statement from Andrew Webb  Chairman:‚ÄúAs previously announced  Michael Carvill  Kenmare‚Äôs founder  will be stepping down as Managing Director after almost four decades. Michael‚Äôs vision  energy and commitment have enabled Kenmare to become one of the largest titanium minerals producers in the world and a name respected and admired throughout the industry. I would like to again express our profound gratitude to Michael for his tremendous contribution to the Company and his on-going support as a consultant.To select Michael‚Äôs successor  the Board conducted a rigorous process  including both external candidates and those on our internal succession plan. Following this  Tom Hickey  Kenmare‚Äôs Finance Director  was chosen to be the Company‚Äôs next Managing Director. Tom has extensive experience in finance and natural resources  including as Chief Financial Officer of Tullow Oil plc  which grew to be a FTSE 100 company during his tenure. The Board felt that Tom‚Äôs combination of financial acumen  capital markets experience and knowledge of Kenmare‚Äôs business made him uniquely qualified to lead the Company at this important time and to continue delivering value for all stakeholders. We congratulate Tom on his appointment and wish Michael all the best in his future endeavours.‚ÄùStatement from Tom Hickey  incoming Managing Director:‚ÄúI have greatly enjoyed working with Michael for the past two years and am delighted to be given the opportunity to lead Kenmare during this exciting phase in its development. We are undertaking one of the largest capital projects in the Company‚Äôs history through the upgrade and transition of Wet Concentrator Plant A  which will allow us to secure production from Moma for decades to come and maintain our first quartile position on the industry revenue to cost curve. Michael leaves Kenmare in a very strong financial position  with an outstanding asset  a unique culture and a great team. I am proud to continue his work  particularly in terms of furthering Kenmare‚Äôs commitment to being a trusted corporate citizen.‚ÄùBackground on Tom HickeyTom joined Kenmare in September 2022 as Finance Director. Since then  he has led the refinancing of the Company‚Äôs previous debt facilities with a $200 million Revolving Credit Facility  which provides additional financial flexibility for Kenmare during the upgrade and transition of Wet Concentrator Plant A to Nataka. He has also taken a central role in the negotiations with the Government of Mozambique relating to the renewal of the Company‚Äôs Implementation Agreement  which governs the Industrial Free Zone forming part of the Moma Mine.Tom has 24 years‚Äô experience as an Executive and Non-Executive Director of various public companies  including eight years as Chief Financial Officer of the African and South American-focused oil and gas producer Tullow Oil plc (‚ÄúTullow‚Äù) from 2000 to 2008. During this time  he developed and implemented the financial strategy that saw Tullow grow from a micro-cap company to a FTSE 100 business valued at $15 billion. He was central to the success of major acquisitions and debt and equity fundings  as well as responsible for capital allocation of an annual budget of over $700 million.Tom also held senior financial roles with the oil and gas exploration company Petroceltic International plc between 2010 and 2016  including latterly as Chief Financial Officer.Tom has strong Board-level experience  having previously served as an Independent Non-Executive Director with United Oil & Gas plc and Petroneft Resources plc. Tom has a Bachelor of Commerce degree and a Diploma in Professional Accounting  both from University College Dublin  and he is a Fellow of the Irish Institute of Chartered Accountants.This announcement is made pursuant to UK Listing Rule 6.4.6.For further information  please contact:Kenmare Resources plcJeremy Dibb / Katharine Sutton / Michael StarkeInvestor Relationsir@kenmareresources.comTel: +353 1 671 0411Mob: + 353 87 943 0367 / + 353 87 663 0875Murray (PR advisor)Paul O‚ÄôKanepokane@murraygroup.ieTel: +353 1 498 0300Mob: +353 86 609 0221Richie Oakleyroakley@murraygroup.ieTel: +353 1 498 0300Mob: +353 87 245 1824About Kenmare ResourcesKenmare Resources plc is one of the world's largest producers of mineral sands products. Listed on the London Stock Exchange and the Euronext Dublin  Kenmare operates the Moma Titanium Minerals Mine in Mozambique. Moma's production accounts for approximately 7% of global titanium feedstocks and the Company supplies to customers operating in more than 15 countries. Kenmare produces raw materials that are ultimately consumed in everyday quality-of-life items such as paints  plastics and ceramic tiles.All monetary amounts refer to United States dollars unless otherwise indicated.",neutral,0.01,0.99,0.0,positive,0.75,0.25,0.0,True,English,"['Managing Director', 'Appointment', 'Wet Concentrator Plant A', '$200 million Revolving Credit Facility', 'largest titanium minerals producers', 'United Oil & Gas plc', 'Moma Titanium Minerals Mine', 'leading global producers', 'largest capital projects', 'Petroceltic International plc', 'internal succession plan', 'first quartile position', 'trusted corporate citizen', 'Industrial Free Zone', 'various public companies', 'University College Dublin', 'UK Listing Rule', 'Paul O‚ÄôKane', 'Petroneft Resources plc', 'South American-focused oil', 'Chief Financial Officer', 'strong financial position', 'additional financial flexibility', 'senior financial roles', 'strong Board-level experience', 'capital markets experience', 'past two years', 'previous debt facilities', 'Tullow Oil plc', 'Independent Non-Executive Director', 'next Managing Director', 'incoming Managing Director', 'gas exploration company', 'Kenmare Resources plc', 'gas producer', 'financial acumen', 'financial strategy', 'natural resources', 'capital allocation', 'extensive experience', '24 years‚Äô experience', 'Moma Mine', 'Finance Director', 'limited process', 'Further updates', 'due course', 'Andrew Webb', 'profound gratitude', 'tremendous contribution', 'going support', 'rigorous process', 'external candidates', 'future endeavours', 'exciting phase', 'outstanding asset', 'unique culture', 'great team', 'Implementation Agreement', 'eight years', 'major acquisitions', 'equity fundings', 'annual budget', 'Commerce degree', 'Professional Accounting', 'Irish Institute', 'Chartered Accountants', 'Jeremy Dibb', 'Katharine Sutton', 'Investor Relations', 'PR advisor', 'Richie Oakley', 'LSE:KMR', 'northern Mozambique', 'four decades', 'important time', 'industry revenue', 'FTSE 100 business', 'FTSE 100 company', 'micro-cap company', 'Michael Carvill', 'central role', 'Michael Starke', 'Tom Hickey', 'The Board', '38 years', 'Group', 'August', 'Appointment', 'ISE', 'zircon', 'successor', 'Statement', 'Chairman', 'founder', 'vision', 'energy', 'commitment', 'world', 'name', 'consultant', 'tenure', 'combination', 'knowledge', 'value', 'stakeholders', 'opportunity', 'development', 'history', 'upgrade', 'transition', 'production', 'work', 'terms', 'Background', 'September', 'refinancing', 'Nataka', 'negotiations', 'Government', 'renewal', 'part', 'African', 'Bachelor', 'Diploma', 'Fellow', 'announcement', 'information', 'kenmareresources', 'Tel', 'Mob', 'Murray', 'pokane', 'roakley', '353']",2024-08-13,2024-08-14,globenewswire.com
44627,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/08/13/2928901/0/en/BGHL-GBP-NAV-s.html,BGHL (GBP): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED      Ordinary Shares      The Directors of Boussard & Gavaudan...,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 12 Aug 2024.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 28.6669 ¬£ 25.6780 Estimated MTD return -0.01 % 0.03 % Estimated YTD return 4.06 % 4.51 % Estimated ITD return 186.67 % 156.78 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 27.00 N/A Premium/discount to estimated NAV -5.81 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 200.00 Premium/discount to estimated NAV N/A -14.32 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 299 516 123 090 Held in treasury N/A N/A Shares Issued 12 299 516 123 090Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 258.5242 Class GBP A Shares (estimated) ¬£ 137.5699The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,1.0,0.0,mixed,0.14,0.27,0.58,True,English,"['BGHL', 'GBP', 'NAV', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'Euro Shares Sterling Shares', 'A N/A Average Price', 'London Stock Exchange plc', 'Guernsey Financial Services Commission', 'N/A Sterling Shares Amsterdam', 'treasury N/A N/A Shares', 'Dutch Financial Supervision Act', 'US Investment Company Act', 'Euro Shares Amsterdam', 'Sterling Shares Shares', 'A N/A Range', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'investment manager fees', 'BG Fund NAV', 'The Shares', 'N/A GBX', 'A Premium/discount', 'Dutch Authority', 'Emmanuel Gavaudan', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'Aug', 'returns', 'AEX', 'LSE', 'Transactions', 'Number', 'Outstanding', 'respect', 'role', 'LLP.', 'Email', 'bgam', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2024-08-13,2024-08-14,globenewswire.com
44628,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/08/13/2929446/0/en/Ramsay-Sante-Ramsay-Sant%C3%A9-has-successfully-refinanced-its-Senior-Debt-Facility.html,Ramsay Sante : Ramsay Sant√© has successfully refinanced its Senior Debt Facility,PRESS RELEASE   Paris  13 August 2024     Ramsay Sant√© has successfully refinanced its Senior Debt Facility    On 13 August 2024  Ramsay Sant√©...,PRESS RELEASEParis  13 August 2024Ramsay Sant√© has successfully refinanced its Senior Debt FacilityOn 13 August 2024  Ramsay Sant√© completed the Amend & Extend process of its ‚Ç¨1 650m Senior Debt facility  including a ‚Ç¨100m revolving credit facility  a ‚Ç¨100m capex facility  and a ‚Ç¨1 450m Term Loan B facility  proactively extending its upcoming 2026-2027 debt maturities to 2029-2031. This transaction was arranged by BNP Paribas and Cr√©dit Agricole CIB as Global Coordinators for Europe and Physical Bookrunners  MUFG as Global Coordinator for Asia and Physical Bookrunner  as well as Natixis CIB as Physical Bookrunner.The Amend & Extend was supported by existing lenders as well as a large number of new investors  allowing Ramsay Sant√© to fully extend its Term Loan B facility (TLB) whilst optimizing pricing during syndication: a ‚Ç¨425m 5-year TLB priced at E+325bps / 99.50 OID (vs E+325-350bps / 99.50 initial guidance) a ‚Ç¨1 025m 7-year TLB priced at E+400bps / 99.75 OID (vs E+400-425bps / 99.50 initial guidance)Ramsay Sant√© is fully engaged in the combination of economic  human et environmental interests in order to create the conditions for a sustainable growth. Therefore  the ESG scheme of existing Term Loan B facility has been reconducted and updated in a specific framework document coordinated by Cr√©dit Agricole CIB and Natixis CIB  which enables a possible adjustment on margin (upwards or downwards) based on the evaluation of specific KPIs related to patient satisfaction  medical care for underserved population & preventive healthcare  employees‚Äô satisfaction & prevention of psychological risks  as well as reduction of CO2 emissions (scope 1&2).Such refinancing will enable Ramsay Sant√© to ensure to all its stakeholders a long-term financing framework and further support the implementation of its key initiatives as part of its ‚ÄúYes We Care 2025‚Äù strategy plan  to offer integrated care pathways with digi-physical solutions to the patients.Pascal Roch√©  Chief Executive Officer of Ramsay Sant√©  says:¬´ In a context of political and financial uncertainty  we have passed a key milestone with the completion of the refinancing of our Senior Debt Facility that offers to Ramsay Sant√© and all its stakeholders a long term and positive framework to foster sustainable and profitable growth. This will allow Ramsay Sant√© to further secure its development towards the strategic objective of the Yes We Care 2025 Plan as a trusted partner of choice to our patients  doctors  employees and payors as the preferred provider and coordinator of care along the patient pathways in Europe. ¬ªAbout Ramsay Sant√©Ramsay Sant√© is the leader in private hospitalisation and primary care in Europe. The Group has 38 000 employees and works with nearly 9 300 practitioners to treat more than 12 million patients per year in its 465 facilities and 5 countries: France  Sweden  Norway  Denmark and Italy. Ramsay Sant√© offers almost all medical and surgical specialities in three domains: Medicine  Surgery  Obstetrics (MSO)  Follow-up Care and Rehabilitation (FCR) and Mental Health.Legally  Ramsay Sant√© is a mission-driven company committed to constantly improving the health of all patients through innovation. Wherever it operates  the Group contributes to public health service missions and the healthcare network. Through its actions and the constant dedication of its teams  Ramsay Sant√© is committed to ensuring the entire patient care journey  from prevention to follow-up care.Every year  the group invests over 200 million euros to support the evolution and diversity of care pathways  in medical  hospital  digital  and administrative aspects. Through this commitment  our Group enhances access to care for all  commits to provide best-in-class healthcare  systematically engages in dialogue with stakeholders and strives to protect the planet to improve health.Facebook: https://www.facebook.com/RamsaySanteInstagram: https://www.instagram.com/ramsaysanteTwitter: https://twitter.com/RamsaySanteLinkedIn: https://www.linkedin.com/company/ramsaysanteYouTube: https://www.youtube.com/c/RamsaySanteCode ISIN and Euronext Paris: FR0000044471Website: www.ramsaysante.frInvestor / Analyst Relations Press RelationsCl√©ment Lafaix Brigitte CachonTel. +33 1 87 86 21 52 Tel. +33 1 87 86 22 11clement.lafaix@ramsaysante.fr brigitte.cachon@ramsaysante.frAttachment,neutral,0.12,0.86,0.01,neutral,0.04,0.95,0.01,True,English,"['Senior Debt Facility', 'Ramsay Sante', 'Ramsay Sant√©', '‚Ç¨1,450m Term Loan B facility', 'existing Term Loan B facility', 'upcoming 2026-2027 debt maturities', '‚Ç¨100m revolving credit facility', 'Cr√©dit Agricole CIB', 'Analyst Relations Press Relations', '‚Ç¨1,650m Senior Debt facility', 'public health service missions', 'Yes We Care 2025 Plan', 'entire patient care journey', '‚Ç¨100m capex facility', 'Chief Executive Officer', 'long-term financing framework', '‚Ç¨425m 5-year TLB', '‚Ç¨1,025m 7-year TLB', 'specific framework document', 'Cl√©ment Lafaix', 'integrated care pathways', 'RamsaySante Code ISIN', 'long term', 'existing lenders', 'PRESS RELEASE', 'Natixis CIB', 'strategy plan', 'patient pathways', 'patient satisfaction', 'positive framework', 'specific KPIs', 'primary care', 'Follow-up Care', 'Ramsay Sant√©', 'BNP Paribas', 'Global Coordinators', 'Physical Bookrunners', 'large number', 'new investors', '50 initial guidance', 'environmental interests', 'ESG scheme', 'possible adjustment', 'underserved population', 'preventive healthcare', 'psychological risks', 'CO2 emissions', 'key initiatives', 'digi-physical solutions', 'Pascal Roch√©', 'financial uncertainty', 'key milestone', 'profitable growth', 'strategic objective', 'trusted partner', 'preferred provider', 'private hospitalisation', 'surgical specialities', 'three domains', 'Mental Health', 'mission-driven company', 'healthcare network', 'constant dedication', '200 million euros', 'administrative aspects', 'class healthcare', 'medical care', 'medical, hospital', 'Extend process', 'The Amend', 'sustainable growth', 'Such refinancing', 'Euronext Paris', 'employees‚Äô satisfaction', 'The Group', '12 million patients', 'Brigitte Cachon', '38,000 employees', '13 August', 'transaction', 'Europe', 'MUFG', 'Asia', 'pricing', 'syndication', '50 OID', 'vs', '400bps', '99.75 OID', 'combination', 'human', 'order', 'conditions', 'margin', 'evaluation', 'prevention', 'reduction', 'stakeholders', 'implementation', 'context', 'political', 'completion', 'development', 'choice', 'doctors', 'payors', 'leader', '9,300 practitioners', '465 facilities', '5 countries', 'France', 'Sweden', 'Norway', 'Denmark', 'Italy', 'Medicine', 'Surgery', 'Obstetrics', 'MSO', 'Rehabilitation', 'FCR', 'innovation', 'actions', 'teams', 'evolution', 'diversity', 'digital', 'commitment', 'access', 'dialogue', 'planet', 'Facebook', 'Instagram', 'Twitter', 'LinkedIn', 'YouTube', 'Website', 'Tel.', 'clement', 'Attachment']",2024-08-13,2024-08-14,globenewswire.com
44629,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/08/13/2928909/0/en/Cabka-2024-Half-Year-Major-improvement-in-operating-margins-but-sales-behind-last-year.html,Cabka 2024 Half Year: Major improvement in operating margins  but sales behind last year,PRESS RELEASE       Online investor presentation and Q&A at 10.30 CET on 13 August 2024...,PRESS RELEASEOnline investor presentation and Q&A at 10.30 CET on 13 August 2024 via:https://channel.royalcast.com/landingpage/cabka/20240813_1/Amsterdam  Netherlands - 13 August 2024 - Cabka N.V. (together with its subsidiaries ‚ÄúCabka‚Äù  or the ‚ÄúCompany‚Äù)  a company specialized in transforming hard to recycle plastic waste into innovative Reusable Transport Packaging (RTP)  listed at Euronext Amsterdam  today reports its non-audited 2024 Half Year results.Highlights 2024 Half YearSales of ‚Ç¨ 92.3 million 11% lower than prior year (2023HY: ‚Ç¨104.3 million)  fully driven by softer demand and lower prices in Q1  whilst Q2 sales remained stable versus last year. In Europe  Portfolio sales grew at a record of 13%  whilst Customised Solutions increased with 7% YoY. Continued soft market demand in our Contract Manufacturing business  resulted in a decline of ‚Ç¨9.4 million (-53%) YoY.In the US  our Portfolio business grew with 13.8% as a result of our new sales strategy. However  our US Customised Solutions business noted a significant decline of ‚Ç¨ 10.4 million  where key customers deliberately restricted CAPEX spending.Gross profit from operations at ‚Ç¨ 46.6 million (2023HY: ‚Ç¨ 48.5 1 million) representing a major improved margin of 4pp to 50.5% over sales compared to last year (2023HY: 46.5% 1 ).at ‚Ç¨ 46.6 million (2023HY: ‚Ç¨ 48.5 million) representing a major improved margin of 4pp to 50.5% over sales compared to last year (2023HY: 46.5% ). Net result amounted to ‚Ç¨ -1.9 million  entirely driven by the lower sales performance in Q1 (2023HY: ‚Ç¨ 0.8 million)amounted to ‚Ç¨ -1.9 million  entirely driven by the lower sales performance in Q1 (2023HY: ‚Ç¨ 0.8 million) Net Working Capital in control at ‚Ç¨ 38.6 million or 20.0% of sales.in control at ‚Ç¨ 38.6 million or 20.0% of sales. CAPEX of ‚Ç¨ 9.3 million (2023HY: ‚Ç¨12.9 million)  including maintenance & replacement investments of ‚Ç¨ 4.6 million  5% of sales.of ‚Ç¨ 9.3 million (2023HY: ‚Ç¨12.9 million)  including maintenance & replacement investments of ‚Ç¨ 4.6 million  5% of sales. Raw material intake amounted to 86%  which is substantially above the average recycling rate for plastic packaging waste in the EU of 41% 2   and above the overall plastic waste recycling rate of only 14% 3amounted to 86%  which is substantially above the average recycling rate for plastic packaging waste in the EU of 41%   and above the overall plastic waste recycling rate of only 14% Alexander Masharov appointed CEO at Extraordinary General Meeting of Shareholders on 1 August 2024.Cabka CEO Alexander Masharov  commented:‚ÄúSince my start at Cabka  I‚Äôve seen a company built on a strong foundation with a dedicated team of people that has demonstrated resilience and innovation under challenging market conditions. As 2024 commenced  we anticipated a gradual start  with Q1 sales significantly impacted by the lower demand in some of our end markets and intentional price reductions we implemented in our customer pricing strategy.Our Q2 sales is in line with our earlier projections  with Quarter-on-Quarter sales showing a recovery of 9% from the very slow first quarter. Despite our end markets being impacted by persistent inflation and ongoing geopolitical issues  we have seen our order intake progressively increase in most of our strategic segments.In Europe  our Portfolio business demonstrated record growth of 12.8%  whilst our EU Customized Solutions business remained resilient to market conditions  resulting in 6.6% growth year-on-year. Weak market demand however persisted in our Contract Manufacturing sales segment  with a ‚Ç¨9.4 million decline compared to H1 2023.In North America  our portfolio business performed very well with a notable 13.8% increase as our concerted efforts to win new customer deals started to bear fruits. However  challenging market conditions continue to severely impact our customized solutions segment with key customers not committing to any further capex spend for the time being  resulting in a ‚Ç¨10.4 million decline versus H1 2023.Gross margin significantly improved compared to prior year with 4pp  as we continue to focus on our internal production capacities and strategic cost management across all our segments. Our fixed cost base remained relatively stable  despite inflationary pressure. The lower sales  however  led to a deterioration of our operational EBITDA. Our focus within the organisation will be on additional cost saving initiatives to further enhance our operational efficiencies and boost our sales organisation. Although the half year EBITDA margin of 11.3% is not at our guidance level  we remain confident that our full year margin will recover to the 13-15% range.Looking ahead for the remainder of the year  we expect customer demand in some of our end markets to remain muted  whilst other segments will continue to grow. As we continue to navigate these challenging market circumstances with agility and resilience  we consider it prudent to adjust our outlook for the year. Therefore  we lower our sales guidance to ‚Ç¨ 180-185 million  reflecting the slow start of the year.Together with the leadership team of Cabka  I will revisit our business strategy. We will remain committed to our mission of transforming hard to recycle plastic waste into valuable and innovative RTP solutions. Sustainable growth and value creation will form the foundation of our Strategy 2030  which we intend to share in more detail during our planned Capital Markets Day to be hosted on 25 November 2024 at our Cabka plant in Ieper  Belgium.‚ÄùCondensed bridge from operational to IFRS consolidated statement of profit and loss  2024HY unaudited 4Condensed income statement bridgeoperations to IFRS4 in ‚Ç¨ million2024 HY2023 HY (restated)5ChangeRevenues 92.3 104.3 -11% Other operating income items 1.7 0.2 645% Total Operating Income 94.0 104.5 -10% Expenses for materials  energy and purchased services (47.5) (56.0) -15% Gross Profit from operations 46.6 48.5 -4% Operating expenses (36.2) (35.0) 3% EBITDA from operations 10.4 13.5 -23% Depreciation  amortization and impairment of intangible and tangible fixed assets (9.7) (8.0) 21% EBIT /Operating Income 0.7 5.5 -87% Financial results (2.0) (1.5) 40% Earnings before taxes (1.3) 4.0 -133% Taxes (0.6) (1.0) -37% Net income from operations (1.9) 3.0 -165% Non-operational and exceptional items6 0.0 (2.2) Non-controlling interest - - Net result reported IFRS (1.9) 0.8 n.m.OutlookBased on the current challenging market conditions  we expect the US customized solutions and contract manufacturing segments to remain under pressure  whilst our other strategic segments continue to perform well. In light of this  we expect sales to be in the range of ‚Ç¨ 180-185 million  with a recovery in our EBITDA margin towards 13-15%  reflecting an estimated EBITDA range of ‚Ç¨ 23-27 million.Share priceOn 30 June 2024 the Cabka shares closed at ‚Ç¨ 3.84.Cabka share capital per30 June 2024 30.06.2024 30.06.2023 ISIN Ordinary Shares issued 24 710 600 24 380 213 CABKA / NL00150000S7 Ordinary Shares in treasury 15 994 378 15 989 978 DSC2S / NL00150002R5 Total Ordinary Shares 40 704 978 40 370 191 Special Shares 97 778 97 778 Total shares 40 802 756 40 467 969Events after June 30  2024On 1 August 2024  an Extraordinary General Meeting of Shareholders confirmed the appointment of Alexander Masharov as Chief Executive Officer and a member of the Management Board  for a term ending directly following the Annual General Meeting in 2028.Proposed distribution 2023FYThe proposed distribution for Full Year 2023 of ‚Ç¨ 0.15 per share will be paid on Friday 16 August 2024.Financial Calendar 202416 August 2024 Dividend* Payment Date 21 October 2024 Trading Update Q3 2024 25 November 2024 Capital Markets Day 18 March 2025 Publication Preliminary Results 2024* Reference to ‚Äòdividend‚Äô refers to proposed distributionFor more information  please contact:Nadia Lubbe  Investor & Press contactIR@cabka.com  or n.lubbe@cabka.com;+49 152 243 254 79www.investors.cabka.comCommercial contact: info@cabka.comwww.cabka.comAbout CabkaCabka is in the business of recycling plastics from post-consumer and post-industrial waste into innovative reusable transport packaging (RTP)  like pallets- and large container solutions enhancing logistics chain sustainability. ECO product are mainly construction and road safety products produced exclusively out of post-consumer waste.Cabka is leading the industry in its integrated approach closing the loop from waste  to recycling  to manufacturing. Backed by its own innovation center it has the rare industry knowledge  capability  and capacity of making maximum use bringing recycled plastics back in the production loop at attractive returns. Cabka is fully equipped to exploit the full value chain from waste to end-products.Cabka is listed at Euronext Amsterdam as of 1 March 2022 under the CABKA ticker with international securities identification number NL00150000S7.DisclaimerAll results in the press release are based on regular operations excluding extraordinary items  unless mentioned otherwise. The qualification extraordinary item is a management accounting term to indicate this is not part of regular operations. The financial statements in the appendix are based on IFRS and do not distinguish between operational or extraordinary items. See appendix I. for definitions of operational items by management.The content of this press release may include statements that are  or may be deemed to be  ‚Äò‚Äôforward-looking statements‚Äô‚Äô. These forward-looking statements may be identified by the use of forward-looking terminology  including the terms ‚Äò‚Äôbelieves‚Äô‚Äô  ‚Äò‚Äôestimates‚Äô‚Äô  ‚Äò‚Äôplans‚Äô‚Äô  ‚Äò‚Äôprojects‚Äô‚Äô  ‚Äò‚Äôanticipates‚Äô‚Äô  ‚Äò‚Äôexpects‚Äô‚Äô  ‚Äò‚Äôintends‚Äô‚Äô  ‚Äò‚Äômay‚Äô‚Äô  ‚Äò‚Äôwill‚Äô‚Äô or ‚Äò‚Äôshould‚Äô‚Äô or  in each case  their negative or other variations or comparable terminology  or by discussions of strategy  plans  objectives  goals  future events or intentions. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements reflect the Company‚Äôs current view with respect to future events and are subject to risks relating to future events and other risks  uncertainties and assumptions relating to the Company‚Äôs business  results of operations  financial position  liquidity  prospects  growth  or strategies.Readers are cautioned that any forward-looking statements are not guarantees of future performance. Given these uncertainties  the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this press release. The Company undertakes no obligation to publicly update or revise the information in this press release  including any forward-looking statements  except as may be required by law.This document contains information that qualifies as inside information within the meaning of Article 7(1) of Regulation (EU) No 596/2014 on market abuse.1 The presentation of the prior year income statement of has been adjusted to reflect the new classification of transportation cost and FX gains and losses. For further information refer to our Half Year Report 2024.2 Packaging waste by wate management company statisics published by eurostat data covering up to 2021.3 Systemiq April 2022 report Reshaping plastics. Pathway to a circular climate neutral plastics system in Europe4 The condensed income statement provides operational and non-operational result items for insight on underlying operational performance. The statements in the attached Half Year Report 2024 provide integral IFRS statements without this distinction.5 The presentation of the prior year income statement of has been adjusted to reflect the new classification of transportation cost and FX gains and losses. For further information refer to our Half Year Report 2024.6 For more information on the non-operational and exceptional items during the half year  please refer to our Half Year Report 2024Attachments,neutral,0.11,0.87,0.02,mixed,0.24,0.18,0.58,True,English,"['Cabka 2024 Half Year', 'last year', 'Major improvement', 'operating margins', 'sales', 'overall plastic waste recycling rate', 'innovative Reusable Transport Packaging', 'additional cost saving initiatives', 'Contract Manufacturing sales segment', 'US Customised Solutions business', 'EU Customized Solutions business', 'half year EBITDA margin', 'average recycling rate', 'plastic packaging waste', 'Cabka CEO Alexander Masharov', 'customized solutions segment', 'Contract Manufacturing business', 'fixed cost base', 'Online investor presentation', 'major improved margin', 'Extraordinary General Meeting', 'intentional price reductions', 'ongoing geopolitical issues', 'internal production capacities', 'strategic cost management', 'challenging market circumstances', 'customer pricing strategy', 'new customer deals', 'Net Working Capital', 'Raw material intake', 'challenging market conditions', 'soft market demand', 'Weak market demand', '2024 Half Year results', 'full year margin', 'Cabka N.V.', 'slow first quarter', 'new sales strategy', 'lower sales performance', 'customer demand', 'Gross margin', 'operational EBITDA', 'Portfolio business', 'lower demand', 'order intake', 'slow st', 'softer demand', 'lower prices', 'Quarter sales', 'strategic segments', 'prior year', 'last year', 'PRESS RELEASE', 'Q&A', 'key customers', 'Gross profit', 'Net result', 'replacement investments', 'strong foundation', 'dedicated team', 'end markets', 'earlier projections', 'persistent inflation', 'North America', 'notable 13.8% increase', 'concerted efforts', 'inflationary pressure', 'operational efficiencies', 'guidance level', '13-15% range', 'Q2 sales', 'Portfolio sales', 'sales guidance', 'significant decline', '‚Ç¨9.4 million decline', '‚Ç¨10.4 million decline', 'other segments', 'Euronext Amsterdam', 'gradual start', 'sales organisation', 'CAPEX spending', 'Q1 sales', 'record growth', '6.6% growth', '10.30 CET', '13 August', 'channel', 'royalcast', 'landingpage', 'Netherlands', 'subsidiaries', 'Company', 'RTP', 'Highlights', 'Europe', '7% YoY', 'operations', '4pp', '23HY', 'control', 'maintenance', 'Shareholders', '1 August', 'people', 'resilience', 'innovation', 'recovery', 'H1', 'fruits', 'time', 'deterioration', 'focus', 'remainder', 'agility', 'outlook']",2024-08-13,2024-08-14,globenewswire.com
44630,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/08/13/2929468/0/en/Medsenic-BioSenic-patent-granted-in-Japan-for-more-protection-of-its-therapeutic-platform.html,Medsenic/BioSenic patent granted in Japan for more protection of its therapeutic platform,PRIVILEGED INFORMATION      Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of......,PRIVILEGED INFORMATIONComposition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration.Enriched IP portfolio protects arsenic trioxide (ATO) use combined with copper ions delivery  which has demonstrated increased therapeutic potential for indications ranging from immune to cancer and infectious diseases.Mont-Saint-Guibert  Belgium  13 ao√ªt 2024  6.00pm CET ‚Äì BioSenic (Euronext Brussels and Paris: BIOS)  the clinical-stage company specializing in serious autoimmune and inflammatory diseases  today announces the granting of a key patent by the Japan Patent Office to expand protection of the arsenic trioxide (ATO) platform. The patent  titled ‚ÄúUse of metal ions to potentiate the therapeutic effects of arsenic ‚Äù covers the use of ATO platform in combination with metal ions such as copper. This combination has shown the ability to significantly improve the treatment of autoimmune diseases and could be applied to the treatment of various forms of cancer conditions and infectious pathologies related to cytokine storms. Similar protection had been granted in Europe and Australia last year  together with a first patent acceptance in China  which opened the doors for further divisional applications in addition to the primary decision limited to graft-versus-host disease (GvHD).BioSenic is exploring the therapeutic use of ATO for several indications. The company has recently published peer-reviewed data from several preclinical studies elucidating ATO‚Äôs mechanisms for modulating immune responses  and the ability of certain metal ions to enhance this therapeutic potential. The actual growing portfolio of intellectual property rights is part of a strategy to build dense and meaningful protection for its lead product  paving the way for clinical and commercial developments by BioSenic and interested partners  particularly in the field of autoimmunity.The new patent  granted to BioSenic‚Äôs subsidiary company Medsenic  involves two main immediate areas of application. The first one is in immune- and autoimmune-related diseases ‚Äì specifically  the BioSenic‚Äôs lead project in 2024  chronic GvHD and  later  systemic sclerosis and systemic lupus erythematosus. The second is in oncology  where ATO has already demonstrated exceptional results for patients  including complete remission in acute promyelocytic leukaemia. These patents will support BioSenic‚Äôs plans for international clinical trials in pathologies with unmet medical needs  toward the company‚Äôs long-term goal of seeking market access approvals for its various formulations  optimizing the original properties of arsenic salts ‚Äì alone or in combination.Fran√ßois Rieger  PhD  Chairman and CEO of BioSenic said: ‚ÄúThis newly granted regional patent for Japan further consolidates our intellectual property rights on the formulations and compositions of matter related to the first-in-class properties of arsenic salts  which we find to generally reorient organisms toward normal function and homeostasis in various cells and organs. We are happy to open new chapters in the continuous  worldwide effort in trying to control chronic or lethal diseases with no real cure.‚ÄùThe expected availability of an oral formulation that combines arsenic and copper puts BioSenic in a unique position to build on clinical successes in its fields of applications. As a result  BioSenic will be able to continue clinical development with proprietary original formulations containing arsenic and new active ingredients such as metal ions  increasing the potency of its products  and minimizing secondary side effects.The Japanese patent  corresponding to Application 2021-569115 filed on May 20  2020  is now granted to Medsenic  a subsidiary of BioSenic. Similar regional patents on the same subject were granted by European Union Intellectual Property Office (EP3972613) in April 2023  by China National Intellectual Property Administration in August 2023  and by the Australian and Canadian Patent Offices in December 2023.About BioSenicBioSenic is a leading biotech company specializing in the development of clinical assets issued from its Medsenic‚Äôs arsenic trioxide (ATO) platform. Key target indications for the autoimmune platform include graft-versus-host-disease (GvHD)  systemic lupus erythematosus (SLE)  and now systemic sclerosis (SSc).Following the merger in October 2022  BioSenic combined the strategic positionings and strengths of Medsenic and Bone Therapeutics. The merger specifically enables Medsenic/Biosenic to develop an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/oral ATO (OATO).BioSenic is based in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert  Belgium. Further information is available at http://www.biosenic.com.About the main Medsenic/BioSenic technology platformThe ATO platform provides derived active products with immunomodulatory properties and fundamental effects on the activated cells of the immune system. One direct application is its use in onco-immunology to treat GvHD (Graft-versus-Host Disease) in its chronic  established stage. cGvHD is one of the most common and clinically significant complications affecting long-term survival of allogeneic hematopoietic stem cell transplantation (allo-HSCT).Medsenic has been successful in a phase 2 trial with its intravenous formulation  Arscimed¬Æ  which has orphan drug designation status by FDA and EMA. The company is heading towards an international phase 3 confirmatory study  with its new  IP-protected  OATO formulation. Another selected target is moderate-to-severe forms of systemic lupus erythematosus (SLE)  using the same oral formulation. ATO has shown good safety and significant clinical efficacy on several affected organs (skin  mucosae  and the gastrointestinal tract). Systemic sclerosis is now full part of the clinical pipeline of Medsenic/BioSenic. This serious chronic disease badly affects skin  lungs  or vascularization  and has no current effective treatment. Preclinical studies on pertinent animal models are positive  giving good grounds to launch a phase 2 clinical protocol  using new immunomodulatory formulations of APIs recognized to be active on the immune system.The company is currently focusing its present R&D and clinical activities on a selective  accelerated development of its autoimmune platform.Note: The allogeneic cell therapy platform-originating from the previous listed company Bone Therapeutics company  may be of renewed interest by using isolated and purified differentiated bone marrow Mesenchymal Stromal Cells (MSCs) as a starting material for further isolation of passive or active biological subcellular elements. Indeed  these cells may provide new subcellular vesicles potentially able to deliver a unique and proprietary approach to organ repair. BioSenic is now involved in determining new patentable approaches in this complex area of cell therapy.For further information  please contact:BioSenic SAFran√ßois Rieger  PhD  CEOTel: +33 (0)671 73 31 59investorrelations@biosenic.comCertain statements  beliefs and opinions in this press release are forward-looking  which reflect the company or  as appropriate  the company directors‚Äô current expectations and projections about future events. By their nature  forward-looking statements involve a number of risks  uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including  but not limited to  changes in demand  competition and technology  can cause actual events  performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result  the company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions or circumstances on which these forward-looking statements are based. Neither the company nor its advisers or representatives nor any of its subsidiary undertakings or any such person‚Äôs officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.,neutral,0.03,0.97,0.0,mixed,0.39,0.18,0.43,True,English,"['Medsenic/BioSenic patent', 'therapeutic platform', 'Japan', 'protection', 'European Union Intellectual Property Office', 'China National Intellectual Property Administration', 'two main immediate areas', 'main Medsenic/BioSenic technology platform', 'intellectual property rights', 'Enriched IP portfolio', 'actual growing portfolio', 'acute promyelocytic leukaemia', 'unmet medical needs', 'market access approvals', 'Fran√ßois Rieger', 'continuous, worldwide effort', 'Louvain-la-Neuve Science Park', 'several preclinical studies', 'systemic lupus erythematosus', 'secondary side effects', 'Japan Patent Office', 'Canadian Patent Offices', 'international clinical trials', 'leading biotech company', 'new active ingredients', 'first patent acceptance', 'proprietary original formulations', 'Key target indications', 'The ATO platform', 'One direct application', 'Similar regional patents', 'copper ions delivery', 'first one', 'key patent', 'several indications', 'systemic sclerosis', 'original properties', 'autoimmune platform', 'new patent', 'therapeutic effects', 'fundamental effects', 'ATO) platform', 'new chapters', 'new arsenal', 'Japanese patent', 'Similar protection', 'metal ions', 'PRIVILEGED INFORMATION', 'various routes', 'therapeutic potential', 'infectious diseases', '6.00pm CET', 'Euronext Brussels', 'serious autoimmune', 'inflammatory diseases', 'autoimmune diseases', 'various forms', 'cytokine storms', 'primary decision', 'host disease', 'peer-reviewed data', 'lead product', 'commercial developments', 'autoimmune-related diseases', 'lead project', 'exceptional results', 'complete remission', 'long-term goal', 'various formulations', 'class properties', 'normal function', 'various cells', 'lethal diseases', 'real cure', 'expected availability', 'oral formulation', 'unique position', 'clinical successes', 'same subject', 'clinical assets', 'strategic positionings', 'Bone Therapeutics', 'various anti-inflammatory', 'anti-autoimmune formulations', 'immunomodulatory properties', 'Further information', 'active products', 'activated cells', 'clinical-stage company', 'ATO/oral ATO', 'matter patent', 'arsenic salts', 'arsenic trioxide', 'immune responses', 'meaningful protection', 'immune system', 'therapeutic use', 'cancer conditions', 'infectious pathologies', 'divisional applications', 'clinical development', 'ATO) use', 'subsidiary company', 'chronic GvHD', 'Composition', 'Mont-Saint-Guibert', 'Belgium', 'Paris', 'granting', 'combination', 'treatment', 'Australia', 'doors', 'addition', 'mechanisms', 'part', 'strategy', 'dense', 'way', 'interested', 'field', 'autoimmunity', 'oncology', 'patients', 'plans', 'PhD', 'Chairman', 'CEO', 'organisms', 'homeostasis', 'organs', 'potency', 'May', 'April', 'August', 'December', 'graft', 'versus', 'host-disease', 'SLE', 'SSc', 'merger', 'October', 'strengths', 'OATO', '2024']",2024-08-13,2024-08-14,globenewswire.com
44631,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/08/13/2929015/0/en/BioSenic-S-A-Transparency-notification-received-from-ABO-Infinium-Americas-OpCo-LTD.html,BioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD.,REGULATED INFORMATION¬†Article 14 of the Law of 2 May 2007 on disclosure of major holdings  Mont-Saint-Guibert  Belgium  August 13  2024  1.00pm CEST...,REGULATED INFORMATIONArticle 14 of the Law of 2 May 2007 on disclosure of major holdingsMont-Saint-Guibert  Belgium  August 13  2024  1.00pm CEST ‚Äì BIOSENIC (Euronext Brussels and Paris: BIOS)  the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy  today announces that it has received a transparency notification from ABO Infinium Americas OpCo LTD. The details of the transparency notification are set out below and the full text of the transparency notification can be consulted on the website of BioSenic  under the heading ‚ÄúMajor shareholders & transparency notices‚Äù.The transparency notification indicates that the voting rights attached to BioSenic's shares held by ABO Infinium Americas OpCo LTD. have crossed above the threshold of 5% as a result of the acquisition of shares of BioSenic.The notification received from ABO Infinium Americas OpCo LTD. dated 9 August 2024 contains the following information:Reason for the notification: Acquisition or transfer of voting securities or voting rightsNotification by: A parent company or controlling personPerson subject to the notification requirement: ABO Infinium Americas OpCo LTD. ABO Securities Omega Financial Corporation Mr Pierre VannineuseTransaction date: 1 st July 2024July 2024 Threshold that is crossed: 5%Denominator: 251 312 817Notified details:Voting rights Previous notification After the transaction Holders of voting rights # of voting rights # of voting rights % of voting rights Mr Pierre Vannineuse N/A 0 0.00% Omega Financial Corporation N/A 0 0.00% ABO Securities N/A 0 0.00% ABO Infinium Americas OpCo LTD. N/A 20 588 234 8.19% Total voting rights 20 588 234 8.19%Full chain of controlled undertakings through which the holding is effectively held: ABO Infinium Americas OpCo LTD. (303 Shriley Street  Nassau  Bahamas) is 100% owned by ABO Securities (71 Fort Street  Georges Town  Grand Cayman  Cayman Island). ABO Securities is 100% owned by Omega Financial Corporation (71 Fort Street  Georges Town  Grand Cayman  Cayman Island). Omega Financial Corporation is 100% owned by Pierre Vannineuse.About BioSenicBioSenic is a leading biotech company specializing in the development of clinical assets issued from its Medsenic‚Äôs arsenic trioxide (ATO) platform. Key target indications for the autoimmune platform include graft-versus-host-disease (GvHD)  systemic lupus erythematosus (SLE)  and now systemic sclerosis (SSc).Following the merger in October 2022  BioSenic combined the strategic positionings and strengths of Medsenic and Bone Therapeutics. The merger specifically enables Medsenic/Biosenic to develop an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/oral ATO (OATO).BioSenic is based in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert  Belgium. Further information is available at http://www.biosenic.com.About the main Medsenic/BioSenic technology platformThe ATO platform provides derived active products with immunomodulatory properties and fundamental effects on the activated cells of the immune system. One direct application is its use in onco-immunology to treat GvHD (Graft-versus-Host Disease) in its chronic  established stage. cGvHD is one of the most common and clinically significant complications affecting long-term survival of allogeneic hematopoietic stem cell transplantation (allo-HSCT).Medsenic has been successful in a phase 2 trial with its intravenous formulation  Arscimed¬Æ  which has orphan drug designation status by FDA and EMA. The company is heading towards an international phase 3 confirmatory study  with its new  IP-protected  OATO formulation. Another selected target is moderate-to-severe forms of systemic lupus erythematosus (SLE)  using the same oral formulation. ATO has shown good safety and significant clinical efficacy on several affected organs (skin  mucosae  and the gastrointestinal tract). Systemic sclerosis is now full part of the clinical pipeline of Medsenic/BioSenic. This serious chronic disease badly affects skin  lungs  or vascularization  and has no current effective treatment. Preclinical studies on pertinent animal models are positive  giving good grounds to launch a phase 2 clinical protocol  using new immunomodulatory formulations of APIs recognized to be active on the immune system.The company is currently focusing its present R&D and clinical activities on a selective  accelerated development of its autoimmune platform.Note: The allogeneic cell therapy platform-originating from the previous listed company Bone Therapeutics company  may be of renewed interest by using isolated and purified differentiated bone marrow Mesenchymal Stromal Cells (MSCs) as a starting material for further isolation of passive or active biological subcellular elements. Indeed  these cells may provide new subcellular vesicles potentially able to deliver a unique and proprietary approach to organ repair. BioSenic is now involved in determining new patentable approaches in this complex area of cell therapy.For further information  please contact:BioSenic SAFran√ßois Rieger  PhD  CEOTel: +33 (0)671 73 31 59investorrelations@biosenic.comCertain statements  beliefs and opinions in this press release are forward-looking  which reflect the company or  as appropriate  the company directors‚Äô current expectations and projections about future events. By their nature  forward-looking statements involve a number of risks  uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including  but not limited to  changes in demand  competition and technology  can cause actual events  performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result  the company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions or circumstances on which these forward-looking statements are based. Neither the company nor its advisers or representatives nor any of its subsidiary undertakings or any such person‚Äôs officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.,neutral,0.0,1.0,0.0,mixed,0.64,0.04,0.33,True,English,"['ABO Infinium Americas OpCo LTD.', 'BioSenic S.A.', 'Transparency notification', 'purified differentiated bone marrow Mesenchymal Stromal Cells', 'ABO Infinium Americas OpCo LTD', 'allogeneic hematopoietic stem cell transplantation', 'ABO Securities Omega Financial Corporation', 'orphan drug designation status', 'international phase 3 confirmatory study', 'active biological subcellular elements', 'allogeneic cell therapy platform', 'main Medsenic/BioSenic technology platform', 'new, IP-protected, OATO formulation', 'Mr Pierre Vannineuse N/A', 'Voting rights Previous notification', 'ABO Securities N', 'new subcellular vesicles', 'controlling person Person', 'Louvain-la-Neuve Science Park', 'One direct application', 'same oral formulation', 'several affected organs', 'current effective treatment', 'pertinent animal models', 'present R&D', 'new patentable approaches', 'previous listed company', 'Bone Therapeutics company', 'systemic lupus erythematosus', 'phase 2 clinical protocol', 'leading biotech company', 'Key target indications', 'serious chronic disease', 'selective, accelerated development', 'significant clinical efficacy', 'The ATO platform', 'new immunomodulatory formulations', 'Total voting rights', 'activated cells', 'voting securities', 'new arsenal', 'active products', 'phase 2 trial', 'intravenous formulation', 'ATO) platform', 'autoimmune platform', 'serious autoimmune', 'systemic sclerosis', 'anti-autoimmune formulations', 'Graft-versus-Host Disease', 'significant complications', 'clinical assets', 'clinical pipeline', 'clinical activities', 'immunomodulatory properties', 'clinical-stage company', 'parent company', 'REGULATED INFORMATION', 'major holdings', 'Euronext Brussels', 'inflammatory diseases', 'full text', 'Major shareholders', 'transparency notices', 'following information', 'Full chain', 'controlled undertakings', '71 Fort Street', 'Georges Town', 'Grand Cayman', 'Cayman Island', 'arsenic trioxide', 'strategic positionings', 'various anti-inflammatory', 'ATO/oral ATO', 'Further information', 'fundamental effects', 'immune system', 'long-term survival', 'severe forms', 'good safety', 'gastrointestinal tract', 'full part', 'Preclinical studies', 'good grounds', 'starting material', 'proprietary approach', 'organ repair', 'transparency notification', 'notification requirement', 'Transaction date', 'July 2024 Threshold', 'Notified details', 'Article', 'Law', '2 May', 'disclosure', 'Mont-Saint-Guibert', 'Belgium', '1.00pm', 'CEST', 'Paris', 'website', 'heading', 'shares', 'result', 'acquisition', 'Reason', 'transfer', 'Denominator', 'Nassau', 'Bahamas', 'host-disease', 'GvHD', 'SLE', 'SSc', 'merger', 'October', 'strengths', 'onco-immunology', 'common', 'HSCT', 'Arscimed', 'FDA', 'skin', 'mucosae', 'lungs', 'vascularization', 'APIs', 'Note', 'interest', 'isolated', 'MSCs', 'isolation', 'passive', 'unique']",2024-08-13,2024-08-14,globenewswire.com
44632,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/08/13/2928915/0/en/Progress-on-share-buyback-programme.html,Progress on share buyback programme,Progress on share buyback programme  ING announced today that  as part of our ‚Ç¨2.5 billion share buyback programme announced on 2 May 2024  the company......,Progress on share buyback programmeING announced today that  as part of our ‚Ç¨2.5 billion share buyback programme announced on 2 May 2024  the company repurchased 16 768 469 shares during the week of 5 August 2024 up to and including 9 August 2024.The shares were repurchased at an average price of ‚Ç¨15.01 for a total amount of ‚Ç¨251 621 919.02. For detailed information on the daily repurchased shares  individual share purchase transactions and weekly reports  see the ING website at www.ing.com/investorrelations.In line with the purpose of the programme to reduce the share capital of ING  the total number of shares repurchased under this programme to date is 95 152 159 ordinary shares at an average price of ‚Ç¨15.99 for a total consideration of ‚Ç¨1 521 875 978.89. To date approximately 60.88% of the maximum total value of the share buyback programme has been completed.Note for editorsFor more on ING  please visit www.ing.com. Frequent news updates can be found in the Newsroom or via X @ING_news feed. Photos of ING operations  buildings and its executives are available for download at Flickr.Press enquiries Investor enquiries Marc Smulders ING Group Investor Relations +31 20 576 5000 +31 20 576 6396 Marc.Smulders@ing.com Investor.Relations@ing.comING PROFILEING is a global financial institution with a strong European base  offering banking services through its operating company ING Bank. The purpose of ING Bank is: empowering people to stay a step ahead in life and in business. ING Bank‚Äôs more than 60 000 employees offer retail and wholesale banking services to customers in over 40 countries.ING Group shares are listed on the exchanges of Amsterdam (INGA NA  INGA.AS)  Brussels and on the New York Stock Exchange (ADRs: ING US  ING.N).ING aims to put sustainability at the heart of what we do. ING‚Äôs sustainability efforts have been recognised externally by environmental  social and governance (ESG) rating agencies and other benchmarks. In 2023  Sustainalytics assessed our management of ESG material risk as ‚Äòstrong‚Äô. In July 2023  ING's ESG rating by MSCI was reconfirmed as 'AA'. ING‚Äôs shares are included in the sustainability indices of Euronext  STOXX  FTSE Russell and Morningstar.Important legal informationElements of this press release contain or may contain information about ING Groep N.V. and/ or ING Bank N.V. within the meaning of Article 7(1) to (4) of EU Regulation No 596/2014 (‚ÄòMarket Abuse Regulation‚Äô).ING Group‚Äôs annual accounts are prepared in accordance with International Financial Reporting Standards as adopted by the European Union (‚ÄòIFRS- EU‚Äô). In preparing the financial information in this document  except as described otherwise  the same accounting principles are applied as in the 2023 ING Group consolidated annual accounts. All figures in this document are unaudited. Small differences are possible in the tables due to rounding.Certain of the statements contained herein are not historical facts  including  without limitation  certain statements made of future expectations and other forward-looking statements that are based on management‚Äôs current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results  performance or events to diÔ¨Äer materially from those expressed or implied in such statements. Actual results  performance or events may diÔ¨Äer materially from those in such statements due to a number of factors  including  without limitation: (1) changes in general economic conditions and customer behaviour  in particular economic conditions in ING‚Äôs core markets  including changes affecting currency exchange rates and the regional and global economic impact of the invasion of Russia into Ukraine and related international response measures (2) changes affecting interest rate levels (3) any default of a major market participant and related market disruption (4) changes in performance of financial markets  including in Europe and developing markets (5) fiscal uncertainty in Europe and the United States (6) discontinuation of or changes in ‚Äòbenchmark‚Äô indices (7) inflation and deflation in our principal markets (8) changes in conditions in the credit and capital markets generally  including changes in borrower and counterparty creditworthiness (9) failures of banks falling under the scope of state compensation schemes (10) non-compliance with or changes in laws and regulations  including those concerning financial services  financial economic crimes and tax laws  and the interpretation and application thereof (11) geopolitical risks  political instabilities and policies and actions of governmental and regulatory authorities  including in connection with the invasion of Russia into Ukraine and the related international response measures (12) legal and regulatory risks in certain countries with less developed legal and regulatory frameworks (13) prudential supervision and regulations  including in relation to stress tests and regulatory restrictions on dividends and distributions (also among members of the group) (14) ING‚Äôs ability to meet minimum capital and other prudential regulatory requirements (15) changes in regulation of US commodities and derivatives businesses of ING and its customers (16) application of bank recovery and resolution regimes  including write down and conversion powers in relation to our securities (17) outcome of current and future litigation  enforcement proceedings  investigations or other regulatory actions  including claims by customers or stakeholders who feel misled or treated unfairly  and other conduct issues (18) changes in tax laws and regulations and risks of non-compliance or investigation in connection with tax laws  including FATCA (19) operational and IT risks  such as system disruptions or failures  breaches of security  cyber-attacks  human error  changes in operational practices or inadequate controls including in respect of third parties with which we do business and including any risks as a result of incomplete  inaccurate  or otherwise flawed outputs from the algorithms and data sets utilized in artificial intelligence (20) risks and challenges related to cybercrime including the eÔ¨Äects of cyberattacks and changes in legislation and regulation related to cybersecurity and data privacy  including such risks and challenges as a consequence of the use of emerging technologies  such as advanced forms of artificial intelligence and quantum computing (21) changes in general competitive factors  including ability to increase or maintain market share (22) inability to protect our intellectual property and infringement claims by third parties (23) inability of counterparties to meet financial obligations or ability to enforce rights against such counterparties (24) changes in credit ratings (25) business  operational  regulatory  reputation  transition and other risks and challenges in connection with climate change and ESG-related matters  including data gathering and reporting (26) inability to attract and retain key personnel (27) future liabilities under defined benefit retirement plans (28) failure to manage business risks  including in connection with use of models  use of derivatives  or maintaining appropriate policies and guidelines (29) changes in capital and credit markets  including interbank funding  as well as customer deposits  which provide the liquidity and capital required to fund our operations  and (30) the other risks and uncertainties detailed in the most recent annual report of ING Groep N.V. (including the Risk Factors contained therein) and ING‚Äôs more recent disclosures  including press releases  which are available on www.ING.com.This document may contain ESG-related material that has been prepared by ING on the basis of publicly available information  internally developed data and other third-party sources believed to be reliable. ING has not sought to independently verify information obtained from public and third-party sources and makes no representations or warranties as to accuracy  completeness  reasonableness or reliability of such information.Materiality  as used in the context of ESG  is distinct from  and should not be confused with  such term as defined in the Market Abuse Regulation or as defined for Securities and Exchange Commission (‚ÄòSEC‚Äô) reporting purposes. Any issues identified as material for purposes of ESG in this document are therefore not necessarily material as defined in the Market Abuse Regulation or for SEC reporting purposes. In addition  there is currently no single  globally recognized set of accepted definitions in assessing whether activities are ‚Äúgreen‚Äù or ‚Äúsustainable.‚Äù Without limiting any of the statements contained herein  we make no representation or warranty as to whether any of our securities constitutes a green or sustainable security or conforms to present or future investor expectations or objectives for green or sustainable investing. For information on characteristics of a security  use of proceeds  a description of applicable project(s) and/or any other relevant information  please reference the offering documents for such security.This document may contain inactive textual addresses to internet websites operated by us and third parties. Reference to such websites is made for information purposes only  and information found at such websites is not incorporated by reference into this document. ING does not make any representation or warranty with respect to the accuracy or completeness of  or take any responsibility for  any information found at any websites operated by third parties. ING specifically disclaims any liability with respect to any information found at websites operated by third parties. ING cannot guarantee that websites operated by third parties remain available following the publication of this document  or that any information found at such websites will not change following the filing of this document. Many of those factors are beyond ING‚Äôs control.Any forward-looking statements made by or on behalf of ING speak only as of the date they are made  and ING assumes no obligation to publicly update or revise any forward-looking statements  whether as a result of new information or for any other reason.This document does not constitute an oÔ¨Äer to sell  or a solicitation of an oÔ¨Äer to purchase  any securities in the United States or any other jurisdiction.Attachment,neutral,0.44,0.55,0.01,mixed,0.25,0.02,0.73,True,English,"['share buyback programme', 'Progress', 'Marc Smulders ING Group Investor Relations', '2023 ING Group consolidated annual accounts', 'New York Stock Exchange', 'individual share purchase transactions', 'ING Groep N.V.', 'International Financial Reporting Standards', 'ING Bank N.V.', '‚Ç¨2.5 billion share buyback programme', 'operating company ING Bank', 'currency exchange rates', 'international response measures', 'Frequent news updates', 'same accounting principles', 'global economic impact', 'major market participant', 'state compensation schemes', 'global financial institution', 'ESG material risk', 'financial economic crimes', 'strong European base', 'Market Abuse Regulation', 'general economic conditions', 'particular economic conditions', 'maximum total value', 'ESG) rating agencies', 'Marc.Smulders', 'related market disruption', 'wholesale banking services', 'daily repurchased shares', 'ING Group shares', 'other forward-looking statements', 'Important legal information', 'Investor enquiries', 'share capital', 'ESG rating', 'financial services', 'financial information', 'financial markets', 'other benchmarks', 'EU Regulation', 'European Union', 'total amount', 'total consideration', 'ING website', 'ING operations', 'ING PROFILE', 'ING US', 'average price', 'detailed information', 'weekly reports', 'Press enquiries', 'INGA NA', 'INGA.AS', 'FTSE Russell', 'press release', 'IFRS- EU', 'Small differences', 'historical facts', 'future expectations', 'current views', 'unknown risks', 'actual results', 'customer behaviour', 'core markets', 'rate levels', 'developing markets', 'fiscal uncertainty', 'United States', 'principal markets', 'capital markets', 'counterparty creditworthiness', 'geopolitical risks', 'political instabilities', 'regulatory authorities', 'regulatory risks', 'regulatory frameworks', 'prudential supervision', 'stress tests', 'regulatory restrictions', 'total number', '95,152,159 ordinary shares', 'sustainability efforts', 'tax laws', 'sustainability indices', '16,768,469 shares', 'Progress', '2 May', '5 August', '9 August', 'investorrelations', 'line', 'purpose', 'Note', 'editors', 'Newsroom', 'Photos', 'buildings', 'executives', 'download', 'Flickr', 'people', 'life', 'business', '60,000 employees', 'retail', 'customers', '40 countries', 'exchanges', 'Amsterdam', 'Brussels', 'ADRs', 'heart', 'social', 'governance', 'Sustainalytics', 'management', 'July', 'MSCI', 'Euronext', 'STOXX', 'Morningstar', 'Elements', 'meaning', 'Article', 'accordance', 'document', 'figures', 'tables', 'rounding', 'limitation', 'assumptions', 'uncertainties', 'performance', 'events', 'factors', 'regional', 'invasion', 'Russia', 'Ukraine', 'interest', 'default', 'discontinuation', 'inflation', 'deflation', 'borrower', 'failures', 'banks', 'scope', 'compliance', 'regulations', 'interpretation', 'application', 'policies', 'governmental', 'connection', 'less', 'dividends', 'distributions', 'members', 'minimum']",2024-08-13,2024-08-14,globenewswire.com
44633,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2024/08/13/2928895/0/en/Valneva-Reports-Half-Year-2024-Financial-Results-and-Provides-Corporate-Updates.html,Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates,First-Half Sales Performance in Line with Full-Year 2024 Guidance   Total revenues of ‚Ç¨70.8¬†million  including product sales of ‚Ç¨68.3 million  in line......,"First-Half Sales Performance in Line with Full-Year 2024 GuidanceTotal revenues of ‚Ç¨70.8 million  including product sales of ‚Ç¨68.3 million  in line with anticipated supply and sales phasingNet Profit of ‚Ç¨34.0 million  including proceeds from PRV saleOperating profit of ‚Ç¨46.7 million compared to an operating loss of ‚Ç¨35.0 million in the first half of 2023Cash position of ‚Ç¨131.4 million Substantially lower cash burn expected in the second half of 2024 as Valneva completed its cost contributions to the agreed R&D budget for its partnered Lyme disease program in the second quarter Significantly extended cash runway with update of debt financing agreement 1Full-year 2024 Financial Guidance ConfirmedExpected total revenues between ‚Ç¨170 million and ‚Ç¨190 million  including ‚Ç¨160 million to ‚Ç¨180 million of product salesExpected R&D investments between ‚Ç¨60 million and ‚Ç¨75 millionExpected Other income between ‚Ç¨100 million and ‚Ç¨110 million  including ‚Ç¨95 million from the PRV saleStrategic Pipeline Expansion  Strong Clinical and Regulatory ExecutionExclusive worldwide license for S4V Shigella vaccine candidate  adding an attractive Phase 2 clinical asset to Valneva‚Äôs R&D pipeline without impacting full-year or mid-term financial guidance 2Additional marketing authorizations for single-shot IXCHIQ ¬Æ granted in Europe and Canada ahead of initial guidance; Ongoing regulatory reviews in the UK and Brazil; Recommended by ACIP and adopted by U.S. CDC 3granted in Europe and Canada ahead of initial guidance; Ongoing regulatory reviews in the UK and Brazil; Recommended by ACIP and adopted by U.S. CDC New CEPI grant 4 of $41.3 million contributes significantly to Phase 4 costs and other studies supporting broader access to the world‚Äôs first chikungunya vaccineof $41.3 million contributes significantly to Phase 4 costs and other studies supporting broader access to the world‚Äôs first chikungunya vaccine Reported positive six-month data for Phase 3 adolescent study of IXCHIQ¬Æ5; expects to submit label extensions for 12 to 17 years old in the U.S.  Europe and Canada in the second half of 2024IXCHIQ ¬Æ two-year antibody persistence data published in the Lancet Infectious Diseasestwo-year antibody persistence data published in the Lancet Infectious Diseases IXCHIQ ¬Æ pediatric Phase 2 study fully enrolledpediatric Phase 2 study fully enrolled Completed primary vaccinations (three doses) of VALOR Lyme disease Phase 3 trial participants 6Initiated Phase 1 clinical trial for second-generation Zika vaccine candidate7Financial Information(Unaudited results  consolidated per IFRS)‚Ç¨ in million 6 months ended June 30  2024 2023 Total revenues 70.8 73.7 Product sales 68.3 69.7 Net profit / loss 34.0 (35.0) Adjusted EBITDA8 56.2 (28.3) Cash 131.4 204.4Saint-Herblain (France)  August 13  2024 ‚Äì Valneva SE (Nasdaq: VALN; Euronext Paris: VLA)  a specialty vaccine company  today reported its consolidated financial results for the first half of the year  ended June 30  2024. The half year financial report  including the condensed consolidated interim financial report and the half year management report  is available on the Company‚Äôs website (Financial Reports ‚Äì Valneva).Valneva will provide a live webcast beginning at 3 p.m. CEST / 9 a.m. EDT today. This webcast will also be available on the Company‚Äôs website. Please refer to this link: https://edge.media-server.com/mmc/p/mmuf83o5Peter B√ºhler  Valneva‚Äôs Chief Financial Officer  commented  ‚ÄúOur first half sales performance is in line with our expectations. We aim to further capitalize on the travel industry recovery as we focus on ramping up sales for IXCHIQ¬Æ to support our commercial growth  while continuing to execute on our key R&D and regulatory milestones. The successful sale of our PRV and deferral of our loan reimbursement allow us to maintain a solid cash position and  with completion of our payments for the Lyme disease program in the second quarter  we anticipate a significantly lower cash burn in 2024.‚ÄùCommercial PortfolioValneva‚Äôs commercial portfolio is composed of three travel vaccines  IXIARO¬Æ/JESPECT¬Æ  DUKORAL¬Æ and recently launched IXCHIQ¬Æ. The Company also distributes certain third-party products in countries where it operates its own marketing and sales infrastructure.Valneva‚Äôs sales in the first half of 2024 were ‚Ç¨68.3 million compared to ‚Ç¨69.7 million (‚Ç¨64.0 million excluding final COVID-19 vaccine sales) in the first half of 2023. While product sales grew meaningfully in the second quarter and included first sales for IXCHIQ¬Æ  first half 2024 sales were affected by previously reported supply constraints for IXIARO¬Æ and third-party products.JAPANESE ENCEPHALITIS VACCINE IXIARO¬Æ/JESPECT¬ÆIn the first half of 2024  IXIARO¬Æ/JESPECT¬Æ sales increased by 38% to ‚Ç¨41.9 million compared to ‚Ç¨30.3 million in the first half of 2023. The increase primarily reflects sales to the U.S. military  which were minimal in the first half of 2023  as well as increased sales to travelers.CHOLERA / ETEC9-DIARRHEA VACCINE DUKORAL¬ÆIn the first half of 2024  DUKORAL¬Æ sales were ‚Ç¨14.9 million compared to ‚Ç¨17.1 million in the first half of 2023. The decrease was due to reduced marketing investments while Valneva‚Äôs new manufacturing site in Sweden underwent regulatory evaluation and approval.CHIKUNGUNYA VACCINE IXCHIQ¬ÆIXCHIQ¬Æ is the world‚Äôs first and only licensed chikungunya vaccine available to address this significant unmet medical need. The vaccine is now approved in the U.S. 10  Europe11  and Canada12 for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The U.S. launch is underway while first sales in Canada and Europe are anticipated in the fourth quarter of 2024.Following adoption of the U.S. Advisory Committee on Immunization Practices (ACIP)‚Äôs recommendations by the U.S. Centers for Disease Control and Prevention (CDC)13 at the beginning of March 2024  Valneva recognized initial sales of ‚Ç¨1.0 million in the first half of 2024. Key launch metrics  including stocking and re-stocking across all sales channels  active customer accounts  as well as reimbursement for IXCHIQ¬Æ by commercial and MediCare insurance plans continue to track in line with expectations.In addition to ramping up sales  Valneva is focusing on expanding the vaccine‚Äôs label and access. The Company expects marketing authorizations in the UK and Brazil in the second half of 2024 and recently expanded its partnership with CEPI14 to support broader access to the vaccine in Low Middle-Income Countries (LMICs)  post-marketing trials and potential label extensions in children  adolescents and pregnant women. CEPI will provide Valneva up to $41.3 million of additional funding over the next five years  with support from the European Union‚Äôs (EU) Horizon Europe program.Based on positive pivotal six-month Phase 3 data reported in May 202415  Valneva expects to file for potential label extensions for use in adolescents aged 12 to 17 years in the second half of 2024. These data show that a single-dose vaccination with IXCHIQ¬Æ induces a high and sustained immune response in 99.1% of adolescents  and that the vaccine was generally well tolerated. Conducted in Brazil in collaboration with Instituto Butantan  the trial is also expected to support licensure of the vaccine in Brazil  which would be the first potential approval for use in endemic populations.Additionally  Valneva recently completed enrollment of a Phase 2 pediatric trial  VLA1553-221  in children aged 1 to 11 years16  designed to support a Phase 3 pivotal pediatric study and potential future label extension to this age group.The peer-reviewed medical journal  The Lancet Infectious Diseases  also just published the vaccine‚Äôs Phase 3 antibody persistence results two years after vaccination with a single dose. The data show that IXCHIQ¬Æ‚Äôs robust immune response was sustained for two years by 97% of participants and was equally durable in younger and older adults17. These data  which further support the anticipated long-term durability of the immune response  will also be used to potentially expand the vaccine‚Äôs current label. Valneva will continue to measure antibody persistence for a period of at least five years and expects to report three-year durability results later this year.THIRD-PARTY DISTRIBUTIONValneva distributes certain third-party vaccines in countries where it operates its own marketing and sales infrastructure. During the first half of 2024  third-party sales decreased by 37% to ‚Ç¨10.5 million compared to ‚Ç¨16.5 million in the first half of 2023 as a result of anticipated supply constraints.Valneva expects third-party sales to gradually wind down to less than 5% of overall product sales by 2026/2027  allowing the Company to improve gross margins.Clinical Vaccine CandidatesLYME DISEASE VACCINE CANDIDATE ‚Äì VLA15Phase 3 primary vaccination completedValneva and Pfizer are developing VLA15  a Phase 3 vaccine candidate targeting Borrelia  the bacterium that causes Lyme disease. VLA15 is the only Lyme disease program in late-stage clinical development today and has received Fast Track designation from the FDA. VLA15 is a multivalent recombinant protein vaccine that targets six serotypes of Borrelia representing the most common strains found in the United States and Europe.Valneva and Pfizer reported results for the Phase 2 clinical trials of VLA15 in both adult and pediatric populations  in which high levels of antibodies against all six serotypes were observed. Results of Phase 2 trials VLA15-201 and VLA15-202 were published in the peer-reviewed medical journal  the Lancet Infectious Diseases  in June 202418. Additional 18-month booster results from Study VLA15-202 were also published in the same journal in July 202419.In July 2024  Valneva and Pfizer announced completion of primary vaccinations (three doses) of over 9 000 participants in the Phase 3 trial ‚ÄúVaccine Against Lyme for Outdoor Recreationists‚Äù (VALOR)20.Completion of the VALOR trial is still expected by the end of 2025  with the aim for Pfizer to submit a Biologic License Application (BLA) to the FDA and a Marketing Authorization Application (MAA) to the EMA in 2026  subject to positive data.Based on the agreement with Pfizer  Valneva‚Äôs agreed-upon cost contributions for the Lyme disease program were completed in the second quarter of 2024  contributing to a substantially lower expected cash burn in the second half of 2024.SHIGELLA VACCINE CANDIDATE ‚Äì S4VValneva recently entered into a strategic partnership and exclusive licensing agreement with LimmaTech Biologics AG for the development  manufacturing and commercialization of Shigella4V (S4V)  a tetravalent bioconjugate vaccine candidate against shigellosis21.Shigellosis  caused by Shigella bacteria  is the second leading cause of fatal diarrheal disease worldwide. It is estimated that up to 165 million cases of disease and an estimated 600 000 deaths are attributed to Shigella each year22  particularly among children in Low- and Middle-Income Countries (LMICs). No approved Shigella vaccine is currently available and the development of Shigella vaccines has been identified as a priority by the World Health Organization (WHO)23. Shigellosis also affects international travelers from high-income countries and deployed military personnel in endemic regions. The global market for a vaccine against Shigella is estimated to exceed $500 million annually24.Under the terms of the agreement with Valneva  LimmaTech will receive an upfront payment of ‚Ç¨10 million and be eligible to receive additional regulatory  development and sales-based milestone payments of up to ‚Ç¨40 million as well as low double-digit royalties on sales. LimmaTech will conduct a Phase 2 Controlled Human Infection Model study (CHIM) in the U.S. and a Phase 2 pediatric study in LMICs. Both clinical trials are expected to begin in the second half of 2024. Valneva will assume all further development  including CMC (chemistry  manufacturing and controls) and regulatory activities  and be responsible for its commercialization worldwide if approved.The anticipated development path follows a staggered and risk-mitigated strategy  allowing an efficient capital allocation in line with Valneva‚Äôs communicated plan of having a new R&D program in Phase 3 by 2027.ZIKA VACCINE CANDIDATE ‚Äì VLA1601Phase 1 ongoing with second-generation vaccine candidateVLA1601 is a second-generation adjuvanted inactivated vaccine candidate against the mosquito-borne disease caused by the Zika virus (ZIKV). In March 2024  Valneva initiated a Phase 1 clinical trial to investigate the safety and immunogenicity of VLA160125. The randomized  placebo-controlled  Phase 1 trial  VLA1601-102  is planned to enroll approximately 150 participants aged 18 to 49 years in the United States. Participants will receive a low  medium or high dose of VLA1601. In addition  the low dose of VLA1601 will be evaluated with an additional adjuvant. Topline data from the trial are expected in the first half of 2025.Zika disease outbreaks have been reported in tropical Africa  Southeast Asia  the Pacific Islands  and  since 2015  in the Americas. Zika virus transmission persists in several countries in the Americas and in other endemic regions. To date  a total of 89 countries and territories have reported evidence of mosquito transmitted Zika virus infection26; however  surveillance remains limited globally. There are no preventive vaccines or effective treatments available and  as such  Zika remains a public health threat and is included in the FDA‚Äôs Tropical Disease Priority Review Voucher Program27.A vaccine against ZIKV could be a valuable addition to Valneva‚Äôs portfolio against mosquito-borne diseases  which already includes IXCHIQ¬Æ and IXIARO¬Æ.First Half 2024 Financial Review(Unaudited  consolidated under IFRS)RevenuesValneva‚Äôs total revenues were ‚Ç¨70.8 million in the six months ended June 30  2024 compared to ‚Ç¨73.7 million in the six months ended June 30  2023.Valneva‚Äôs total product sales reached ‚Ç¨68.3 million in the six months ended June 30  2024 compared to ‚Ç¨69.7 million in the same period of 2023. The impact of currency fluctuations of ‚Ç¨0.1 million was minimal.Excluding final COVID-19 vaccine sales in the six months ended June 30  2023  travel vaccine sales show a growth of ‚Ç¨4.3 million or 7% year-over-year.IXIARO¬Æ/JESPECT¬Æ sales were ‚Ç¨41.9 million in the six months ended June 30  2024 compared to ‚Ç¨30.3 million in the six months ended June 30  2023. The 38% increase primarily reflects sales to the U.S. military  which were minimal in the first half of 2023  as well as increased sales to travelers. The impact of foreign currency movements in IXIARO¬Æ/JESPECT¬Æ sales was negligible.DUKORAL¬Æ sales were ‚Ç¨14.9 million in the six months ended June 30  2024 compared to ‚Ç¨17.1 million in the comparative period of 2023. This 13% decrease was due to reduced marketing investments while Valneva‚Äôs new manufacturing site in Sweden underwent regulatory evaluation and approval. Foreign currency fluctuations had an immaterial impact on DUKORAL¬Æ sales.Following adoption of the U.S. Advisory Committee on Immunization Practices (ACIP)‚Äôs recommendations by the U.S. Centers for Disease Control and Prevention (CDC) at the beginning of March 2024  Valneva recognized initial sales for IXCHIQ¬Æ of ‚Ç¨1.0 million in the first half of 2024.Third Party product sales were ‚Ç¨10.5 million in the six months ended June 30  2024 compared to ‚Ç¨16.5 million in the six months ended June 30  2023. This 37% decrease was mainly driven by lower sales of Rabipur¬Æ/RabAvert¬Æ and Encepur¬Æ  under the distribution agreement with Bavarian Nordic  due to supply shortages.Other revenues  including revenues from collaborations  licensing and services amounted to ‚Ç¨2.5 million in the six months ended June 30  2024 compared to ‚Ç¨4.1 million in the same period of 2023. The reduction mainly resulted from lower revenue recognition related to the R&D collaboration activities for chikungunya with Instituto Butantan and the divestment of the CTM unit in Sweden in July 2023.Operating Result and adjusted EBITDACosts of goods and services sold (COGS) were ‚Ç¨45.6 million in the six months ended June 30  2024. The gross margin on commercial product sales  excluding IXCHIQ¬Æ  amounted to 47.7% compared to 40.0% in the six months ended June 30  2023. COGS of ‚Ç¨17.8 million related to IXIARO¬Æ product sales  yielding a product gross margin of 57.5%. COGS of ‚Ç¨9.7 million related to DUKORAL¬Æ product sales  yielding a product gross margin of 34.8%. Product gross margins are expected to improve in the second half of the year as the supply shortages during the first half have been resolved. Of the remaining COGS in 2024  ‚Ç¨7.7 million related to the third-party products distribution business  ‚Ç¨4.0 million to IXCHIQ¬Æ  ‚Ç¨2.1 million to idle capacity costs and ‚Ç¨4.6 million to cost of services. In 2023  overall COGS were ‚Ç¨53.8 million  of which ‚Ç¨48.4 million related to cost of goods and ‚Ç¨5.5 million related to cost of services.Research and development expenses amounted to ‚Ç¨29.7 million in the six months ended June 30  2024  compared to ‚Ç¨26.0 million in the six months ended June 30  2023. This increase was mainly driven by higher costs related to the ongoing transfer of operations into the new Almeida manufacturing facility and higher R&D costs for IXCHIQ¬Æ. Marketing and distribution expenses in the first six months of 2024 amounted to ‚Ç¨23.2 million compared to ‚Ç¨20.0 million in the first six months of 2023. The increase is mainly related to ‚Ç¨9.8 million of expenses associated with launch activities for IXCHIQ¬Æ (first half of 2023: ‚Ç¨7.8 million). In the six months ended June 30  2024  general and administrative expenses remained stable at ‚Ç¨22.8 million after ‚Ç¨22.9 million in the same period of 2023. The largest expense categories were employee-related expenses of ‚Ç¨10.5 million and consulting and other services of ‚Ç¨9.6 million.During the first half of 2024  a net gain of ‚Ç¨90.8 million from the sale of the PRV was recorded. The gross proceeds of $103 million were reduced by transaction costs as well as contractual payment obligations related to the sale of the PRV.Other income  net of other expenses decreased to ‚Ç¨6.4 million in the six months ended June 30  2024 from ‚Ç¨14.0 million in the six months ended June 30  2023. In the first half of 2023  Valneva recorded income from grants and tax credits for research and development totaling ‚Ç¨14.9 million  of which ‚Ç¨8.7 million were awarded by Scottish Enterprise (SE) for non-COVID-19 vaccine development (IXCHIQ¬Æ and IXIARO¬Æ).Valneva recorded an operating income of ‚Ç¨46.7 million in the six months ended June 30  2024 compared to an operating loss of ‚Ç¨35.0 million in the comparative period of 2023. The increase was mainly the result of the PRV sale.Adjusted EBITDA (as defined below) profit in the six months ended June 30  2024 was ‚Ç¨56.2 million  whereas in the six months ended June 30  2023 an adjusted EBITDA loss of ‚Ç¨28.3 million was recorded.Net ResultIn the six months ended June 30  2024  Valneva generated a net profit of ‚Ç¨34.0 million  mainly resulting from the sale of the PRV in February 2024. This compared to a net loss of ‚Ç¨35.0 million in the first half of 2023.Finance expense and currency effects in the first half of 2024 resulted in a net finance expense of ‚Ç¨12.8 million  compared to a net finance expense of ‚Ç¨3.9 million in the first half of 2023. This increase was mainly due to ‚Ç¨5.7 million higher interest expenses on loans resulting from the amendment of the Deerfield Management Company and OrbiMed (D&O) loan facility. Additionally foreign exchange losses of ‚Ç¨1.7 million were recorded in the first half of 2024 compared to gains of ‚Ç¨4.5 million observed in the first half of 2023  primarily related to the development of the USD and GBP exchange rates to the EUR.Cash Flow and LiquidityNet cash used in operating activities amounted to ‚Ç¨66.3 million in the six months ended June 30  2024 compared to ‚Ç¨65.4 million of cash used in operating activities in the same period of 2023. Cash outflows in the first half of 2024 were largely derived from the operating loss for the period (net of gains from PRV sale) amounting to ‚Ç¨56.9 million and from working capital in the amount of ‚Ç¨31.2 million  which includes all payments to the Lyme disease clinical program as per the R&D budget agreed between Pfizer and Valneva. In 2023  changes in working capital were higher  mainly related to higher payments to Pfizer in conjunction with the Lyme disease program  reducing the refund liability.Cash inflows from investing activities amounted to ‚Ç¨87.6 million in the six months ended June 30  2024 compared to cash outflows of ‚Ç¨6.6 million in the six months ended June 30  2023. While both years include outflows from construction activities across production sites in Scotland and Sweden  the sale of the PRV positively impacted 2024 by ‚Ç¨90.8 million.Net cash used in financing activities increased to ‚Ç¨16.6 million in the six months ended June 30  2024 from ‚Ç¨9.5 million in the six months ended June 30  2023. This increase was primarily due to ‚Ç¨5.4 million higher interest payments resulting from the increase in the D&O loan facility.Cash and cash equivalents were ‚Ç¨131.4 million as at June 30  2024  compared to ‚Ç¨126.1 million at December 31  2023.Non-IFRS Financial MeasuresManagement uses and presents IFRS results as well as the non-IFRS measure of Adjusted EBITDA to evaluate and communicate its performance. While non-IFRS measures should not be construed as alternatives to IFRS measures  management believes non-IFRS measures are useful to further understand Valneva‚Äôs current performance  performance trends  and financial condition.Adjusted EBITDA is a common supplemental measure of performance used by investors and financial analysts. Management believes this measure provide additional analytical tools. Adjusted EBITDA is defined as net profit / (loss) for the period before income tax  finance income/expense  foreign exchange (gain)/loss  amortization  depreciation  and impairment (excluding impairment loss of disposal).A reconciliation of Adjusted EBITDA to operating loss  which is the most directly comparable IFRS measure  is set forth below:‚Ç¨ in million 6 months ended June 30 (unaudited results  consolidated per IFRS) 2024 2023 Net profit / (loss) 34.0 (35.0) Add: Income tax benefit (0.2) (3.8) Total Finance income (0.8) (0.5) Total Finance expense 12.0 8.9 Foreign exchange (gain)/ loss ‚Äì net 1.7 (4.5) Amortization 2.5 3.2 Depreciation 7.0 5.4 Impairment  excluding impairment loss of disposal - (1.9) Adjusted EBITDA 56.2 (28.3)About ValnevaWe are a specialty vaccine company that develops  manufactures  and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach  applying our deep expertise across multiple vaccine modalities  focused on providing either first-  best- or only-in-class vaccine solutions.We have a strong track record  having advanced multiple vaccines from early R&D to approvals  and currently market three proprietary travel vaccines  including the world‚Äôs first and only chikungunya vaccine  as well as certain third-party vaccines.Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development  which is partnered with Pfizer  the world‚Äôs most clinically advanced Shigella vaccine candidate  as well as vaccine candidates against the Zika virus and other global public health threats. More information is available at www.valneva.com.Valneva Investor and Media ContactsLaetitia Bachelot-FontaineVP  Global Communications and European Investor RelationsM +33 (0)6 4516 7099Laetitia.bachelotfontaine@valneva.comJoshua Drumm  Ph.D.VP  Global Investor RelationsM +001 917 815 4520joshua.drumm@valneva.comForward-Looking StatementsThis press release contains certain forward-looking statements relating to the business of Valneva  including with respect to guidance for certain financial results in fiscal year 2024 and mid-term outlook on financial results  cash position  and other business developments  including results of ongoing clinical trials  the timing and possible occurrence of further or initial regulatory approvals of its product candidates  the anticipated size of markets for approved products and sales of those products  receipt of funding from external sources  supply of products sold by Valneva  and relationships with current business partners. In addition  even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release  those results or developments of Valneva may not be indicative of future results. In some cases  you can identify forward-looking statements by words such as ""could "" ""should "" ""may "" ""expects "" ""anticipates "" ""believes "" ""intends "" ""estimates "" ""aims "" ""targets "" or similar words. These forward-looking statements are based on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results  performance or achievements to be materially different from any future results  performance or achievement expressed or implied by these forward-looking statements. These risks and uncertainties include those developed or identified in any public documents filed with the French financial markets authority (Autorit√© des march√©s financiers) and the U.S. Securities and Exchange Commission made or to be made by Valneva. In particular  the expectations of Valneva could be affected by  among other things  uncertainties involved in the development and manufacture of vaccines (including in relation to organic or strategic expansion of Valneva‚Äôs clinical pipeline)  unexpected clinical trial results  unexpected regulatory actions or delays  competition in general  currency fluctuations  the impact of the global and European financial crisis and other global economic or political events  the ability to obtain or maintain patent or other proprietary intellectual property protection  the cancellation of existing contracts  the impact of a pandemic  and changes in the regulatory environment in which Valneva operates. The occurrence of any of these risks and uncertainties could substantially harm Valneva‚Äôs business  financial condition  prospects and results of operations. In light of these risks and uncertainties  there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in this press release as of the date hereof and disclaims any intention or obligation to publicly update or revise any forward-looking statements  whether as a result of new information  future events  or otherwise.1 Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed - Valneva2 Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World‚Äôs Most Clinically Advanced Tetravalent Shigella Vaccine Candidate - Valneva3 ACIP Vaccine Recommendations and Schedules | CDC4 CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World‚Äôs First Chikungunya Vaccine - Valneva5 Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine - Valneva6 Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion - Valneva7 Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate - Valneva8 For additional information on Adjusted EBITDA  please refer to the ‚ÄúNon-IFRS Financial Measures‚Äù section at the end of the PR9 Indications differ by country - Please refer to Product / Prescribing Information (PI) / Medication Guide approved in your respective countries for complete information  incl. dosing  safety and age groups in which this vaccine is licensed  ETEC = Enterotoxigenic Escherichia coli (E. Coli) bacterium.10 Valneva Announces U.S. FDA Approval of World‚Äôs First Chikungunya Vaccine  IXCHIQ¬Æ - Valneva11 Valneva Receives Marketing Authorization in Europe for the World‚Äôs First Chikungunya Vaccine  IXCHIQ¬Æ - Valneva12 Valneva Announces Health Canada Approval of the World‚Äôs First Chikungunya Vaccine  IXCHIQ¬Æ - Valneva13 ACIP Vaccine Recommendations and Schedules | CDC14 CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World‚Äôs First Chikungunya Vaccine - Valneva15 Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine - Valneva16 Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine - Valneva17 https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00357-8/fulltext18 Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases - Valneva19 Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised  controlled  phase 2 trial - The Lancet Infectious Diseases20 Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion - Valneva21 LimmaTech Biologics AG22 Shigellosis | CDC Yellow Book 202423 Immunization  Vaccines and Biologicals (who.int)24 Valneva‚Äôs Initial internal assessment25 Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate - Valneva26 Zika virus disease (who.int)27 Tropical Disease Priority Review Voucher Program | FDAFull-year 2024 Financial Guidance ConfirmedAttachment",neutral,0.0,1.0,0.0,mixed,0.47,0.08,0.45,True,English,"['Half Year 2024 Financial Results', 'Corporate Updates', 'Valneva', 'Lancet Infectious Diseases IXCHIQ ¬Æ pediatric Phase 2 study', 'U.S. CDC New CEPI grant 4', 'VALOR Lyme disease Phase 3 trial participants', 'IXCHIQ ¬Æ two-year antibody persistence data', 'S4V Shigella vaccine candidate', 'second-generation Zika vaccine candidate7', 'attractive Phase 2 clinical asset', 'consolidated interim financial report', 'JAPANESE ENCEPHALITIS VACCINE IXIARO', 'final COVID-19 vaccine sales', 'half year management report', 'half year financial report', 'Phase 1 clinical trial', 'Phase 3 adolescent study', 'Lyme disease program', 'first half sales performance', 'positive six-month data', 'U.S. military', 'R&D budget', 'debt financing agreement', 'R&D investments', 'Strategic Pipeline Expansion', 'Exclusive worldwide license', 'R&D pipeline', 'consolidated financial results', 'Peter B√ºhler', 'Chief Financial Officer', 'travel industry recovery', 'key R&D', 'first chikungunya vaccine', 'First-Half Sales Performance', 'Ongoing regulatory reviews', 'three travel vaccines', 'ETEC9-DIARRHEA VACCINE DUKORAL¬Æ', 'mid-term financial guidance', 'lower cash burn', 'specialty vaccine company', 'Additional marketing authorizations', 'solid cash position', 'Full-year 2024 Financial Guidance', 'IXIARO¬Æ/JESPECT¬Æ sales', 'first half 2024 sales', 'Phase 4 costs', 'Strong Clinical', 'Financial Information', 'Financial Reports', 'first sales', 'single-shot IXCHIQ ¬Æ', 'second half', 'Regulatory Execution', 'three doses', 'Unaudited results', 'regulatory milestones', 'Full-Year 2024 Guidance', 'initial guidance', 'cash runway', 'product sales', 'sales phasing', 'sales infrastructure', 'Total revenues', 'Net Profit', 'Operating profit', 'cost contributions', 'second quarter', 'Other income', 'other studies', 'broader access', 'label extensions', 'primary vaccinations', 'Euronext Paris', 'commercial growth', 'successful sale', 'loan reimbursement', 'Commercial Portfolio', 'third-party products', 'The Company', 'PRV sale', 'operating loss', 'live webcast', 'supply constraints', 'Valneva SE', 'IXCHIQ¬Æ', 'proceeds', 'update', 'Europe', 'Canada', 'Brazil', 'ACIP', 'IFRS', '6 months', 'June', 'EBITDA8', 'Saint-Herblain', 'France', 'Nasdaq', 'VLA', 'website', 'CEST', '9 a', 'link', 'media', 'server', 'mmc', 'mmuf83o5', 'expectations', 'deferral', 'completion', 'payments', 'countries', 'increase', 'travelers', 'CHOLERA']",2024-08-13,2024-08-14,globenewswire.com
44634,EuroNext,Bing API,https://finance.yahoo.com/news/3-high-growth-stocks-significant-133344986.html,3 High Growth Stocks With Significant Insider Ownership On Euronext Amsterdam,The Euronext Amsterdam has shown resilience amidst global market volatility  with the pan-European STOXX Europe 600 Index clawing back sharp losses to end slightly higher. As Eurozone government bond yields rise and retail sales suggest consumers are still struggling ,The Euronext Amsterdam has shown resilience amidst global market volatility  with the pan-European STOXX Europe 600 Index clawing back sharp losses to end slightly higher. As Eurozone government bond yields rise and retail sales suggest consumers are still struggling  investors are increasingly looking for stable growth opportunities. In this context  companies with high insider ownership can be particularly appealing as they often signal strong confidence from those closest to the business. Here we explore three high-growth stocks on Euronext Amsterdam that boast significant insider ownership.Top 5 Growth Companies With High Insider Ownership In The NetherlandsName Insider Ownership Earnings Growth BenevolentAI (ENXTAM:BAI) 27.8% 62.8% Envipco Holding (ENXTAM:ENVI) 36.7% 69.2% Ebusco Holding (ENXTAM:EBUS) 33.2% 107.8% Basic-Fit (ENXTAM:BFIT) 12% 78.3% MotorK (ENXTAM:MTRK) 35.8% 108.4% PostNL (ENXTAM:PNL) 35.8% 36.4%Click here to see the full list of 6 stocks from our Fast Growing Euronext Amsterdam Companies With High Insider Ownership screener.Let's explore several standout options from the results in the screener.Simply Wall St Growth Rating: ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ‚òÜOverview: Basic-Fit N.V.  with a market cap of ‚Ç¨1.43 billion  operates fitness clubs through its subsidiaries.Operations: Revenue segments for Basic-Fit N.V. include ‚Ç¨505.17 million from Benelux and ‚Ç¨626.41 million from France  Spain  and Germany.Insider Ownership: 12%Revenue Growth Forecast: 15.1% p.a.Basic-Fit has shown notable growth potential with a forecasted earnings increase of 78.3% per year  outpacing the Dutch market's 19.5%. Despite a volatile share price and interest payments not well covered by earnings  recent results are promising: H1 2024 revenue rose to ‚Ç¨584.76 million from ‚Ç¨500.42 million  and net income improved to ‚Ç¨4.18 million from a loss of ‚Ç¨6.12 million last year. Insider buying has been more frequent than selling in the past three months  albeit in modest volumes.ENXTAM:BFIT Earnings and Revenue Growth as at Aug 2024Simply Wall St Growth Rating: ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ‚òÜOverview: Envipco Holding N.V.  with a market cap of ‚Ç¨343.26 million  designs  develops  manufactures  assembles  markets  sells  leases  and services reverse vending machines (RVM) for collecting and processing used beverage containers primarily in the Netherlands  North America  and Europe.Operations: Envipco Holding N.V. generates revenue through the design  development  manufacture  assembly  marketing  sale  leasing  and servicing of reverse vending machines (RVM) for collecting and processing used beverage containers in the Netherlands  North America  and Europe.Story continuesInsider Ownership: 36.7%Revenue Growth Forecast: 33.5% p.a.Envipco Holding  a growth company with high insider ownership in the Netherlands  has shown promising financial performance. For Q1 2024  sales surged to ‚Ç¨27.44 million from ‚Ç¨10.41 million year-over-year  turning a net loss of ‚Ç¨2.57 million into a net income of ‚Ç¨0.147 million. Forecasts indicate revenue growth at 33.5% annually and earnings at 69.16%  both outpacing market averages. Despite recent share price volatility and past shareholder dilution  insiders have been buying more shares than selling in the last three months.ENXTAM:ENVI Ownership Breakdown as at Aug 2024Simply Wall St Growth Rating: ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ‚òÜOverview: MotorK plc  with a market cap of ‚Ç¨267.15 million  provides software-as-a-service solutions for the automotive retail industry across Italy  Spain  France  Germany  and the Benelux Union.Operations: The company's revenue segment primarily consists of Software & Programming  which generated ‚Ç¨42.50 million.Insider Ownership: 35.8%Revenue Growth Forecast: 22.1% p.a.MotorK's revenue is forecast to grow 22.1% annually  outpacing the Dutch market's 9.9%. Despite a net loss of ‚Ç¨6.48 million for H1 2024  this is an improvement from ‚Ç¨7.8 million a year ago. The company expects profitability within three years  with earnings projected to grow at 108.44% annually. Recent executive changes include Zoltan Gelencser as the new CFO  bringing extensive global finance experience from firms like Vodafone and eBay.ENXTAM:MTRK Earnings and Revenue Growth as at Aug 2024Seize The OpportunityGain an insight into the universe of 6 Fast Growing Euronext Amsterdam Companies With High Insider Ownership by clicking here.Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.Elevate your portfolio with Simply Wall St  the ultimate app for investors seeking global market coverage.Searching for a Fresh Perspective?This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock  and does not take account of your objectives  or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.Companies discussed in this article include ENXTAM:BFIT ENXTAM:ENVI and ENXTAM:MTRK.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively  email editorial-team@simplywallst.com,neutral,0.01,0.99,0.0,mixed,0.2,0.27,0.54,True,English,"['3 High Growth Stocks', 'Significant Insider Ownership', 'Euronext Amsterdam', 'Name Insider Ownership Earnings Growth BenevolentAI', 'Fast Growing Euronext Amsterdam Companies', 'Simply Wall St Growth Rating', 'Eurozone government bond yields', 'extensive global finance experience', 'pan-European STOXX Europe 600 Index', 'recent share price volatility', 'Envipco Holding N.V.', 'High Insider Ownership screener', 'volatile share price', 'The Euronext Amsterdam', 'stable growth opportunities', 'Top 5 Growth Companies', 'notable growth potential', 'significant insider ownership', 'several standout options', 'Basic-Fit N.V.', 'reverse vending machines', 'past shareholder dilution', 'Recent executive changes', 'global market volatility', 'past three months', 'last three months', 'automotive retail industry', 'new warning signs', 'global market coverage', 'Revenue Growth Forecast', 'promising financial performance', 'ENVI Ownership Breakdown', 'long-term focused analysis', 'three high-growth stocks', 'Insider buying', 'Ebusco Holding', 'three years', 'growth company', 'recent results', 'new CFO', 'The Opportunity', 'financial advice', 'financial situation', 'earnings increase', 'market cap', 'Dutch market', 'Revenue segments', 'sharp losses', 'retail sales', 'strong confidence', 'full list', 'fitness clubs', 'interest payments', 'net income', 'modest volumes', 'beverage containers', 'North America', 'service solutions', 'Zoltan Gelencser', 'ultimate app', 'Fresh Perspective', 'historical data', 'unbiased methodology', 'fundamental data', 'net loss', 'BFIT Earnings', 'MTRK Earnings', 'H1 2024 revenue', 'The Netherlands', 'Benelux Union', 'analyst forecasts', 'MotorK plc', '6 stocks', 'resilience', 'consumers', 'investors', 'context', 'business', 'ENXTAM', 'BAI', 'PostNL', 'PNL', 'Overview', 'subsidiaries', 'Operations', 'France', 'Spain', 'Germany', 'frequent', 'Aug', 'markets', 'leases', 'services', 'RVM', 'collecting', 'processing', 'design', 'development', 'manufacture', 'assembly', 'marketing', 'leasing', 'servicing', 'Story', 'Q1', 'averages', 'insiders', 'shares', 'software', 'Italy', 'Programming', 'improvement', 'profitability', 'firms', 'Vodafone', 'eBay', 'insight', 'universe', 'portfolio', 'alerts', 'article', 'nature', 'commentary', 'recommendation', 'account', 'objectives']",2024-08-14,2024-08-14,finance.yahoo.com
44635,EuroNext,Bing API,https://nz.finance.yahoo.com/quote/KKPNF/news/,Koninklijke KPN N.V. (KKPNF) latest stock news & headlines ‚Äì Yahoo Finance,As global markets navigate through rising trade tensions and shifting economic indicators  the Euronext Amsterdam presents a unique landscape for dividend stock considerations. In this environment  understanding the resilience and potential of dividend ...,Simply Wall St.As global markets navigate through rising trade tensions and shifting economic indicators  the Euronext Amsterdam presents a unique landscape for dividend stock considerations. In this environment  understanding the resilience and potential of dividend-yielding stocks becomes particularly pertinent for investors looking to stabilize their portfolios in July 2024.,neutral,0.0,1.0,0.0,neutral,0.01,0.98,0.01,True,English,"['Koninklijke KPN N.V.', 'latest stock news', 'Yahoo Finance', 'KKPNF', 'headlines', 'Simply Wall St.', 'rising trade tensions', 'shifting economic indicators', 'dividend stock considerations', 'global markets', 'Euronext Amsterdam', 'unique landscape', 'dividend-yielding stocks', 'environment', 'resilience', 'potential', 'investors', 'portfolios', 'July']",2024-08-14,2024-08-14,nz.finance.yahoo.com
44636,EuroNext,Bing API,https://finance.yahoo.com/news/top-euronext-paris-growth-companies-060331618.html,Top Euronext Paris Growth Companies With High Insider Ownership For August 2024,The French stock market has shown resilience amid global volatility  with the CAC 40 Index adding 0.25% recently despite broader economic concerns. As investors navigate these uncertain times  companies with strong growth potential and high insider ownership can offer a compelling investment opportunity due to the alignment of interests between management and shareholders.,The French stock market has shown resilience amid global volatility  with the CAC 40 Index adding 0.25% recently despite broader economic concerns. As investors navigate these uncertain times  companies with strong growth potential and high insider ownership can offer a compelling investment opportunity due to the alignment of interests between management and shareholders.Top 10 Growth Companies With High Insider Ownership In FranceName Insider Ownership Earnings Growth Groupe OKwind Soci√©t√© anonyme (ENXTPA:ALOKW) 24.8% 36% VusionGroup (ENXTPA:VU) 13.4% 25.7% Adocia (ENXTPA:ADOC) 11.9% 63% Icape Holding (ENXTPA:ALICA) 30.2% 35.1% Arcure (ENXTPA:ALCUR) 21.4% 27.5% La Fran√ßaise de l'Energie (ENXTPA:FDE) 19.9% 31.9% S.M.A.I.O (ENXTPA:ALSMA) 17.3% 35.2% Munic (ENXTPA:ALMUN) 29.4% 149.2% OSE Immunotherapeutics (ENXTPA:OSE) 25.6% 5.9% MedinCell (ENXTPA:MEDCL) 15.8% 71.1%Click here to see the full list of 23 stocks from our Fast Growing Euronext Paris Companies With High Insider Ownership screener.Let's review some notable picks from our screened stocks.Simply Wall St Growth Rating: ‚òÖ‚òÖ‚òÖ‚òÖ‚òÜ‚òÜOverview: Lectra SA provides industrial intelligence solutions for fashion  automotive  and furniture markets across Northern Europe  Southern Europe  the Americas  and the Asia Pacific with a market cap of ‚Ç¨986.76 million.Operations: Revenue segments for the company are as follows: Americas: ‚Ç¨172.65 million  Asia-Pacific: ‚Ç¨118.54 million  and Segment Adjustment: ‚Ç¨209.13 million.Insider Ownership: 19.6%Lectra SA  a prominent growth company with high insider ownership in France  reported half-year sales of ‚Ç¨262.29 million  up from ‚Ç¨239.55 million last year  though net income slightly declined to ‚Ç¨12.51 million from ‚Ç¨14.47 million. Despite this dip  earnings are forecasted to grow significantly at 29.3% annually over the next three years  outpacing the French market's 12.2%. The stock is trading at nearly half its estimated fair value and analysts predict a 32.8% price increase.ENXTPA:LSS Earnings and Revenue Growth as at Aug 2024Simply Wall St Growth Rating: ‚òÖ‚òÖ‚òÖ‚òÖ‚òÜ‚òÜOverview: OVH Groupe S.A. offers public and private cloud services  shared hosting  and dedicated server solutions globally  with a market cap of approximately ‚Ç¨1.07 billion.Operations: The company's revenue segments include Public Cloud (‚Ç¨169.01 million)  Private Cloud (‚Ç¨589.61 million)  and Web Cloud (‚Ç¨185.43 million).Insider Ownership: 10.5%OVH Groupe  with significant insider ownership  is expected to become profitable within three years. The company‚Äôs revenue growth forecast of 10% per year outpaces the French market's average. Recent innovations include the launch of ADV-Gen3 Bare Metal servers powered by AMD EPYC 4004 processors  enhancing performance and sustainability. Despite a volatile share price and low future return on equity (1.7%)  OVH trades at 35% below its estimated fair value  indicating potential undervaluation.Story continuesENXTPA:OVH Earnings and Revenue Growth as at Aug 2024Simply Wall St Growth Rating: ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ‚òÜOverview: Eurazeo SE is a private equity and venture capital firm that focuses on growth capital  acquisitions  leveraged buyouts  and investments in mid-market and listed public companies  with a market cap of approximately ‚Ç¨4.97 billion.Operations: Eurazeo generates revenue from its private equity and venture capital activities  including growth capital  acquisitions  leveraged buyouts  and investments in mid-market and listed public companies.Insider Ownership: 12.1%Eurazeo  with substantial insider ownership  is forecast to become profitable within three years and achieve a revenue growth rate of 45.2% annually  outpacing the French market. Despite reporting a net loss of ‚Ç¨104.56 million for H1 2024 and a diluted loss per share from continuing operations of ‚Ç¨1.43  analysts expect the stock price to rise by 36.6%. Trading at 83.3% below its estimated fair value suggests potential undervaluation despite recent challenges in earnings performance.ENXTPA:RF Earnings and Revenue Growth as at Aug 2024Key TakeawaysInvestigate our full lineup of 23 Fast Growing Euronext Paris Companies With High Insider Ownership right here.Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.Elevate your portfolio with Simply Wall St  the ultimate app for investors seeking global market coverage.Ready For A Different Approach?This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock  and does not take account of your objectives  or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.Companies discussed in this article include ENXTPA:LSS ENXTPA:OVH and ENXTPA:RF.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively  email editorial-team@simplywallst.com,neutral,0.08,0.92,0.0,negative,0.0,0.21,0.78,True,English,"['Top Euronext Paris Growth Companies', 'High Insider Ownership', 'August', 'Name Insider Ownership Earnings Growth Groupe OKwind Soci√©t√© anonyme', 'S.M.A.I.O', 'Fast Growing Euronext Paris Companies', 'Simply Wall St Growth Rating', 'OVH Groupe S.A.', 'ADV-Gen3 Bare Metal servers', 'High Insider Ownership screener', 'latest price-sensitive company announcements', 'significant insider ownership', 'substantial insider ownership', 'Top 10 Growth Companies', 'broader economic concerns', 'compelling investment opportunity', 'La Fran√ßaise', 'industrial intelligence solutions', 'dedicated server solutions', 'AMD EPYC 4004 processors', 'strong growth potential', 'revenue growth forecast', 'revenue growth rate', 'prominent growth company', 'venture capital firm', 'venture capital activities', 'listed public companies', 'long-term focused analysis', 'global market coverage', 'next three years', 'private cloud services', 'volatile share price', 'French stock market', 'growth capital', 'OVH Earnings', 'LSS Earnings', 'RF Earnings', 'earnings performance', 'global volatility', 'Public Cloud', 'French market', '32.8% price increase', 'potential undervaluation', 'Web Cloud', 'market cap', 'market movements', 'Revenue segments', 'stock price', 'CAC 40 Index', 'uncertain times', 'Icape Holding', 'full list', 'notable picks', 'Lectra SA', 'furniture markets', 'Northern Europe', 'Southern Europe', 'Asia Pacific', 'Segment Adjustment', 'half-year sales', 'net income', 'fair value', 'Recent innovations', 'future return', 'net loss', 'diluted loss', 'recent challenges', 'Key Takeaways', 'full lineup', 'close eye', 'ultimate app', 'Different Approach', 'historical data', 'analyst forecasts', 'unbiased methodology', 'financial advice', 'financial situation', 'fundamental data', 'qualitative material', 'private equity', 'OSE Immunotherapeutics', 'leveraged buyouts', 'Eurazeo SE', 'continuing operations', 'ENXTPA:ADOC', 'resilience', 'investors', 'alignment', 'interests', 'management', 'shareholders', 'France', 'ALOKW', 'VusionGroup', 'Adocia', 'ALICA', 'Arcure', 'ALCUR', 'Energie', 'FDE', 'ALSMA', 'Munic', 'ALMUN', 'MedinCell', 'MEDCL', '23 stocks', 'Overview', 'automotive', 'Americas', 'Asia-Pacific', 'dip', 'analysts', 'Aug', 'hosting', 'average', 'launch', 'sustainability', 'low', 'Story', 'acquisitions', 'investments', 'mid-market', 'H1', 'Trading', 'power', 'portfolio', 'article', 'nature', 'commentary', 'recommendation', 'account', 'objectives', 'position', '36.']",2024-08-14,2024-08-14,finance.yahoo.com
44637,EuroNext,Bing API,https://uk.finance.yahoo.com/news/top-3-dividend-stocks-watch-060535862.html,Top 3 Dividend Stocks To Watch On Euronext Paris,Click this link to deep-dive into the 34 companies within our Top Euronext Paris Dividend Stocks screener. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your ...,The French stock market has experienced a modest uptick  with the CAC 40 Index adding 0.25% amidst mixed signals from global markets and economic indicators. As volatility continues to shape investor sentiment  dividend stocks offer a compelling option for those seeking steady income and potential capital appreciation. In this context  identifying robust dividend stocks becomes crucial. Companies that consistently pay dividends often exhibit strong financial health and resilience  making them attractive in uncertain times.Top 10 Dividend Stocks In FranceName Dividend Yield Dividend Rating Vicat (ENXTPA:VCT) 6.75% ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ Rubis (ENXTPA:RUI) 7.25% ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ CBo Territoria (ENXTPA:CBOT) 6.86% ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ Samse (ENXTPA:SAMS) 6.10% ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ‚òÜ Arkema (ENXTPA:AKE) 4.53% ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ‚òÜ VIEL & Cie soci√©t√© anonyme (ENXTPA:VIL) 4.01% ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ‚òÜ Caisse R√©gionale de Cr√©dit Agricole Mutuel du Languedoc Soci√©t√© coop√©rative (ENXTPA:CRLA) 5.92% ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ‚òÜ Exacompta Clairefontaine (ENXTPA:ALEXA) 4.47% ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ‚òÜ Piscines Desjoyaux (ENXTPA:ALPDX) 8.40% ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ‚òÜ Eiffage (ENXTPA:FGR) 4.54% ‚òÖ‚òÖ‚òÖ‚òÖ‚òÜ‚òÜClick here to see the full list of 34 stocks from our Top Euronext Paris Dividend Stocks screener.ADVERTISEMENTLet's review some notable picks from our screened stocks.Simply Wall St Dividend Rating: ‚òÖ‚òÖ‚òÖ‚òÖ‚òÜ‚òÜOverview: CFM Indosuez Wealth Management SA  with a market cap of ‚Ç¨601.65 million  provides banking and financial solutions to private investors  businesses  institutions  and professionals in Monaco and internationally through its subsidiaries.Operations: CFM Indosuez Wealth Management SA generates revenue primarily from its wealth management services  amounting to ‚Ç¨196.38 million.Dividend Yield: 7.6%CFM Indosuez Wealth Management offers a mixed picture for dividend investors. While its dividend yield of 7.62% places it in the top 25% of French market payers  its past payments have been volatile and unreliable. The payout ratio is reasonable at 70.8%  indicating coverage by earnings  but historical instability raises concerns about sustainability. Earnings grew by 40.1% last year  suggesting potential for future dividends despite insufficient data to guarantee long-term stability.Story continuesENXTPA:MLCFM Dividend History as at Aug 2024Simply Wall St Dividend Rating: ‚òÖ‚òÖ‚òÖ‚òÖ‚òÜ‚òÜOverview: Colas SA constructs and maintains transport infrastructure worldwide  with a market cap of ‚Ç¨5.71 billion.Operations: Colas SA generates revenue from several segments including Roads France-Overseas France/IO (‚Ç¨5.97 billion)  Roads EMEA (‚Ç¨3.36 billion)  Canada Routes (‚Ç¨2.38 billion)  Roads United States (‚Ç¨2.24 billion)  Railways and Other Activities (‚Ç¨1.38 billion)  and Roads Asia-Pacific (‚Ç¨471 million).Dividend Yield: 4.2%Colas has shown growth in dividend payments over the past decade  yet these have been volatile. The current payout ratio of 81.3% indicates dividends are covered by earnings  and a cash payout ratio of 58.9% suggests they are sustainable through cash flows. Despite a recent earnings increase of 22.8%  the company's high debt level and lower-than-top-tier dividend yield (4.2%) compared to the French market's top payers (5.35%) may pose risks for investors seeking stable income.ENXTPA:RE Dividend History as at Aug 2024Simply Wall St Dividend Rating: ‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ‚òÜOverview: VIEL & Cie  soci√©t√© anonyme  is an investment company offering interdealer broking  online trading  and private banking services across various regions including Europe  the Middle East  Africa  the Americas  and Asia-Pacific with a market cap of ‚Ç¨612.29 million.Operations: VIEL & Cie  soci√©t√© anonyme  generates revenue from three main segments: Professional Intermediation (‚Ç¨1006.77 million)  Stock Exchange Online (‚Ç¨65.12 million)  and Contribution from Holdings (‚Ç¨0.21 million).Dividend Yield: 4%VIEL & Cie soci√©t√© anonyme offers a stable and growing dividend  with payments increasing over the past 10 years. Dividends are well covered by both earnings (payout ratio: 25.8%) and cash flows (cash payout ratio: 20.1%). Trading at 39% below its estimated fair value  it provides good value for investors. However  its dividend yield of 4.01% is lower than the top quartile in France (5.56%). Earnings grew by 33.4% last year  supporting dividend reliability.ENXTPA:VIL Dividend History as at Aug 2024Turning Ideas Into ActionsClick this link to deep-dive into the 34 companies within our Top Euronext Paris Dividend Stocks screener.Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.Ready To Venture Into Other Investment Styles?This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock  and does not take account of your objectives  or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.Companies discussed in this article include ENXTPA:MLCFM ENXTPA:RE and ENXTPA:VIL.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively  email editorial-team@simplywallst.com,neutral,0.07,0.92,0.0,mixed,0.39,0.23,0.38,True,English,"['Top 3 Dividend Stocks', 'Euronext Paris', 'Top Euronext Paris Dividend Stocks screener', 'Name Dividend Yield Dividend Rating Vicat', 'free Simply Wall St app', 'Languedoc Soci√©t√© coop√©rative', 'Simply Wall St Dividend Rating', 'CFM Indosuez Wealth Management SA', 'Caisse R√©gionale de', 'Cr√©dit Agricole Mutuel', 'Cie soci√©t√© anonyme', 'wealth management services', 'Top 10 Dividend Stocks', 'robust dividend stocks', 'MLCFM Dividend History', 'RE Dividend History', 'tier dividend yield', 'high debt level', 'three main segments', 'VIL Dividend History', 'strong financial health', 'current payout ratio', 'potential capital appreciation', 'Roads United States', 'Other Investment Styles', 'Stock Exchange Online', 'cash payout ratio', 'private banking services', 'French market payers', 'recent earnings increase', 'French stock market', 'top payers', 'top quartile', 'growing dividend', 'dividend reliability', 'Colas SA', 'dividend payments', 'dividend investors', 'several segments', 'Other Activities', 'cash flows', 'online trading', 'financial solutions', 'financial advice', 'market cap', 'modest uptick', 'CAC 40 Index', 'mixed signals', 'global markets', 'economic indicators', 'investor sentiment', 'compelling option', 'steady income', 'uncertain times', 'CBo Territoria', 'Exacompta Clairefontaine', 'Piscines Desjoyaux', 'full list', 'notable picks', 'private investors', 'mixed picture', 'historical instability', 'insufficient data', 'long-term stability', 'transport infrastructure', 'Roads EMEA', 'Canada Routes', 'past decade', 'investment company', 'interdealer broking', 'various regions', 'Middle East', 'Professional Intermediation', 'past 10 years', 'fair value', 'good value', 'personalized updates', 'detailed insights', 'historical data', 'analyst forecasts', 'unbiased methodology', 'past payments', 'Roads France', 'Overseas France', 'stable income', 'future dividends', '34 stocks', 'volatility', 'context', 'Companies', 'resilience', 'ENXTPA', 'Rubis', 'RUI', 'CBOT', 'Samse', 'Arkema', 'AKE', 'VIEL', 'CRLA', 'ALEXA', 'ALPDX', 'Eiffage', 'FGR', 'ADVERTISEMENT', 'Overview', 'businesses', 'institutions', 'professionals', 'Monaco', 'subsidiaries', 'Operations', 'revenue', 'coverage', 'concerns', 'sustainability', 'Aug', 'Railways', 'Asia-Pacific', 'growth', 'risks', 'Europe', 'Africa', 'Americas', 'Contribution', 'Holdings', 'increasing', 'Ideas', 'Actions', 'link', 'shares', 'firms', 'portfolio', 'investments', 'performance', 'globe', 'article', 'nature', 'commentary', 'recommendation', 'account', 'objectives']",2024-08-14,2024-08-14,uk.finance.yahoo.com
